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Abstract
Neuroinflammation is becoming increasingly recognised as key to the pathogenesis
of Alzheimer’s disease and tauopthies. Epidemiological studies report a delay in the
onset of Alzheimer’s in subjects using nonsteroidal anti-inflammatory drugs (NSAIDs).
NSAIDs inhibit enzymes in the cyclooxygenase-2 (COX-2) pathway which play a key
role in synthesising prostaglandin E2 (PGE2) from arachidonic acid. PGE2 has been
implicated in preclinical stages of Alzheimer’s disease, where elevated levels of PGE2
in the cerebrospinal fluid can be found, as well as aberrant amyloid processing in
experimental models of disease. PGE2 signals via 4 E-prostanoid (EP) receptors, EP1-
EP4, all G-protein coupled receptors (GPCR). The EP3 receptor, the most abundant
PGE2 receptor in the brain, is unique in that it is alternatively spliced giving rise to
species specific isoforms. One of the EP3 receptor isoforms, EP3Re, is human specific
and an incidental finding within a project to investigate its distribution in brain,
suggested that it could be associated with tau tangles. The aim of this project was to
further investigate the unknown distribution of EP3Re in human brain, to determine
its signalling mechanism and explore whether any meaningful interaction between
EP3Re, tau and its pathology exists. We use immunohistochemistry, proximity ligation
assays and electron microscopy to map out the distribution of EP3Re in the human
brain and explore the interaction between EP3Re and tau. We also use gene reporter
and second messenger assays to characterise EP3Re signalling and what role if any
this may be playing in tauopathies. We show that EP3Re is expressed throughout the
x
brain, with strong expression in brain stem nuclei, and signals predominantly through
a Gi coupling pathway. Moreover, using a combination of human tissue, primary cell
lines and neurons derived from induced pluripotent stem cells, we show that EP3Re
appears to be associated with tau neurofibrillary tangles in disease. We also show,
using the EP3 agonist sulprostone, that signalling through the receptor increases tau
phosphorylation in our cellular systems. Further work will be required to fully clarify
the specificity of the interaction and understand the mechanism behind this and if
targeting inflammatory EP3Re signalling has the potential to affect tau pathology in
disease.
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Neurodegenerative disorders account for a significant proportion of neurological disease
and represent a significant cause of death and disability worldwide. They are a group
of heterogeneous disorders marked by progressive neuronal loss in specific neuronal pop-
ulations. These include diseases such as motor neuron disease, Parkinson’s, progressive
supranuclear palsy, Huntington’s, multiple system atrophy and the dementias, such as
Alzheimer’s disease and frontotemporal dementia. Among the list of neurodegenerative
disorders, the dementias have the highest burden of disease with Alzheimer’s disease
accounting for 60-70% of all dementias (Gaugler et al., 2016). It is estimated that the
global incidence of dementia in 2016 was 43.8 million, an increase by over 20 million
since 1990 (Nichols et al., 2019) and it will exceed globally 100 million by 2050 (Nichols
et al., 2019). With no cure at present, this creates a significant public health problem.
Neurodegenerative disorders are characterised pathologically by the accumulation
of a misfolded or abnormal protein aggregates in the affected disease area (Gan et al.,
2018). Examples of this include α-synuclein inclusions in Parkinson’s, amyloid plaques
and tau aggregates in Alzheimer’s and huntingtin inclusions in Huntington’s (Dehay
et al., 2015; Landles and Bates, 2004). Biochemical characterisation of these inclusions
has contributed significantly to our understanding of the underlying mechanism of
disease with the pathological role of the protein forming the aggregates being sup-
ported by molecular and genetic studies. Indeed, the presence of aggregates in distinct
brain regions is associated with neurodegeneration with mutations in genes encoding
these proteins leading to familial forms of the disease (Dehay et al., 2015; Goedert,
2003; Murrell et al., 2000; Wszolek et al., 2006). Examples of this include mutations
in SNCA, the gene encoding α-synuclein, that forms the characteristic Lewy bodies
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associated with Parkinson’s disease (Appel-Cresswell et al., 2013; Pasanen et al., 2014;
Polymeropoulos et al., 1997; Proukakis et al., 2013; Singleton et al., 2003). The APP
gene which encodes amyloid precursor protein (APP) leading to plaque formation and
early onset Alzheimer’s (Murrell et al., 1991) and the trinucleotide repeat in the HTT
gene which encodes huntingtin leading to Huntington’s (MacDonald et al., 1993).
Disorders typified by the presence of aggregated tau inclusions are referred to as
tauopathies. These are a group of degenerative conditions that consist of dementias
and movement disorders (Götz et al., 2019). Despite the variable phenotype, they are
thought to share similar disease mechanisms due to the presence of filamentous tau
inclusions(Gendron and Petrucelli, 2009). The pathological role of these inclusions is
supported by genetic studies that show mutations in MAPT, the gene encoding tau, to
be sufficient to cause disease (Strang et al., 2019).
1.2 Tau
1.2.1 Tau protein
Tau is a microtubule-associated protein encoded by the MAPT (microtubule-associated
protein tau) gene. Under normal physiological conditions, tau is abundantly expressed
in neurons and contributes to stabilising neuronal microtubules and promote their
assembly, which is key to regulating transport along the axon and promoting axonal
outgrowth (Evans et al., 2004; Goedert et al., 1989; Mietelska-Porowska et al., 2014).
Beyond microtubule assembly and stability, several other physiological roles of tau have
been (Ittner et al., 2010) described. Tau deficient mice show impaired hippocampal
long term potentiation (LTP) and long term depression (LTD) consistent with a physi-
ological role of tau in synaptic plasticity and memory (Biundo et al., 2018; Kimura
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et al., 2014). Tau has also been identified under normal physiological conditions at
pre- and post- synaptic terminals (Tai et al., 2012) and has been shown to mediate
post-synaptic targeting of the Src kinase Fyn to NMDA receptors (Ittner et al., 2010)
further supporting a role for tau at synapses. Tau’s interaction with Fyn has also
been shown to be an important component of oligodendroglial process growth (Klein
et al., 2002). Klein et al show that disrupting Fyn-Tau binding by culturing tau
deficient oligodendrocytes results in a reduction in the length and number of processes.
Tau has also been shown to inhibit histone deacetylase-6 (HDAC6), the main tubulin
deacetylase (Perez et al., 2009). This highlights a potential mechanism through which
tau could regulate microtubule function independent of microtubule binding.
The MAPT gene is situated on chromosome 17q21.31 (Hutton et al., 1998) and
in normal adult brain, 6 tau isoforms are expressed by MAPT pre-mRNA alternative
splicing (Goedert et al., 1989) (Fig. 1.1). The isoforms differ by the presence or absence
of one or two 29 amino acid inserts in the N-terminal domain (inclusion or exclusion of
exons 2 and 3) producing 0N, 1N or 2N tau isoforms, and the presence or absence of
three or four microtubule binding repeats at the C-terminus (inclusion or exclusion of
exon 10) giving rise to either 3R of 4R tau (Goedert and Jakes, 1990; Goedert et al.,
1989; Jakes et al., 1991). The microtubule binding domain at the C-terminal, as the
name suggests, is involved in microtubule binding regulating the rate of microtubule
polymerisation (Friedhoff et al., 2000; Mietelska-Porowska et al., 2014). The N-terminal
region is known as the projection domain as it projects from the microtubule surface
interacting with the plasma membrane, mitochondria, and, other elements of the
neuronal cytoskeleton (Derisbourg et al., 2015).
The expression of the various isoforms are developmentally regulated (Goedert and
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Fig. 1.1 Adapted from Wang and Mandelkow (2015). The 6 tau isoforms are formed by
MAPT pre-mRNA alternative splicing of exon 2, 3 or 10
Jakes, 1990; Goedert et al., 1989). In the human foetal brain only 3R tau is expressed,
whilst in the normal adult brain, both 3R and 4R tau are expressed in equal amounts
(Goedert and Jakes, 1990; Goedert et al., 1989; Richey et al., 1995). Four repeat tau
shows an approximate 3 fold increase in its binding affinity for microtubules compared
to 3R tau and is thus more effective at promoting microtubule assembly, which has
been observed using video microscopy where 4R tau greatly suppresses the rate and
extent of microtubule disassembly (Panda et al., 2003). This developmental change
in isoform expression suggests that tau plays a different role in development from
postnatal time to adulthood possibly reflecting the different functional requirements
of microtubules in foetal and adult neurons. Moreover, tau undergoes several post-
translational modifications, including phosphorylation which regulates its biological
function, indeed tau is hyperphosphorylated during development (Martin et al., 2011).
When tau is phosphorylated it undergoes a conformational change reducing tau’s affin-
ity to microtubules and triggering its detachment from the microtubule (Andorfer et al.,
2003; Goedert et al., 1992; Mietelska-Porowska et al., 2014). Its de-phosphorylation by
tau phosphatases has the opposite effect restoring microtubule binding (Billingsley and
Kincaid, 1997; Goedert et al., 1992). This cycle between kinase mediated phosphoryla-
tion of tau and de-phosphorylation by phosphatases is essential for axonal transport
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and maintaining a balance between the two is important. When tau is bound is to
the microtubule it has been proposed to impede binding of motor proteins, slowing
axonal transport (Ebneth et al., 1998). Other studies propose a different view showing
direct involvement of tau in axonal transport through interaction with cytoskeletal
motor proteins dynein and kinesin (Cuchillo-Ibanez et al., 2008; Magnani et al., 2007;
Rodríguez-Martín et al., 2013). In vitro binding assays have shown tau binds to the
p150 domain of the dynein cofactor dynactin, whilst Hanger et al show not only does
tau bind to kinesin but tau’s ability to interact with kinesin is modulated by tau
phosphorylation. When tau phosphorylation by GSK3β is inhibited, this impairs tau’s
ability to interact with kinesin and slows axonal transport of tau (Cuchillo-Ibanez
et al., 2008). Other post-translational modifications include glycosylation, methylation,
glycation, ubiquitination, acetylation and truncation (Martin et al., 2011).
1.2.2 Tauopathies
Structurally tau is a highly soluble natively unfolded protein, however, under patho-
logical conditions, it becomes hyperphosphorylated forming neurofibrillary tangles
comprised of insoluble tau aggregates (Fig. 1.2) (Friedhoff et al., 2000; Goedert et al.,
1992). The formation of neurofibrillary tangles leads to neuronal dysfunction and
eventually cell death. The presence of tau aggregates characterise a group of neu-
rodegenerative diseases collectively known as tauopathies. These include Alzheimer’s
disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD),
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17T),
and Pick disease (PiD) (Spillantini and Goedert, 2013).
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Fig. 1.2 From Brunden et al. (2009). Image depicting a healthy neuron and a diseased
neuron. When tau becomes hyperphosphorylated it detaches from the microtubule and
becomes sequestered into filaments forming NFTs. There is loss of stability of the microtubule
which dissociates leading to impaired neuronal function and eventually neuronal death.
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1.2.2.1 Alzheimer’s Dementia
Alzheimer’s disease is characterised by two distinct pathologies, intracellular neurofib-
rillary tangles and extracellular amyloid plaques. Neurofibrillary tangles consist of
tau arranged as paired helical filaments or straight filaments. Electron microscopy
reveals both PHFs and SFs to consist of a C-shaped double helical β stacked core
with disordered N- and C- termini projecting away from the core forming the ‘fuzzy
coat’ (Fitzpatrick et al., 2017). Disease filaments are comprised of all 6 tau isoforms
(Fitzpatrick et al., 2017; Goedert et al., 1992).
Braak and Braak show a characteristic pattern of tau pathology distribution in
Alzheimer’s disease that correlates with the clinical presentation of dementia (Bancher
et al., 1993; Braak and Braak, 1991). They identify 6 distinct neuropathological
stages. In early stages (I and II) tau pathology is identified in the transentorhinal
cortex with only mild involvement of the CA1 subfield in the hippocampus. This
then progresses to involve the entorhinal and transentorhinal regions (stage III) with
moderate involvement of the hippocampal formation by stage IV. By stage V and
VI there is severe involvement of the entire hippocampal formation with pathology
extending to the neocortex, involving the striate cortex in the occipital lobe by stage
VI (Fig 1.3) (Braak and Braak, 1991).
Alzheimer’s disease is the most common tauopathy presenting as a gradual decline in
memory and cognitive functions (Cudaback et al., 2015). The onset is insidious with
most patients presenting from age 65. There is a prodromal transitional stage between
ageing and Alzheimer’s referred to as mild cognitive impairment (MCI) characterised
by some memory impairment with preservation of other higher cortical functions (Fan
et al., 2008; Morris et al., 2001; Vuoksimaa et al., 2020). As the degree of neuronal
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Fig. 1.3 Adapted from Vies 2016. Braak and Braak describe 6 distinct neuropathological
stages of tau pathology in Alzheimer’s disease. In stage I-II tau pathology is identified in a
single layer of the transentorhinal cortex. In stage III-IV pathology has now spread to involve
the entorhinal and transentorhinal layer. By stage V-VI the pathology now also involves the
remaining neocortex. These have been shown to correlate with clinical dementia.
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loss is directly correlated to clinical presentation (Gómez-Isla et al., 1997), detection at
this stage is critical for early intervention. Diagnoses is made by a series of cognitive
assessments with cerebrospinal fluid (CSF) biomarkers, such as total tau, phosphory-
lated tau (p-tau181 and p-tau231) and β-amyloid1–42 being increasingly used (Fortea
et al., 2018; Niemantsverdriet et al., 2017). The only current treatment options are
cholinesterase inhibitors and glutamate receptor antagonists (Parsons et al., 2013).
They offer some delay in clinical progression but any symptomatic improvement is
often short lived (Danysz and Parsons, 2003; Winblad et al., 2007). There is no cure.
1.2.2.2 Progressive supranuclear palsy
PSP also known as Steele-Richardson- syndrome is a progressive condition usually
presenting in the mid-60s (Daniel et al., 1995). It is predominantly a movement disorder
classified as a Parkinson plus syndrome (Stacy and Jankovic, 1992). There are three
main subtypes; PSP-Richardson syndrome (PSP-RS), PSP-Parkinson’s (PSP-S) and
PSP-Cerebellar (PSP-C) (Ling, 2016). PSP-RS is the classical and most common
subtype presenting with supranuclear gaze palsy, axial dystonia, postural instability,
parkinsonism and cognitive impairment. In PSP-C there is marked truncal and limb
ataxia, amongst other cerebellar signs, and PSP-P is defined by prominent parkinsonism
(Ling, 2016; Williams, 2006).
While in AD tau deposits are predominantly neuronal, PSP is characterised by the
accumulation of tau aggregates in neurons as well as in glial cells (Kahlson and Colod-
ner, 2015). The presence of the so called ‘tufted astrocytes’, containing dense packed
tau fibrils, is pathognomonic of PSP (Iwasaki et al., 2004; Kahlson and Colodner,
2015). In addition to ‘tufted astrocytes’, there is neurodegeneration accompanied by
the presence of neurofibrillary tangles, neuoropil threads and gliosis. Ultrastructural
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assessment of neurofibrillary tangles in PSP show these to consist of straight filaments
and also identifies globose neuronal tangles (Tellez Nagel and Wiśniewski, 1973). The
principle regions affected by tau pathology are the globus pallidus, subthalamic nuclei
and substantia nigra within the basal ganglia, the dentate nucleus of the cerebellum
and the brainstem nuclei, particularly within the mid brain (Williams et al., 2007). At
later stages dementia can appear and it is associated with the presence of neurofibrillary
tangles with 6 tau isoforms in cortex and hippocampus. A high density of neurofib-
rillary tangles and neuritic threads within the basal ganglia and brainstem is crucial
for a diagnosis of PSP (Hauw et al., 1994). The National Institute for Neurological
Disorders and Stroke (NINDS) criteria require a moderate to severe density of neuronal
tangles and neuritic threads in three out of the following regions; pallidum, subthalamic
nucleus, substantia nigra, or pons, and a low to high density in at least three of the
following sites; striatum, oculomotor complex, medulla, or dentate nucleus (Hauw
et al., 1994).
Clinical diagnosis is more challenging, due to similarities with other neurological
conditions such as Parkinson’s disease. MRI shows significant atrophy of the mid
brain and is often used to support the diagnosis with some studies stating midbrain
volume measurement provides a diagnostic accuracy of 99% in distinguishing PSP from
Parkinson’s disease (Zanigni et al., 2016). Management is symptomatic only with most
parkinsonian features unresponsive to levodopa (Höglinger et al., 2017). Variations
in the MAPT gene have been shown to be associated with PSP. The MAPT gene is
located in a region of extended linkage disequilibrium that is determined by two main
haplotypes, H1 and H2 (Baker et al., 1999; De Silva et al., 2001; Evans et al., 2004;
Liu et al., 2001). Various studies, including genome wide association studies, have
shown a significant association between PSP and the H1 haplotype, and in particular
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the subhaplotype H1c (Baker et al., 1999; Conrad et al., 1997; De Silva et al., 2001;
Höglinger et al., 2011; Myers et al., 2007; Pittman et al., 2005). The H1c haplotype has
been shown to increase MAPT expression, in particular the 4R tau isoform, supporting
a pathological role for tau in PSP (Myers et al., 2007)
1.2.2.3 Corticobasal degeneration
CBD, also part of the Parkinson plus syndromes, can present in a similar manner to
PSP usually between the 5th and 7th decade of life (Williams and Litvan, 2013). There
are progressive movement abnormalities accompanied by higher cortical dysfunction.
Cortical basal syndrome (CBS) consists of patients presenting with motor symptoms
such as akinesia, parkinsonism and rigidity alongside signs of cortical dysfunction and
basal ganglia deficits (Parmera et al., 2016). Several disorders can present with CBS
such as AD and PSP-RS (Parmera et al., 2016). Given the clinical heterogeneity with
several other disorders, a diagnosis of CBD is usually only confirmed at postmortem.
Pathologically there are neuronal and glial tau inclusions including astrocytic plaques
distributed in the cortex, basal ganglia, diencephalon and brainstem (Kouri et al.,
2011). Similar to PSP, CBD is associated with the MAPT H1 haplotype (Pittman
et al., 2005) and tau aggregates formed by filaments containing 4R tau isoforms. Given
the clinical and pathological similarities, it has been proposed that PSP and CBD are
the same disease on different ends of a disease spectrum.
1.2.2.4 Pick’s disease
Pick’s disease is a sporadic disorder characterised by severe atrophy of the frontal,
parietal and temporal lobes and is thus classified as a frontotemporal dementia (Weder
et al., 2007). Patients often present with language impairment and personality change.
There are three main clinical syndromes, which reflect the initial distribution of
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pathology; frontal variant, progressive fluent aphasia and progressive non-fluent aphasia
(Hodges, 2001; Olney et al., 2017; Weder et al., 2007). Pathologically there are spherical
tau neuronal inclusion consisting of straight filaments known as Pick bodies as well as
ballooned neurons known as Pick cells, present in the dentate gyrus and cortex (Olney
et al., 2017; Probst et al., 1996). Pick bodies consist uniquely of 3R tau isoforms
(Probst et al., 1996) as recently confirmed by cryo-electron microscopy (Falcon et al.,
2018). Diagnosis is made by detailed cognitive testing supported by imaging but can
only be truly confirmed post mortem (Hodges, 2001).
1.2.2.5 FTDP-17T
FTDP-17T is a familial disorder which presents usually around the 5th to 6th decade
of life. Alongside Pick’s disease, it is a cause of frontotemporal lobe degeneration
(Olney et al., 2017; Spillantini et al., 1998; Wszolek et al., 2006). Clinically there is
evidence of frontal lobe dysfunction with behavioural or personality change, cognitive
impairment and Parkinsonism (Wszolek et al., 2006). Inheritance is predominantly
autosomal dominant and due to genetic mutations in the MAPT gene (Hutton et al.,
1998; Spillantini et al., 1998). To date over 60 different mutations in MAPT have been
identified (Strang et al., 2019). The discovery of tau mutations in FTDP-17T demon-
strate that abnormalities in tau alone are sufficient to cause pathology and disease
(Spillantini and Goedert, 2013). Most of the mutations identified in FTDP-17T fall
into three major categories, mutations that affect regulation of tau alternative splicing,
missense or deletion mutations that impact on tau interaction with microtubules, or,
favour tau assembly (Ghetti et al., 2015; Goedert et al., 2000; Strang et al., 2019).
Splicing mutations disrupt the alternative splicing of exon 10 resulting in an imbalance
of 3R and 4R tau isoforms, which are normally expressed in equal amounts in the
normal human adult brain (Goedert and Jakes, 2005).
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Missense mutations within the microtubule binding domain impair tau’s ability to
promote microtubule assembly, with some promoting tau aggregation, resulting in a
loss of function and impaired axonal transport (Ingram and Spillantini, 2002; Strang
et al., 2019). Deleterious effects of these mutations have also been attributed to their
causing conformational changes in tau increasing its propensity to form a β sheet
conformation enhancing misfolding and aggregation (Lathuilière et al., 2017).
All the cases with FTDP-17T where the brain has been examined, show tau ag-
gregates that, depending on the MAPT mutation, contain different tau isoforms and
resemble the tau pathology observed in sporadic tauopathies such as PSP, CBD, AD
and Pick disease supporting the involvement of tau in the neurodegenerative process
also in sporadic tauopathies. Although identifying these mutations has increased our
understanding of possible mechanisms in tauopathies, the exact events leading to
formation of neurofibrillary tangles is still poorly understood.
1.2.2.6 Mechanisms in tau pathology
Since hyperphosphorylated tau was identified as a key component of neurofibrillary tan-
gles (Grundke-Iqbal, 1986), this has been one of the most well studied post translational
modifications. Hyperphosphorylation of tau is thought to be a critical and early event
leading to tau misfolding and aggregation (Dorard et al., 2016; Jin et al., 2015; Wang
et al., 2013). Under normal physiological conditions, 80% of tau is bound to micro-
tubules (Šimić et al., 2016). In AD brains, the level of tau phosphorylation is increased
3-4 fold, causing dissociation of tau from the microtubules, altering tau function and
increasing the amount of tau free to aggregate (Wang et al., 2013). Some of the main ki-
nases in the brain that have been found to phosphorylate tau include glycogen synthase
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kinase 3β (GSK3β) (which has been strongly implicated in the pathology of AD), cyclin
dependent kinase 5 (Cdk5), stress activated protein kinase c-Jun N-terminal kinase
(SAPK/JNK) and mitogen activated protein kinases (MAPK) (Dolan and Johnson,
2010; Engmann et al., 2011; Medina and Avila, 2014). The pathogenic events leading
to aberrant tau phosphorylation however remain unknown, although targeting kinase
activity remains an important therapeutic strategy. There is evidence to suggest that
in tauopathies there is a downregulation in phosphatase activity, leading to an imbal-
ance between phosphorylation and dephosphorylation contributing to aberrant tau
phosphorylation (Gong et al., 2000; Park et al., 2018; Sontag et al., 2004). Cleaved tau
fragments have also been identified in regions associated with tau pathology in various
tauopathies with an observed upregulation of caspase 3 (Delobel et al., 2008; Rohn et al.,
2002). Proteolytic cleavage by caspase 3 has been shown to promote tau aggregation
with caspase 3 cleaved tau species being more prone to phosphorylation (Gamblin et al.,
2003; Means et al., 2016; Rissman et al., 2004; Zilka et al., 2006). It has been proposed
that cleavage is an early event in disease development as the presence of truncated tau
has been noted prior to the appearance of significant aggregation (Rissman et al., 2004).
The mechanism by which tau phosphorylation and aggregation lead to neuronal
death is not understood. The loss of tau function, and subsequent dysregulation of
axonal transport, is thought to be only part of the mechanism by which tau pathology
results in neuronal death. Tau knockout mice display a mild phenotype of muscle
weakness (Lei et al., 2014) which suggest that in addition to a loss, there is also a
toxic gain of function involved. In addition to tau, the neuronal microtubule network
is supported by other microtubule associated proteins (MAPs), such as MAP1 and
MAP2 (Kapitein and Hoogenraad, 2015). These should compensate for the loss of
functional tau, however, hyperphosphorylated tau has been shown to not only sequester
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normal tau, but also both MAP1 and MAP2 (Alonso et al., 1997). The resulting
transport defects are known to be a key feature of tauopathies contributing to neu-
rodegeneration, although other mechanisms are also likely to be involved (De Vos
et al., 2008). Microtubules provide tracts for cellular transport of cargo from pre-
and postsynaptic sites, including mitochondria. Both mitochondrial and synaptic
dysfunction have been observed in tauopathies (Rodríguez-Martín et al., 2016; Vogels
et al., 2019). Perturbations in axonal transport could very well be contributing to
this and animal models provide evidence that tau mutations are sufficient to cause
mitochondrial and synaptic dysfunction (Rodríguez-Martín et al., 2016; Yoshiyama
et al., 2007).
1.3 Inflammation and neurodegeneration
Neuro-inflammation, in the context of neurodegeneration is typified by morphological
changes in glial cells, astrocytes and microglia, which become activated secreting low
to moderate levels of inflammatory mediators such as prostaglandins and cytokines
(Woodling and Andreasson, 2016). As this reaction does not differ significantly between
neurodegenerative diseases it was initially thought to be common to various disease pro-
cesses, however, increasing evidence seems to show that neuro-inflammation in itself is
pathogenic (Heneka et al., 2015; Heppner et al., 2015; Metcalfe and Figueiredo-Pereira,
2010). There is a strong correlation between peripheral inflammation and cognitive
deficits (Walker et al., 2017). Systemic infections have long been associated with cogni-
tive impairment with one study showing 60% of elderly patients admitted with infection
related delirium going on to develop dementia at a 3 year follow up compared to 18.5%
of elderly patients without delirium (Rockwood, 1999). Several autoimmune disorders,
which display marked systemic inflammation, are associated with an increased risk
of dementia that in one study was reported to be 51% in the case of systemic lupus
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erythematosus (SLE) (Gendelman et al., 2018). Systemic inflammation damages the
integrity of the blood brain barrier allowing inflammatory cytokines and peripheral
immune cells to cross causing tissue injury and triggering brain specific inflammatory
responses thought to contribute to disease pathology (Abbott et al., 2003; Nation
et al., 2019). Compromises in blood brain barrier integrity secondary to inflammation
have been observed in cardiovascular disease, obesity and type 2 diabetes mellitus,
all risk factors for developing Alzheimer’s (Gustafson et al., 2007; Hawkins et al.,
2006; Pooja Naik et al., 2014). More recently Walker et al., in a longitudinal study
spanning 20 years, showed that higher levels of circulating inflammatory markers in
midlife is associated with cognitive deficits as well as smaller brain volumes later in life,
particularly in regions associated with Alzheimer’s pathology such as the hippocampus
(Walker et al., 2019, 2017).
The pathogenic role of inflammation is further supported by genome wide associ-
ation studies (GWAS) identifying several genes involved in immune system regulation
and inflammatory signalling as being risk factors for Alzheimer’s (Gandhi and Wood,
2010; Jonsson et al., 2013; Kim et al., 2009; Zhang et al., 2015). The first significant
risk gene for late onset AD identified was the apolipoprotein E4 gene, APOE (Bertram
and Tanzi, 2009), a cholesterol transporter which also plays a role in modulating the
neuro-inflammatory response of glial cells (Guo et al., 2004). Since then, several other
risk genes involved in microglial function have been identified, including TREM2,
CD33, SHIP1, CR1 and ABCA7 (Hollingworth et al., 2011; Jonsson et al., 2013; Naj
et al., 2011). Microglia are the resident macrophages in the brain, with numbers
normally tightly regulated (Perry and Holmes, 2014). During chronic inflammation, as
seen in neurodegeneration, there is microglial proliferation and a sustained microglial
response due to microglial priming, leading to neuronal toxicity. Priming is the concept
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that microglia, following exposure to an initial stimulus, subsequent stimuli cause an
exaggerated release of inflammatory cytokine, mediators and prostaglandins (Cun-
ningham, 2013; Heneka et al., 2015; Levi et al., 1998). In early Alzheimer’s, it has
been proposed that the presence of amyloid plaques leads to microglial activation and
priming. In support of this, microglia and activated astrocytes are commonly observed
in post-mortem brains derived from individuals with Alzheimer’s dementia (Kitazawa
et al., 2004). Evidence from mouse models and in vitro work suggests this initial
inflammatory response is beneficial with microglia phagocytosing the abnormal protein
aggregates (Lee and Landreth, 2010; Michaud et al., 2013). However, a sustained
response results in large abnormal microglia that are no longer able to process the
phagocytosed material (Caldeira et al., 2017). This has been demonstrated in vitro,
where cultured microglial display impaired phagocytic function following prolonged
exposure to aggregated amyloid (Caldeira et al., 2017). This reduction in microglial
efficiency is coupled with an increase in inflammatory cytokines and prostaglandin
production thought to aggravate pathology (Kinney et al., 2018; Wang et al., 2015).
More microglia and peripheral macrophages are then recruited to assist the failing
microglia further exacerbating the inflammatory response driving disease pathology
through a feed-forward loop. This inflammatory response, involving the secretion of
cytokines and increased prostaglandin production, has been proposed as a potential
link between amyloid plaques and subsequent development of tau neurofibrillary tangles
(Kinney et al., 2018; Kitazawa et al., 2004), although this has yet to be demonstrated
in humans.
1.4 Prostaglandins
Prostaglandins are key inflammatory mediators belonging to the eicosanoid family,
signalling molecules resulting from oxidation of arachidonic acids (Park et al., 2006).
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Prostaglandins can be constitutively expressed at low levels but their synthesis is greatly
increased in the presence of trauma or inflammatory stimuli resulting in several of the
cardinal signs of acute inflammation. In response to mechanical, immunological and
infectious stimuli, arachidonic acid is released from the cell membrane by phospholipase
A where it is oxygenated by cyclo-oxygenase enzymes (COX) to form prostaglandin H2
(PGH2) (Ricciotti and FitzGerald, 2011). There are two isoforms of COX, COX-1 and
COX-2. COX-1 is constitutively expressed and is responsible for prostaglandin pro-
duction involved in normal physiology and housekeeping functions whereas, COX-2 is
induced under inflammatory conditions and is thus involved in prostaglandin associated
with injury and inflammation (Fitzpatrick, 2004). Non-steroidal anti-inflammatory
drugs (NSAIDs), a group of drugs used to treat conditions characterised by pain
and/or inflammation, function by inhibiting COX enzymes preventing downstream
prostaglandin production (Cryer and Feldman, 1998) as PGH2, a common substrate
for the production of 4 main terminal prostaglandins; PGD2, PGE2, PGF2 and PGI2.
Thromboxane A2, a prostanoid, is also generated through this pathway (Fig. 1.4).
Prostaglandin E2 (PGE2) is the most abundant prostaglandin in the human body and
has multiple physiological and pathological functions including pyrexia, vascular perme-
ability, smooth muscle contraction and relaxation, mucosal protection and modulation
of inflammation (Inoue et al., 2002; Ivanov and Romanovsky, 2004; Kalinski, 2012).
PGE2 is considered an important link between the peripheral immune system and the
brain. PGE2 exerts its effects through four E-prostanoid (EP) receptors, EP1, EP2,
EP3 and EP4 (Andreasson, 2010) which are all G-protein coupled receptors (GPCR).
The differences between each receptor in intracellular signalling pathways and tissue
expression explains the versatility of PGE2 that can exert multiple effects, including
anti- and pro-inflammatory actions, depending on the receptor and its location.
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Fig. 1.4 In response to injury, phospholipase A releases arachidonic acid from the cell
membrane. Arachidonic acid is then oxygenated by COX-1 or COX-2 to form PGH2 which is
then converted by tissue specific isomerases to various prostanoids. NSAIDs work by inhibiting
COX enzymes thus affecting all prostaglandin production. COX = cyclooxygenase, NSAID
= non-steroidal anti-inflammatory drug, PGH2 = prostaglandin H2, PGD2 = prostaglandin
D2, PGF2 = prostaglandin F2, PGE2 = prostaglandin E2, PGI2 = prostaglandin I2.
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1.4.1 The PGE2 EP receptors
Reflecting the broad spectrum of pharmacological and physiological effects of PGE2,
all 4 EP receptors are expressed throughout the body, with particularly high expression
noted in the brain (Andreasson, 2010; Sugimoto and Narumiya, 2007). Each receptor
has a different signal transduction pathways with signaling through the EP1 recep-
tor increasing intracellular calcium levels, EP2 and EP4 increasing cyclic adenosine
monophosphate (cAMP), and EP3 inhibiting this, although splice variants of the EP3
receptor do differ in their actions (Friis et al., 2005; Hatae et al., 2002a; Kim et al., 2002).
The EP1 receptor has been implicated in regulating impulsive behavior under stress.
Matsuoka et al showed that EP1 deficient mice display abnormal behavior traits
including impulsive and aggressive behavior (Matsuoka et al., 2005). This phenotype
is reproducible by pharmacological inhibition of the EP1 receptor. EP1 deficient
mice also display a significant increase in dopaminergic activity (Kitaoka et al., 2007;
Matsuoka et al., 2005). Administration of a dopamine antagonist appeared to reverse
the phenotype suggesting PGE2 modulates dopamine via EP1 (Kitaoka et al., 2007;
Matsuoka et al., 2005). EP1 also functions to regulate cerebral blood flow inducing
vasoconstriction in both peripheral and cerebral vasculature (Jadhav et al., 2004; Norel
et al., 2004; Rutkai et al., 2009). The EP4 receptor, unlike EP1, is responsible for PGE2
induced vasodilation and smooth muscle relaxation (Thibodeau et al., 2016; Yokoyama
et al., 2013). EP4 is expressed in endothelial cells, as well as neurons, mediating vasodi-
lation under normal physiological conditions in various vascular beds in the peripheral
and central circulation (Narumiya and FitzGerald, 2001). Although this is yet to be
demonstrated in neurological disorders, in other systemic disorders such as sepsis and
rheumatoid arthritis, EP4 has been shown to mediate anti-inflammatory effects of
PGE2 through inhibition of inflammatory cytokines and downregulation of adhesion
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molecules on monocytes (Fushimi et al., 2007; Sakamoto et al., 2004; Takahashi et al.,
2002). The EP2 receptor within the CNS is involved in synaptic plasticity and long
term potentiation (Yang et al., 2009). Expressed in the hippocampus, EP2 deficient
mice show significant cognitive deficits and increased anxiety (Savonenko et al., 2009).
In contrast to EP2, PGE2 signalling through the EP3 receptor has been shown to have
detrimental effects on long term potentiation and synaptic plasticity with EP3 being
implicated in postoperative cognitive impairment (Maingret et al., 2017; Xiao et al.,
2018). The distribution of the EP receptors has been mapped in rodent brains, which
show the EP3 and EP4 receptors as being the most widely expressed (Markovič et al.,
2017; Sugimoto and Narumiya, 2007).
1.4.2 The EP3 receptor
The EP3 receptor is encode by the PTGER3 gene which, has 12 coding exons and
uniquely amongst the PGE2 receptors, generates multiple isoforms as a result of
alternative splicing events (Fig. 1.5). These range in size from 365 to 431 amino acids.
Each isoform differs in length due to variations in the carboxyl-terminal tail suggesting
different intracellular downstream signalling effects. To date, 9 isoforms in humans
have been identified, EP3Ia, EP3Ib, EP3II, EP3III, EP3IV, EP3V, EP3VI, EP3e and
EP3f (Kotani et al., 1997). The EP3 receptor is thought to mediate several functions
of PGE2 within the central nervous system, including modulation of neurotransmitter
release through calcium inhibition (Nakamura et al., 2002) however the functional role
of individual isoforms has never been explored. The e isoform has the shortest carboxyl-
terminal tail (6 amino acids beyond the common region). EP3 is thought to play a role
in energy homeostasis and metabolic regulation. EP3 deficient mice have been shown
to not only develop an obese phenotype but also have elevated insulin and leptin levels
with associated insulin resistance (Ceddia et al., 2016; Sanchez-Alavez et al., 2007).
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Fig. 1.5 The EP3 receptor. Alternative splicing of the PTGER3 gene gives rise to species
specific isoforms. Each isoform differs by the intracellular C-terminus (Kotani et al., 1997).
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These mice are hyperphagic and obese on a chow diet. The mechanism is thought to be
through impaired lipolysis and increased adipose tissue deposition. EP3 deficient mice
display greater energy intake during their resting phase mimicking ’night time’ eating.
They show increased sleep fragmentation with inability to consolidate sleep in their rest
periods (Sanchez-Alavez et al., 2007). PGE2 has been shown to play an important role
in sleep regulation. PGE2 when directly injected into the histaminergic tuberomamil-
lary nucleus in the posterior hypothalamus promotes wakefulness (Huang et al., 2003)
which is thought to be mediated through histamine release from the medial preoptic
area and frontal cortex (Huang et al., 2003; McKinley et al., 2015). The disrupted
sleep/wake cycle noted in EP3 knock mice as well as the EP3 expression observed in
the medial preoptic area, suggests an involvement of EP3 signalling. PGD2, another
endogenous prostaglandin that has been shown to bind to the EPR3 receptor, also plays
an important role in arousal and sleep (Hayaishi, 2000; Urade and Hayaishi, 2000, 2011).
The EP3 receptors are G-protein coupled receptors (GPCR) belonging to the rhodopsin-
like family of GPCRs (class A), the largest class of GPCRs (Vassilatis et al., 2003).
These are 7 trans-membrane receptor proteins that, upon ligand binding undergo a
conformational change resulting in an intracellular signalling cascade transduced by a
heterotrimeric G-protein. The heterotrimeric G protein consists of 3 main subunits,
α, β and γ. GPCRs interact directly with the α subunit, of which there are 4 major
classes, Gs, Gi, Gq and G12 (Oka et al 2009). They each interact with different second
messenger molecules, such as cyclic adenosine monophosphate (cAMP), diacylglycerol
(DAG), inositol trisphosphate (IP3) or calcium. The EP3 receptor is unique among the
E-prostanoid receptors due to its ability to couple to multiple Gα subunits. Which α
subunit is determined by the carboxyl-terminal tail of EP3, which differs amongst each
isoform. EP3 receptors signal predominantly via adenyl cyclase inhibition through Gi
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coupling and calcium mobilisation by the Gβγ subunit of the Gi protein however they
have also been shown to couple to Gs promoting cAMP production (Kozaki et al., 2007;
Sugimoto and Narumiya, 2007). Gi coupling in the mouse EP3 receptor isoforms have
been well characterised. Three different isoforms have been recognised, EP3α, EP3γ
and EP3β with varying degrees of constitutive Gi activity thought to be determined
by the length of the carboxy-terminal tail (Hizaki et al., 1997). Indeed, when this is
completely truncated, the receptor remains constitutively active independent of its
agonist (Hizaki et al., 1997). It has been proposed that it is the diversity of isoforms
generated through alternative splicing that create the differing PGE2 dose response
curves. The EP3γ isoform has also been shown to couple to Gs, promoting adenyl
cyclase production. The diversity of isoforms generated through alternative splicing is
thought to contribute to the wide variety of PGE2 effects, however, the physiological
relevance of differing EP3 transduction pathways is yet to be determined. Studies in
the bovine isoforms have shown EP3 Gs and Gi coupling, as well as their coupling to
G13 resulting in neurite retraction and dendritic pruning that are essential components
of memory formation (Katoh et al., 1996). This effect has been shown to be mediated
through activation of small GTPase Rho, one of the few EP3 signalling cascades
associated with a specific biological function.
Studies of EP3 signalling in COS-7 cells show that EP3 has also the ability to modulate
other signalling cascades through intracellular cross talk. Hatae et al have shown that
EP3 can increase adenyl cyclase production from PGE2-EP2 signalling (Hatae et al.,
2002b). This occurs regardless of the carboxy-terminal tail structure and is believed to
be mediated by EP3 induced calcium mobilisation and phospholipase C production
resulting in EP2-induced cAMP formation (Hatae et al., 2002b; Yamaoka et al., 2009).
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1.4.3 Prostaglandin signalling and Neurodegeneration
Inhibiting PGE2 signalling as a means of targeting inflammation in disease has been
an important strategy for a long time but has only recently been seen as a potential
therapeutic target for managing neurodegenerative disease. The role of inflammatory
prostaglandin signalling was first highlighted through epidemiological data showing
that patients taking NSAIDs had a 50% reduction in the risk of developing Alzheimer’s
compared to the general population (McGeer et al., 1996). PGE2, the most abundant
prostaglandin in the CNS, became of particular importance when it was reported to be
significantly elevated in the cerebrospinal fluid (CSF) of patients with early AD and
declining as the disease progresses, suggesting a role in early pathology (Combrinck
et al., 2006). It has also been reported to be elevated in other neurodegenerative dis-
eases, in amyotrophic later sclerosis (ALS) in particular, where it has been found to be
elevated in the CSF of patients as well as in mouse models of disease (Almer et al., 2002).
The COX-2 pathway and prostaglandin signalling have been shown to be neuro-
toxic in several experimental models of neurodegenerative disease where they promote
synaptic toxicity and accelerate neuronal damage (Andreasson, 2010; Bazan et al., 2002;
Liang et al., 2005a; Shi et al., 2012c). Di Giorgio et al demonstrated that astrocytes
release PGE in amyotrophic lateral sclerosis which is directly toxic to motor neurons
(Di Giorgio et al., 2008). In support of this finding, administration of COX-2 inhibitors
has been shown to prolong survival in mouse models of ALS and delays the onset of
motor symptoms (Pompl et al., 2003). The relationship between prostaglandins and
Alzheimer’s is complex with both neuroprotective and neurotoxic effects (Hatae et al.,
2002b; Heppner et al., 2015). Whether PGE2 exerts a neuroprotective or neurotoxic
effect is dependent on which receptor, as well as cell type it acts through (Hatae et al.,
2002b). Wei L et al (Wei et al., 2010) propose that PGE2 signalling via EP1 and
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EP3 exert neurotoxic effects while EP4 is neuroprotective. McChullogh et al showed
that administration of PGE2 to hippocampal neurons protected them from glutamate
toxicity in model of cerebral ischaemia, whilst administration of a specific EP1 and
EP3 agonist elicited excitotoxicity and induced neuronal death (McCullough et al.,
2004). This suggests the other EP receptors must have a neuroprotective role that is
eliminated when PGE2 signals only through EP1 and EP3. The relationship between
neuronal toxicity and signalling via the EP2 receptor is more complex with studies
suggesting a protective role in acute inflammation but a more toxic one in models of
chronic inflammation. In models of focal ischaemia, where neuronal death is induced
through excitotoxicity, PGE2 signalling via EP2 is sufficient to rescue neurons (Liu
et al., 2005). This ability is however eliminated on inhibition of protein kinase A (PKA)
suggesting that this is mediated through EP2 coupling with Gs increasing cAMP
production (Liu et al., 2005). In contrast to this, EP2 has been shown to mediate the
inflammatory oxidative response driving secondary neuronal damage in the context of
chronic inflammation (Liang et al., 2005a, 2008; Montine et al., 2002). In glial cells
activated by an inflammatory stimulus such as LPS or amyloid peptides, EP2 promotes
expression of pro-inflammatory genes leading to an increase in production of reactive
oxygen species resulting in neuronal death (Liang et al., 2005a; Montine et al., 2002;
Shie et al., 2005). In mouse models of ALS deletion of the EP2 receptor prolongs
survival and improves motor symptoms (Liang et al., 2008).
The relationship between prostaglandin signalling and amyloid in Alzheimer’s has been
extensively looked at by the Andreasson Lab in Stanford (Andreasson, 2010; Bazan
et al., 2002; Figueiredo-Pereira et al., 2016; Johansson et al., 2015; Liang et al., 2005a;
Shi et al., 2012c; Wei et al., 2010; Wood, 2012; Woodling and Andreasson, 2016).
They have demonstrated that deletion of the PGE2 EP2 receptor reduces amyloid
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burden in a mouse model of Alzheimer’s (Liang et al., 2005a). They suggest this may
be through increased clearance and/or reduced generation of Aβ42. In the presence
of EP2, they found an increase in β-CTF, a product of amyloid precursor protein
(APP) cleavage by BACE1, suggesting EP2 modulates BACE1 cleavage increasing
generation of Aβ42. EP2 has also been shown to impair microglial function resulting in
reduced Aβ42 clearance (Johansson et al., 2015). Inhibiting microglial EP2 signalling
not only decreases inflammation but in mouse models of disease also rescues memory
(Johansson et al., 2015). The EP3 receptor has also been shown to increase BACE1
activity contributing to Aβ42 generation (Shi et al., 2012c). Post-mortem tissue of
individuals with mild cognitive impairment and Alzheimer’s show an upregulation of
EP3 (Shi et al., 2012c). In control subjects EP3 is expressed at basally low levels in
neurons whilst in individuals with Alzheimer’s, not only is it upregulated, but EP3 is
expressed in glial cells as well as neurons, particularly in areas surrounding amyloid
plaques (Shi et al., 2012c). EP3 has also been implicated in synaptic dysfunction with
Andreasson et al (2012) showing that deletion of the EP3 receptor in a mouse model
of Alzheimer’s rescues loss of pre-synaptic proteins (Shi et al., 2012c).
Unlike amyloid there is less published data on the interaction of prostaglandins and
tau. It is generally accepted that neuro-inflammation plays an important role in the
formation of tau tangles at the onset of the disease. In a review by Metcalfe et al.
(Metcalfe and Figueiredo-Pereira, 2010), they propose a model by which an initial stim-
ulus promotes inflammation. This activates glial cells releasing inflammatory markers,
such as prostaglandins, which induce neurotoxicity. This then leads to impairment of
the ubiquitin/proteasome pathway and activation of caspase which in turn cleaves tau,
an important posttranslational modification which plays an important role in the gener-
ation of paired helical filaments and tangles. Arnaud et al. (2009) demonstrated this in
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cell culture where they induced caspase mediated cleavage of tau using prostaglandin J2.
Results of intervention trials inhibiting PGE2 signalling in humans have been var-
ied. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) trial
randomised patients to either celecoxib (a COX-2 selective inhibitor), naproxen (a
non-selective COX inhibitor) or placebo (ADAPT Research Group et al., 2009). The
study unfortunately had to be terminated early due to adverse cardiac and gastric side
effects, and no benefit was noted at the time the study was terminated with 7 patients
who had been symptomatic at the start of the trial showing a deterioration in their
symptoms. A four year follow up study was however done, which showed individuals
who had been randomised to naproxen in the original study, or, who had previously
been on naproxen prior to the study, had a 60% reduction in their risk of developing
AD compared to the placebo group (Breitner et al., 2011). From this information they
concluded that in order to be beneficial, NSAIDs must be taken for at least 3 years and
early in the course of disease suggesting that prostaglandin signalling is likely to play
a role in the early and pre-clinical stages of disease. This hypothesis is supported by
epidemiological data as well as other intervention trials (McGeer et al., 1996; Szekely
et al., 2004).
1.5 G Protein coupled receptors
As described above all EP receptors are G-protein coupled receptors (GPCRs), a
large family of membrane bound receptors unique to eukaryotes. They have been
remarkably conserved throughout evolution (De Mendoza et al., 2014) and share similar
architecture, all containing seven alpha helical trans-membrane domains connected
by three intracellular and three extracellular loops with an intracellular C-terminus
(Kobilka, 2007). The domains form a pocket within the cell membrane and upon ligand
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binding undergo a conformational change allowing the GPCR to act as a guanine
nucleotide exchange factor (GEF) for an associated heterotrimeric guanine nucleotide
binding protein (G-protein) resulting in an intracellular signalling cascade (Fredriksson
et al., 2003; Kobilka, 2007). The G-protein complex consists of an α and a βγ subunit.
The G-protein is activated on exchange of guanine diphosphate (GDP) to guanosine
triphosphate (GTP) allowing the α subunit to dissociate from the βγ allowing both
subunit to interact with second messengers as determined by the alpha subunit. There
are four main classes of α subunit, Gαs, Gαi, Gαq, and Gα12/13. Gs, or stimulatory
G-protein, stimulates adenyl cyclase converting adenosine triphosphate (ATP) into
cyclic adenosine monophosphate (cAMP) activating cAMP regulated proteins whilst
Gi, has the opposite effect, inhibiting adenyl cyclase production, reducing cAMP
levels (Gurevich and Gurevich, 2017). Gq activates phospholipase C which releases
inositol-1,4,5-triphosphate (IP3) and diacyl glycerol (DAG) from the cell membrane
by hydrolysing membrane phospholipids. These in turn increase intracellular calcium.
The fourth class of G-protein, G12/13 function by activating GEFs for Rho small
GTPases. Some GPCRs are promiscuous and can couple to several different classes of
G-protein (Kostenis et al., 2005; Maudsley et al., 2005; Okashah et al., 2019). GPCRs
are deactivated upon hydrolysis of GDP to GTP by intrinsic GTPase activity within
the Gα subunit allowing the α and βγ subunits to bind again terminating the signalling
cascade. Regulators of G-protein signalling (RGS) are proteins that have the ability
to accelerate this process by influencing the GTPase activity (De Vries et al., 2000).
In the presence of a continuous stimulus, the receptor can be desensitised by binding
to arrestin (Black et al., 2016). The receptor is first phosphorylated by G-protein
coupled receptor kinases (GRK) allowing arrestins to bind to the cytoplasmic face
of the receptor blocking any further G-protein coupling. Arrestin then directs the
receptor for internalisation where it is packaged in endosomes and either recycled, back
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to the cell membrane, or directed to lysosomes for degradation (Latorraca et al., 2018;
Lohse and Hoffmann, 2014).
Fig. 1.6 GPCRs are coupled to a heterotrimeric G protein consisting of an α and βγ. On
activation by ligand binding, the G-protein α subunit dissociates from the βγ subunit allowing
them to interact with second messengers signalling a signalling cascade. GPCRs couple to
four main classes of G-protein determined by the α subunit; Gαs, Gαi, Gαq and Gα12/13.
Gαs stimulates adenyl cyclase which converts ATP to cAMP. Gαi opposes this, inhibiting
adenyl cyclase production. Gαq activates phospholipase C, hydrolysing PIP2 from the cell
membrane releasing IP3 and DAG which in turn increase calcium levels and activate PKC
which continues the signal transduction cascade regulating various downstream proteins.
Gα12/13 activates RhoGEFs. ATP = Adenosine triphosphate, cAMP = cyclic Adenosine
monophosphate, PIP2 = Phosphatidylinositol 4,5-bisphosphate, DAG = Diacylglycerol, IP3
= Inositol triphosphate, Ca2+ = Calcium, PKC = Protein kinase C, RhoGEF = Rho guanine
nucleotide exchange factor.
GPCR’s are responsible for multiple biological processes in humans mediating re-
sponses to hormones and neurotransmitters (Betke et al., 2012; Neubig and Siderovski,
2002). Their extensive involvement in pathophysiological processes make them one of
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the most studied drug targets with GPCR modulators increasingly used as potential
therapy for central nervous system disorders (Hauser et al., 2017; Neubig and Siderovski,
2002). Due to their expression on the plasma membrane they are easily accessible.
Recent advances in structural biology and receptor pharmacology have also increased
our ability to modulate these receptors making them a highly druggable and an ideal
therapeutic target.
GPCRs are one of the most promising therapeutic targets for neurological disorders
(Hauser et al., 2017; Neubig and Siderovski, 2002) and there is increasing awareness
of the role they are likely to play in dementia and other neurodegenerative diseases
(Hauser et al., 2017; Huang et al., 2017; Neubig and Siderovski, 2002; Thathiah and De
Strooper, 2009). They play a wide role in the peripheral and nervous system with over
90% of non-sensory GPCRs being expressed in the brain (Gainetdinov et al., 2004).
GPCRs fine tune many critical functions within the central nervous system and act
as receptors to several neurotransmitters such as glutamate, GABA, serotonin and
dopamine (Betke et al., 2012). Disrupted cholinergic, glutamatergic, adrenergic and
serotonergic neurotransmission is seen in Alzheimer’s and, to date, targeting this group
of GPCRs has been the predominant focus of therapeutic intervention (Dall’Igna et al.,
2007; Heaney and Kinney, 2016; Teng et al., 2010; Zhu et al., 2015).
The metabotropic glutamate receptors (mGluR), a family of GPCRs that modu-
late the neurotransmitter glutamate, have been implicated in the development of
Alzheimer’s (Thathiah and De Strooper, 2011) with pharmacological inhibition of
mGluR5 alleviating amyloid pathology and improving cognitive function in a mouse
model of Alzheimer’s (Hamilton et al., 2014). The mGluR5 is now considered to act
as a receptor for β-amyloid modulating toxicity and neuronal death (Beraldo et al.,
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2016; Hamilton et al., 2014). The muscarinic acetylcholine receptors M1 and M3 when
stimulated promote the secretion of soluble amyloid precursor protein (sAPP) with
subsequent reduction in insoluble βamyloid generation (Lee et al., 1995). This effect is
blocked by M1 and M3 receptor antagonists. Furthermore, M1 acetylcholine receptors
play an important role in learning and memory consolidation making the muscarinic
acetylcholine receptors an attractive target for therapeutic intervention (Scarpa et al.,
2020). The β2 adrenergic receptor has also been implicated in disease. Deletion of
the receptor in a mouse model of tauopathies results in amelioration of tau pathology
(Wisely et al., 2014). This is associated, and thought to be mediated, by a reduction in
tau kinase activity, specifically GSK3β and CDK5 (Wisely et al., 2014). Other GPCRs
that have been implicated in disease pathology, and proposed therapeutic targets,
include the serotonin receptors (Woods et al., 2012; Yamazaki et al., 2015; Zhang et al.,
2013, 2015) and orphan receptors, such as G-protein coupled receptor 3 (GPR3), where
the endogenous ligand is unknown (Huang et al., 2015; Thathiah and De Strooper,
2009). The presence of amyloid pathology has also been shown to generate a toxic
environment thought to induce GPCR oligomerisation and sequestration of the Gα
subunit impairing GPCR signalling (AbdAlla et al., 2009; Suo et al., 2004). This has
been shown with the angiotensin 2 receptor, with the resulting reduction in receptor
activity correlating well with hippocampal neurodegeneration and tau phosphorylation
(AbdAlla et al., 2009). Alterations in gene expression profiles between controls and
patients with Alzheimer’s for a number of GPCRs has been shown (Blalock et al., 2004).
Alongside GPCRs that regulate neurotransmission, differences are noted in expression
profiles of GPCRs involved in hormone regulation and inflammation (Blalock et al.,
2004). Changes observed correlated with the pathological severity of disease (Blalock
et al., 2004).
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GPCRs have been traditionally targeted with agonists and antagonists but with
recent advances it has become increasingly clear that allosteric ligands altering selective
downstream signals, but not all, will allow for precisely targeted interventions making
GPCRs particularly attractive therapeutic targets (Conn et al., 2009; Nickols and
Conn, 2014; Zhao et al., 2016).
1.6 Data leading to project
This project emerged from a collaborative study between the Farooqi (Metabolic
Research Laboratories, Institute of Metabolic Science, University of Cambridge) and
Spillantini (Department of Clinical Neuroscience, University of Cambridge) laboratories.
The PGE2 EP3 receptor is involved in multiple biological processes including en-
ergy homeostasis. Selective deletion of the EP3 receptor in mice leads to obesity
(Ceddia et al., 2016). As there is a high degree of conservation between the pathways
that regulate energy balance across species, as part of the genetics of obesity study,
it was hypothesised that disruption of EP3 in humans might also lead to obesity. To
identify genetic variants in the gene encoding EP3, PTGER3, intron/exon boundaries
were sequenced in 300 individuals of mixed European descent with severe, early onset
obesity (mean body mass index (BMI) standard deviation score 3.5; age of onset<10
years) who had been recruited to the Genetics of Obesity Study (GOOS) (Farooqi
et al., 2003). The data on individuals with severe obesity was compared to 1400
control individuals from a large UK population-based study, the Ely study (Williams
et al., 1995) and publicly available exome sequencing data. A frameshift mutation
affecting a primate specific isoform of the EP3 receptor, EP3Re, was identified. As
EP3 localises to neurons, select regions within the human brain were stained with
the EP3Re antibody to determine the receptors expression. Whilst staining what had
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been identified as a control brain, it was noted that some of the neurons contained tau
neurofibrillary tangles which were being identified by the EP3Re antibody suggesting
a possible association between the EP3Re isoform and tau tangles. Although the
frameshift mutation in severely obese individuals was later also identified in control
subjects, the finding of a PGE2 receptor identifying with tau tangles warranted further
investigation and is the main focus of this project.
1.7 Aim of the project
With epidemiological and experimental data suggesting a role for PGE2 in Alzheimer’s
and primary tauopathies, this incidental finding could suggest a mechanism linking
prostaglandin signalling with tau pathology through this primate specific EP3Re
isoform and thus needed to be further explored. The hypothesis was that in early
stages of Alzheimer’s and tauopathies, following an initial inflammatory insult, such as
generation of amyloid or abnormal tau processing, PGE2 signals via EP3Re, which in
turn interacts with tau influencing tau hyperphosphorylation, aggregation and tangle
formation leading to disease progression.
To determine this, we set out with 3 main objectives:
1. To establish the distribution and function of EP3Re in the human brain
2. To explore the physical interaction between EP3Re and tau. Does EP3Re
co-localise with tau neurofibrillary tangles in disease?
3. To understand the functional role of EP3Re in tauopathies. Is the receptor
contributing to tau pathology?
This study will show the distribution of the human specific EP3Re receptor not
previously described as well as identify the second messenger through which it functions.
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In Alzheimer’s disease tau pathology has been shown to correlate better with the level
of cognitive impairment (Braak and Braak, 1991; Brier et al., 2016) suggesting that
targeting neurofibrillary tangles, has the potential to alter disease progression. As
there is little published data on the pathway linking PGE2, EP3 and tau, this makes
the project novel with significant implications for future treatment strategies.
Chapter 2
MATERIAL AND METHODS
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2.1 Materials
2.1.1 Antibodies
Antibodies used for immunohistochemistry, immunofluorescence, immunoblotting and
immunoprecipitation can be found below in Tables 2.1 and 2.2.
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Table 2.1 List of primary antibodies
2.1.2 Human brain samples
Post mortem paraffin embedded sections were obtained from 5 Alzheimer’s patients, 5
PSP patients and 5 age and gender matched controls from the Cambridge Brain Bank.
Diagnosis was made based on the clinical presentation as well as the pathology on
autopsy. Three serial sections from 15 different brain regions from each subject were
used for this study. Frozen tissue was also obtained from the same regions.
Frozen tissue for a Parkinson’s disease patient was obtained from the Oxford brain
bank.
Ethical approval was obtained for the use of all human tissue presented in this thesis.
Clinical characteristics of patients can be seen in Tables 2.3 and 2.4.
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Table 2.2 List of secondary antibodies















































Table 2.3 Characteristics of control brain samples
Case reference
number
Gender Age (y) Cause of death1
NP16.28 M 68 Pneumonia IHC, WB
NP16.59 F 60 Influenza A IHC
NP16.154 M 35 Hodgkin’s lymphoma IHC
NP16.184 F 69 Congestive Cardiac Failure IHC, WB
NP16.202 M 73 Rectosigmoid carcinoma IHC, WB
Table 2.4 Characteristics of case brain samples
Case reference
number
Gender Age (y) Diagnosis
NP16.42 M 78 PSP IHC, WB, IP, PLA, EM
NP16.69 F 79 PSP IHC, WB, IP, PLA, EM
NP16.102 F 73 PSP IHC, WB, IP, PLA
NP16.178 F 73 PSP IHC, WB
NP15.293 F 65 PSP IHC, WB
NP16.41 F 91 AD IHC, WB, IP, PLA, EM
NP16.115 M 78 AD IHC, WB
NP16.116 M 66 AD IHC, WB, IP, PLA, EM
NP16.216 M 82 AD IHC, WB
NP16.242 M 89 AD IHC, WB, IP, PLA, EM
NP133.2014 M 80 PD EM
NP11.85 M 70 PD IHC
NP13.74 M 60 MSA IHC
NP16.163 F 70 Pick’s disease EM
NP11.85 M 70 FTLD-TDP43 IHC
PSP - Progressive supranuclear palsy, AD - Alzheimer’s dementia, PD - Parkinson’s disease, FTLD -
Frontotemporal lobar degeneration, TDP43 - TAR DNA-binding protein 43, MSA - Multiple system
atrophy, IHC - immunohistochemistry, WB - western blotting, IP - immunoprecipitation, PLA -
proximity ligation assay, EM - electron microscopy.
1Cause of death as listed on the death certificate.
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2.1.3 P301S mouse sections
Paraffin embedded sections taken from homozygous P301S tau transgenic mice and
wild type C57/BL6J mice were kindly provided by Dr Jack Brelstaff. P301S tau mice
are a transgenic model of tauopathy that express mutant P301S tau under a Thy1
promoter (Allen et al., 2002). Pathologically, the P301S mice display widespread tau
pathology both in the peripheral and central nervous system. The clinical phenotype
consists of progressive motor impairment, neuronal death and cognitive decline which
starts at around 3 months and progresses up to 5 months when the mice have to be
killed due to the motor phenotype (Hampton et al., 2010). All brain sections used
were from mice sacrificed at 5 months of age.
2.1.4 cDNA constructs
The following cDNA constructs were used for experiments:
2.1.4.1 PTGER3
cDNA constructs for PTGER3 were created and provided by Elena Avale from the
Farooqi laboratory (IMS, University of Cambridge).
cDNA encoding the wild type splice variant 8 (e isoform) of the human PTGER3
gene was synthesised by GenScript (Piscataway, NJ, USA). This was N-terminally
fused with FLAG-tag and ligated into pcDNA3.1 using EcoRI/XhoI sites cloned into
pCMV-scipt (Stratagene, CA, USA). All constructs were verified by DNA sequence
analysis by MWG-Biotech AG (Ebersberg, Germany).
2.1.4.2 MAPT and MAPT with the P301S point mutation
cDNA constructs for MAPT (0N4R) with a C-terminal venus tag and MAPT with the
P301S point mutation were kindly donated from the McEwan laboratory (Dementia
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Research Institute, University of Cambridge). These were created as described in
McEwan et al. (2017).
2.1.5 Reporter gene vectors
Constructs used for Luciferase reporter gene assays were provided by Jacek Mokrosinski
(IMS, University of Cambridge) and originally obtained from Agilent.
• pNFAT-Luc: construct encoding Nuclear Factor of activated T cells (NFAT)
binding sequence upstream of a luciferase reporter
• pFA2-CREB: Plasmid expressing the N-terminal 280 amino acid of cAMP Re-
sponse Element Binding protein (CREB) fused to Gal4 DNA binding domain
• Gαδ6qi4myr: Construct encoding chimeric G-protein as described by Kostenis
et al 2001. Mutant Gαq construct lacking the characteristic highly conserved
six amino acid extension bearing four residues of G4αi sequence at the extreme
C-terminus, replaced with the corresponding Gαq sequence.
• p-FR-Luc: Plasmid containing a synthetic promoter with 5 tandem repeats of
the yeast GAL4 binding sites that control expression of the Photinus pyralis
(American firefly) luciferase gene.
For plasmids used in Nanobit® protein-protein interactions please see section 2.2.18.
For full sequences of constructs see Appendix 1.
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2.2 Methods
2.2.1 Immunohistochemistry
Human and mouse brain paraffin embedded sections were treated in xylene overnight
to remove the paraffin. They were then rehydrated through an ethanol series 100%,
95%, 70%, 50% and washed 3x in PBS (pH7.4). Sections that were destined to be
stained for EP3e at this stage underwent heat induced epitope retrieval in 10mM
citrate buffer (pH6) (Hussaini et al., 2013). The sections were then quenched for 20min
in buffer containing 20% methanol, 10% hydrogen peroxide and 70% PBS for 1hr, and,
the non-specific background blocked with 1hr incubation in 5% horse serum (Vector
Laboratories) at room temperature. Sections were then incubated in the appropriate
primary antibody in PBS with 0.3% Triton x100 overnight at 4°C. Sections were
then washed 3 times in PBS containing 0.3% Triton x100, incubated in appropriate
biotinylated secondary antibody at room temperature for 2hrs, then incubated for
1hr at room temperature with Avidin Biotin Complex (ABC) staining kit reagent
(Thermoscientific), washed 3 times in PBS containing 0.3% Triton x100, and, finally
developed using DAB peroxidase (HRP) (Vector laboratories) according to substrate
kit instructions. Some sections were counterstained with Cresyl Violet to visualise
tissue morphology, rehydrated through an ethanol series then cleaned in xylene, and,
mounted in DPX mounting medium. Sections were examined using an Olympus BX50
microscope and images were captured by a QImaging Retiga 2000R CCD camera.
2.2.2 Antibody pre-adsorption test
Anti-PTGER3 antibody was incubated in 1mg/ml PTGER3 blocking peptide (Abcam
151180) or tau aggregates obtained by sarkosyl extraction, followed by guanidinium
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treatment and de-phosphorylation (see 2.2.4 and 2.2.5) for 2hr at room temperature.
The adsorbed antibody was then used as the primary antibody for immunohistochem-
istry and western blotting to ensure specificity of the staining and of the antibody.
Other controls performed to ensure staining specificity were omission of primary anti-
body and staining of mouse brain tissue sections considering that the antibody was
considered to recognise specifically human PTGER3.
2.2.3 Protein extraction
Total protein was extracted from different brain regions or cells for experiments in
radioimmunoprecipitation (RIPA) buffer ( 50mMTris-HCl, 150mM Sodium chloride,
1% Nonidet P-40, 0.5% 10%Sodium deoxycholate, 0.1% 10%SDS) containing protease
inhibitors (Roche Diagnostics) and phosphatase inhibitors (Sigma). For cell extraction,
cells were placed on ice, rinsed in PBS and lysed in RIPA buffer. For brain tissue,
100mg of tissue was homogenised in RIPA buffer on ice. The cell lysate, or brain
homogenate was then centrifuged for 20min at 4°C at 22000g. The supernatant was
then collected and stored at -20°C or used immediately for immunoblotting.
2.2.4 PHF tau extraction
Insoluble filamentous tau extraction was done using the method described by Goedert
et al (Goedert et al., 1992). Briefly, 100-200mg of post mortem AD or PSP frozen
brain tissue was homogenised in 1-2ml of A68 buffer (10mM TRIS-HCl pH7.4, 0.8M
NaCl, 1mM EGTA, 10% sucrose) on ice. The homogenate was then spun at 22000g
for 20min at 4°C and the supernatant collected. The pellet was then re-suspended
in half the original volume of A68 buffer, spun again at 22000g for 20min at 4°C,
and the 2 supernatants combined. The pooled supernatant was then incubated with
N-Lauryl-sarkosine (Sigma), at a final concentration of 1%, for 1hr with rotation at
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room temperature before being spun at 100000g for 1hr at 4°C. The supernatant was
removed and kept as the soluble fraction, whilst the pellet was reconstituted in 50mM
TRIS-HCl pH7.4 using 0.1ml/mg of initial tissue weight. The insoluble tau was either
used immediately or stored at -20°C.
2.2.5 Alkaline phosphatase and guanidinium treatment
4 M Guanidine hydrochloride (Applichem) was added to sarkosyl-insoluble tau in equal
volumes and the solution was left for 1hr at room temperature to unravel the tau
filaments. The mixture was either dialysed overnight at 4°C against 100ml 50mM
TRIS-HCl pH8.2, 0.1mM EDTA and 1mg/ml PMSF or centrifuged at 100000g for 1hr
at 4°C with the pellet re-suspended in 50mM TRIS-HCl pH 7.4, in order to remove
the guanidine hydrochloride. E.Coli Alkaline phosphatase 18U/ml (Sigma-Aldrich) in
50mM TRIS-HCl pH 7.4 and 5mM MgCl2 was added to the solution which was left
for 4hr at 65°C to de-phosphorylate tau from the disassembled filaments. The solution
was either used immediately or stored at -20°C.
2.2.6 Immunoprecipitation
Immunoprecipitation was done using DynabeadsTM protein G (Invitrogen) following
the manufacturers protocol. Antibodies recognising either total tau (HT7 or Dako
tau – see 2.1.1) or the EP3e receptor (see 2.1.1) were bound to the DynabeadsTM by
adding 10 µg of antibody diluted in 200 µl of PBS with 0.02% Tween20 to the beads
and incubating the solution for 2hr at 4°C with rotation. For the negative controls,
appropriate sera, based on the origin of the antibody, was added to the beads with no
antibody present. To avoid co-elution of the antibody, the antibody was crosslinked to
the beads using 100mM BS3 (Thermoscientific) in conjugation buffer (20mM sodium
phosphate, 0.15mM NaCl pH 7-9) for 30min at room temperature. The solution was
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then quenched in 12.5 µl of quenching buffer (1M TRIS-HCl pH 7.5) for 15min at
room temperature before the beads were washed in PBS with 0.02% Tween20 and
50 µg of PHF tau or soluble protein extract from AD brain added. The sample was
left at 4°C overnight with rotation. The target antigen was then eluted by heating
the beads-antibody-antigen complex for 10mins at 70°C in 20 µl of premixed NuPage
sample buffer with NuPage sample reducing buffer (Invitrogen). The supernatant
was then loaded onto a polyacrylamide gel (10%) for western blot (see 2.2.7), protein
transferred onto a nitrocellulose membrane, and the blot probed for either the presence
of tau or EP3Re.
2.2.7 Immunogold negative stain electron microscopy
2.5 µl of insoluble filamentous tau, extracted as described in 2.2.4, was placed on
glow discharged carbon coated copper grids (Electron Microscopy Sciences). Some
filaments were treated with pronase at this stage. All samples were then blocked for
10min in blocking buffer (0.1% cold water fish skin gelatin in PBS). Primary antibody
recognising the EP3Re receptor was prepared (1:50 diluted in blocking buffer) and
applied to the carbon grids for 1hr. Excess antibody solution was blotted with filter
paper and grids were washed in blocking buffer. Grids were then placed in secondary
antibody (goat anti-rabbit IgG conjugated to 10nm gold diluted 1:20 in blocking buffer)
for 1hr, washed in water and 4 µl of 2% of uranyl acetate placed on each grid. Excess
uranyl acetate was blotted with filter paper leaving a thin film of solution and grids
left to air dry. Electron microscopy images were acquired on a Tecnai G2 Spirit at
120kV with a Gatan Orius SC200B detector.
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2.2.8 Cell culture
2.2.8.1 SHSY5Y cells
SHSY5Y cells are a human neuroblastoma cell line derived from a subclone of the
parental cell line, SK-N-SH generated from a bone marrow biopsy from a metastatic
neuroblastoma (Shipley et al. 2016). When undifferentiated they express markers of im-
mature neurons and have been used in both differentiated and undifferentiated states to
study neurodegenerative disease (Shipley et al. 2016). SHSY5Y cells were maintained
in GibcoTM Roswell Park Memorial Institute medium (RPMI) 1640 (Life technologies)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 1% L-glutamine (Life
Technologies), 100U/ml penicillin and 100 µg/ml streptomycin. Cells were passaged
upon reaching 90% confluence (approximately every 3 days). Cells were kept in T75
flasks (Thermoscientific) and plated onto 6 or 12 well plates for experiments. SHSY5Y
cells were used for microscopy and western blotting.
In some experiments differentiated SHSY5Y cells with a neuronal phenotype were
required. Differentiation of cells was induced by lowering FBS in maintenance media
to 1% and addition of 10µM all trans retinoic acid (Sigma). Cells were kept in differ-
entiation media for 10 days prior to performing experiments with media changed every
3 days.
2.2.8.2 HEK293 cells
Human embryonic kidney 293 cells are a line originally derived from a human embryonic
kidney cell transformed with sheared fragments of human adenovirus type 5 DNA
(Graham et al., 1977). They have been extensively used for expressing recombinant
proteins due to their ease of transfection and efficient translation and protein processing
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(Thomas and Smart, 2005). These made them an ideal cell line for functional studies
of the EP3e receptor. They display a neuronal lineage phenotype and are most likely
of adrenal origin (Stepanenko and Dmitrenko, 2015). HEK293 cells were maintained in
Dulbelco’s modified Eagle Media (DMEM) (Life Technologies) supplemented with 10%
fetal bovine serum (Invitrogen), 1% L-glutamine (Life Technologies), 100U/ml penicillin
and 100 µg/ml streptomycin. HEK293 cells were passaged upon reaching 90% confluence
(approximately every 3 days) and maintained in T75 flasks (Thermoscientific). For
experiments cell were plated onto 6, 12 or 96 well plates (Perkin Elmer). HEK293 cells
were used for signaling assays, microscopy and western blotting.
2.2.8.3 COS7 cells
COS7 (CV-1 in Origin with SV40 genes) are a cell line derived from CV-1 simian
cells transformed by an origin defective mutant of SV40. They are commonly used
as a mammalian production cell for recombinant proteins. They display a fibroblast
phenotype. COS7 cells were maintained in low glucose DMEM (Life Technologies)
supplemented with 10% fetal bovine serum (Invitrogen), 1% L-glutamine (Life Tech-
nologies), 100U/ml penicillin and 100 µg/ml streptomycin. COS7 cells were passaged
on reaching 70% - 80% confluence and maintained in T75 flasks (Thermoscientific).
For experiments cells were plated onto 96 well plates. COS7 cells were used for cAMP
assays.
2.2.8.4 Induced Pluripotent stem cells (iPSC)
Human iPSC derived neurons were used for experiments to understand the functional
significance of EP3Re signalling and its possible relationship with tau. iPSCs generated
from individuals with familial Alzheimer’s and other tauopathies have been shown in
several studies to recapitulate several of the pathological features of the disease making
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them an ideal way of studying the EP3e receptor in pathological conditions in vitro
(Iovino et al., 2015; Muratore et al., 2014; Shi et al., 2012b).
CRL and N279K lines had already been established in the lab from a healthy newborn
male’s fibroblasts (Iovino et al., 2015; Vallier et al., 2009) and from a 43 year old male
respectively.
The following iPSC derived neural stem cells were obtained from Axol generated from
the dermal fibroblast of a 64 year old female;
• hN9 (ax0019) control line
• hN9 MAPT P301L (ax0325) isogenic line edited with CRISPR-Cas9 technology
to introduce the P301L mutation (CCG>CTG) into the MAPT gene. This line
is heterozygous for the P301L mutation where one allele contains the mutation
and the other allele is wild type at the locus.
Maintaining neural stem cells
Maintenance and neuronal differentiation were done according to the Shi protocol
(Shi et al., 2012b). Neural stem cells were maintained in neural maintenance media
(N2B27 media) consisting of a 1:1 mixture N-2 and B-27 containing media. N2 medium
consists of Dulbecco’s Modified Eagle Medium Nutrient mixture F-12 (DMEM/F-12)
GlutaMAX (GibcoTM), N2, 5 µg/ml insulin (Sigma), 1mM L-glutamine (GibcoTM),
100µM non-essential amino acids (GibcoTM), 100µM 2-mercaptoethanol (GibcoTM),
50U/ml penicillin (GibcoTM) and 50mg/ml streptomycin (GibcoTM). B-27 containing
medium consists of Neurobasal medium (GibcoTM), 1%B-27 with vitamin A (GibcoTM),
200mM L-glutamine (GibcoTM), 50U/ml penicillin (GibcoTM) and 50mg/ml strepto-
mycin (GibcoTM). Media was supplemented with fibroblast growth factor (FGF2)
(20ng/ml) and epidermal growth factor (EGF) (20ng/ml) (Peprotech) to prevent cells
differentiating. Cells were plated in 12 well plates coated with 0.01%poly-L-ornithine
(Sigma) followed by 20 µg/ml laminin (Sigma) and media changed every 2 days. Cells
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were passaged when confluent, approximately every 4 days using accutase and plated
in N2B27 media supplemented with 10µM ROCK inhibitor (Tocris Bioscience).
Neuronal differentiation
Once cells had been expanded sufficiently to perform experiments, FGF and EGF were
withdrawn from N2B27 medium and cells treated with µM N-[N-3,5-Difluorophenacetyl)-
L-alanyl]-S-phenylglycine t-butyl ester (DAPT)(Tocris Bioscience) for 2 media changes.
Neurons were maintained in N2B27 media which was changed every other day.
2.2.9 Transfection
Cells were plated in either 96 or 12 well poly-l-lysine coated plates upon reaching
70-90% confluence. Twenty four hours later, normal plating media was replaced with
Opti-MEM (GibcoT M). Plasmid DNA-lipid complexes were prepared consisting of
a 1:1 ratio of Lipofectamine 2000 (Invitrogen) in Opti-MEM at a concentration of
20 µl/ml and 30pmol - 150pmol of cDNA, depending on the DNA construct, diluted
in Opti-MEM media. The DNA-lipofectamine complex was left to incubate for 5min
before being added to cells. Transfection was terminated 5hr later by changing from
Opti-MEM to serum free plating media and cells were used for experiments 24hr later.
2.2.10 siRNA
In order to establish if any changes observed in the SHSY5Y cells following activation
of the EP3 receptor were due to the EP3Re isoform, EP3Re was silenced using siRNA
delivered in lipofectamine.
The following siRNA duplexes were obtained from Qiagen;
• PTGER3 – Predesigned siRNA directed against human PTGER3 (NM_198718)
(Hs_PTGER3_17)
target sequence 5’-CAGCTGAGTTTGTGACTCTAA-3’
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sense strand 5’-GCUGAGUUUGUGACUCUAATT-3’
antisense strand 5’-UUAGAGUCACAAACUCAGCTG-3’
• All stars negative control – validated non-silencing siRNA with no known homol-
ogy to any mammalian gene and of unknown sequence
For siRNA reverse transfection was performed using Lipofectamine RNAiMAX (Invit-
rogen). To establish the ideal concentration of siRNA, 30pmol to 150pmol of siRNA
was mixed with 6µl of Lipofectamine RNAiMAX in 500µl of Opti-MEM medium
(Invitrogen) in a 6 well plate. The complex was left to incubate for 10-20mins at room
temperature before 2.5ml of RPMI media without antibiotics containing 0.3 x 106
SHSY5Y cells was added to each well making a final concentration of 10-50nM siRNA
per well. Seventy-two hours after transfection, cells were lysed in RIPA buffer and
expression of the EP3e receptor analysed using western blotting. If experiments were
to be performed with the selective EP3R agonist Sulprostone (Cayman Chemicals),
72hrs after transfection the media was changed to serum free media and cells were
exposed to Sulprostone 24hrs later.
2.2.11 Immunofluorescence
SHSY5Y, HEK293 or human iPSC derived neurons were plated onto 12 well plates on
coverslips coated in Poly-D-lysine (Sigma) at a concentration of 10 µg/ml. Prior to
staining, cells were washed in Dulbecco’s Phosphate Buffered Saline (DPBS) (Sigma-
Aldrich) and fixed on ice using methanol. They were then gently rinsed in PBS
followed by PBS containing 0.3% Triton x100 to permeabilise cells. For reducing
non-specific background, cells were incubated in 5% horse serum (Vector Laboratories)
for 1hr and then incubated with the appropriate primary antibody overnight at 4°C.
Cells were then washed in PBS containing 0.3% Triton x100 before being incubated
with the appropriate Alexa fluor conjugated secondary antibody for 2hrs at room
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temperature followed by a 10min incubation in 4,6-diamidino-2-phenylindole (DAPI)
(Roche diagnostics) to visualise nuclei. Coverslips were mounted onto glass slides using
FluorSave mounting medium (Calbiochem) and visualised using Leica DMI4000B and
images captured using the Leica DFS3000G camera or Leica SP8 Confocal microscope.
For immunofluorescent staining of paraffin embedded human tissue, sections were
treated in autofluorescence eliminator reagent (Merck) as per the manufacturers protocol
to eliminate lipofuscin-like autofluorescence. Briefly, following immunofluorescence
histochemistry, sections were immersed 5min in PBS, 70% ethanol for 5min and finally
autofluorescence eliminator reagent (Merck) for 5 min. Sections were then immersed
in 3 changes of 70% ethanol for 1min each time and then mounted using FluorSave
mounting medium (Calbiochem).
2.2.12 Proximity ligation assay (PLA)
Proximity ligation assays were performed on paraffin embedded tissue and human
iPSC derived neurons to determine the extent of the interaction between EP3Re and
Tau. Primary antibodies are applied to detect EP3Re and tau followed by a secondary
probe to detect the primary antibodies. If the two proteins are within close proximity
to one another, a signal is detected. PLA were done using a DuolinkTM PLA kit as
per manufacturers protocol. iPSC derived neurons were fixed on ice in methanol and
permeablised with PBS-0.3%Triton x100 whilst paraffin embedded sections underwent
heat induced antigen retrieval in citrate buffer pH6 before being permeablised with
PBS-0.3%Triton x100. Samples were blocked for 1hr at 37°C with DuolinkTM blocking
solution then incubated in primary antibodies diluted in DuolinkTM antibody diluent
overnight. Samples were washed in wash buffer, provided by the manufacturer and
incubated in PLUS and MINUS probes directed against mouse or rabbit antibodies
for 1hr at 37°C. Following incubation in ligase for 30min at 37°C, the signal was
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amplified using a polymerase. Samples were kept for 100min in polymerase diluted in
amplification buffer as provided by the manufacturer at 37°C, washed in wash buffer
and mounted in DuolinkTM In Situ mounting media with DAPI. Slides were left at
37°C for at least 15min before being visualised using Leica DMI4000B and images
captured using the Leica DFS3000G camera or Leica SP8 Confocal microscope.
2.2.13 Western Blot
Following protein extraction from brain tissue or cell lysis, protein concentration was
determined using a BCA assay kit (Novogen) and concentrations were then normalised
using the original extraction buffer. With the exception of the immunoprecipitated
samples, 10 µg of protein was then mixed in sample buffer, Laemmli 3x concentrated
(6.3% SDS, 21% glycerol, 19.6% 1M TRIS pH6.8, 0.035% bromophenol blue, 15.7%
β-mercaptoethanol, 62.6% H2O), boiled for 5min then run on either a pre-prepared
NuPAGETM 4-12% Bis-Tris gradient gel (Invitrogen) or 10% Tris-glycine gel alongside a
SeeBlueTM Plus2pre-stained protein ladder (Invitrogen) or Precision Plus Protein Dual
Colour Standards (Biorad) as a protein molecular weight marker. Electrophoresis was
performed using a constant voltage of 100V for 2-3hr. Proteins were then transferred
from the gel onto a 0.45 µm Nitrocellulose membrane (Thermoscientific) at a constant
amplitude of 300mA for 3hr. The non-specific background on the membrane was then
blocked by incubating the membrane for 1hr either in 5% milk or 5% BSA (Europa) in
TBS with 0.1% Tween20, and, incubated overnight in appropriate primary antibodies
diluted solutions containing 5% milk or 5% BSA. The membrane was then rinsed in
TBS with 0.1% Tween20 and incubated for 3hr in appropriate HRP-linked secondary
antibody. The blot was then developed using SuperSignal® West Dura Extended
Duration Substrate (Thermoscientific) and visualised using a ChemiDoc XRS+ system
(Biorad).
2.2 Methods 59
2.2.14 Luciferase reporter gene assays
Luciferase reporter gene assays have been well described by Cheng et al. (2010) for the
study of G-protein signalling. Due to the reporter gene being significantly downstream
of the initial binding event, there is significant amplification of the binding related
signal, making luciferase reporter gene assays an excellent screening tool for deciphering
EP3Re signalling pathways.
For detection of Gαs and Gαi transduction pathways the PathDetect trans-reporting
system (Agilent) was used, whilst detection of Gαq was done using the PathDetect
cis-reporting system (Agilent). HEK293 cells were plated into poly-l-lysine (sigma)
coated 96 well plates at a density of 40000cells/well and transiently transfected with
the EP3Re construct at concentrations varying from 0 - 10ng/well or empty vector
alongside the reporter vector and destablised luciferase gene (with the exception of
pNFAT-Luc which already has the destablised luciferase gene incorporated into the





Transfection was terminated 5hr later by replacing Opti-MEM with serum free DMEM.
Cells were incubated in ligands targetting the receptor (final concentrations varying
from 0 - 10−6M) at 37°C. After 5hr, media was aspirated and cells were rinsed twice
in PBS containing calcium and magnesium (GibcoTM). Cells were then incubated
60 MATERIAL AND METHODS
Fig. 2.1 Reporter gene assay for deciphering GPCR signal transduction path-
ways. Schematic explaining the use of reporter assays to determine G-protein signalling
pathway. On GPCR activation, the G protein α subunit dissociates from βγ subunit, initiat-
ing a cascade of downstream second messenger pathways, eventually inducing transcription
of the luciferase gene by various response elements including cAMP response element (CRE),
nuclear factor of activated T-cells response element (NFAT-RE) and serum response element
(SRE), emitting a detectable signal that can be measured.
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in steadylite (PerkinElmer) for 20min at room temperature on a shaking platform.
Luminescence was then measured using a microplate scintillation counter (TopCount).
2.2.15 cAMP assay
cAMP levels were measured using HitHunter® (DiscoverX) according to manufacturer’s
instructions. HEK293A cells were plated in 96 well plates at a density of 20000 cells/well
and transiently transfected with EP3e receptor constructs or empty vectors. The
following day cells were washed twice in phosphate buffered saline (PBS), incubated in
assay buffer (DiscoverX) for 30min and cells stimulated by addition of the EP3 specific
agonist, Sulprostone (Cayman chemicals) for 30min at 37°C. Cells were subsequently
incubated in cAMP antibody and detection solution then placed on a shaking platform
for 1hr. Following a 3hr incubation in enzyme solution, luminescence was measured
using a microplate scintillation counter (TopCount). To inhibit Gαi signalling that
could be masking a rise in cAMP, assays were repeated with the addition of Pertussis
toxin (Invitrogen, 1:100).
2.2.16 Inositol phosphate assay
A cell-based radiometric inositol phosphate accumulation assay was performed to
determine the presence of Gq and Gi coupling. The assay incorporates [3H]inositol
into membrane-associated inositol phospholipids and measures GPCR-mediated phos-
pholipase Cβ activation by the measurement of generated [3H]inositol phosphate. All
stages requiring use of radioactive reagents were done by Jacek Mokrosinski (IMS,
University of Cambridge).
HEK293 cells were plated in 96 well plates at a density of 40000 cells/well and
transiently transfected with EP3Re and Gαδ6qi4myr, to asses Gαi coupling, or, EP3Re
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alone to assess Gαq. Gαδ6qi4myr is a chimeric G-protein that converts Gαi cou-
pling into a Gαq signalling pathway allowing Gαi activity to be measured by Inositol
monophosphate (IP1) accumulation. Transfection was terminated after 5hr by replacing
Opti-MEM media with DMEM supplemented with Myo-[2 −3 H]-inositol (5 µl/ml) and
cells cultured overnight. They were then washed in HBSS and kept in HBSS containing
10mM LiCl (assay buffer) for 30min at 37°C in 5% CO2 and stimulated by further
incubation for 1hr with varying concentrations of Sulprostone. The assay buffer was
removed and 10mM ice cold formic acid dispensed over the cells which were left for
30min on ice. Twentyµl/well of cell lysate (formic acid) was transferred onto a new
96 well plate containing polylysine YSi SPA beads (Perkin Elmer). Plates were then
sealed and manually shaken for 10-15 sec. Radioactivity measuring generated inositol
phosphate was measured using a microplate scintillation counter (TopCount) following
an 8hr delay to allow for a more stable signal. Data was analysed using GraphPad
Prism 7.0.
2.2.17 ELISA for FLAG tagged EP3Re
To determine if the presence of wild type or tau with the P301S mutation influenced
EP3Re cells surface expression, we performed ELISA for FLAG. COS-7 or HEK293
cells were plated into 96 well plates at a density of 30-35000 cells/well and transfected
with FLAG tagged EP3Re or empty vector with either constructs for wild type tau
or tau with the P301S mutation. Twenty-four hours after transfection, media was
aspirated and cells were washed in PBS, fixed in 3.7% formaldehyde and incubated
in blocking buffer (3% milk in PBS with 50mM TRIS) for 1hr at room temperature
to reduce non-specific staining. Anti-FLAG primary antibody diluted in blocking
buffer was applied to cells and left overnight at 4°C. The following day, the primary
antibody was aspirated, cells washed in PBS and HRP conjugated goat anti-mouse
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IgG(H+L) diluted in 1.5% milk applied to cells for 2hr at room temperature. The
secondary antibody was then removed, cells washed in PBS and then incubated in
90 µl/well of the HRP substrate 3,3’,5’,5 - Tetramethylbenzidine (Sigma) for 5 - 20min
at room temperature. This reaction was terminated on addition of 60 µl per well of
0.5M Sulfuric acid. One-hundredµl from each well was transferred to a new 96 well
plate and absorbance measured at 450nm using a microplate reader (Tecan M1000).
2.2.18 NanoLuc® Binary Technology (NanoBIT ®) Protein-
Protein interaction (PPI)
NanoBIT® PPI systems allow for detection of protein interactions in live cells and
was used to assess the dynamic interaction between EP3Re and tau with and without
the P301S mutation. NanoBIT® is a structural complementation reporter system
composed of a Large BiT (LgBiT; 18kDa) subunit and a small complimentary peptide.
For the study of protein:protein interactions, the complimentary peptide is a Small
BiT (SmBiT; 11 amino acid peptide), which has been optimized to have low affinity
for LgBiT. The LgBiT and SmBiT subunits are expressed as fusions to target proteins
of interest and expressed in cells. When the two proteins interact, the subunits come
together to form an active enzyme and generate a bright luminescent signal in the
presence of substrate.
2.2.18.1 Creation of constructs for NanoBIT® experiments
All constructs used for this assay were developed with the assistance of Dr Edson Mendes
de Oliveira (Farooqi lab, Institute of Metabolic Science, University of Cambridge) and
sequences verified by PCR, performed with the assistance of David Clarke (Farooqi
lab, Institute of Metabolic Science, University of Cambridge).
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The following primers were used to introduce restriction sites at either the N-terminus









Each reaction contained 10ng of cDNA, 1 µl of 10mM dNTP, 2µl each of appropriate
forward and reverse primer, 0.25µl of One Taq DNA polymerase (New England BioLab)
and nuclease-free water to make a final volume of 50 µl per reaction. PCR was performed
in a thermal cycler under the following conditions: 94°C for 2min followed by 94°C for
50s, 64°C for 50s, 68°C for 3min for a total of 30x cycles, and finally 68°C for 7min.
The resulting PCR products were run on a 1% agarose gel, extracted from the gel and
cleaned using the NucleoSpin® Gel and PCR Clean-up kit (Macherey Nagel) according
to manufacturers instructions. The PCR products then underwent restriction enzyme
double digestion alongside C-LgBIT, N-LgBIT, C-SmBIT and C-LgBIT constructs
readily available in the lab. The reaction was set up as follows; 1µg DNA, 5µl of 10X
cut smart buffer (New England BioLabs), 10 units XhoI (New England BioLabs), 10
units EcoRI-HF (New England BioLabs) or 10 units of NheI-HF (depending on the
construct) and 50 µl nuclease-free water, and incubated at 37°C for 2hr. The product
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of enzyme digestion was then run on an agarose gel, extracted and cleaned using the
NucleoSpin® Gel and PCR Clean-up kit (Macherey Nagel) according to manufacturers
instructions. The MAPT and EP3e digested constructs were then ligated with the
appropriate LgBIT or SmBIT construct at a molar ratio of 3:1 respectively, 10x T4
DNA ligase buffer (New England BioLabs), T4 DNA ligase (New England BioLabs)
and nuclease-free water to make a final volume of 20 µl per reaction. This was left for
10min at room temperature.
Following transformation, the successful insertion of EP3Re and MAPT into NanoBit®
system LgBit and SmBit vectors was assessed by sequencing using the following primers:
For detection of insertion into C-SmBiT and N-SmBiT constructs:
• Forward primer 5’ ATATTAAGGTGACGCGTGTG
• Reverse primer 5’ CATTCTAGTTGTGGTTTGTCC
For detection of insertion into N-LgBiT constructs:
• Forward primer 5’ CATGCTGTTCCGAGTAAC
• Forward primer 5’ ATATTAAGGTGACGCGTGTG
• Reverse primer 5’ CATTCTAGTTGTGGTTTGTCC
For detection of insertion into C-LgBiT constructs:
• Forward primer 5’ CATGCTGTTCCGAGTAAC
• Reverse primer 5’ GAAGACACCTGACGACCCTC
• Reverse primer 5’ CATTCTAGTTGTGGTTTGTCC
Plasmid maps for constructs used in experiments can be seen in figures 2.2 and 2.3.
Constructs with the MAPT P310S mutation were created by site directed mutage-
nesis of MAPT constructs.
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Fig. 2.2 Circular maps of plasmids containing EP3Re used in interaction assays
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Fig. 2.3 Circular maps of plasmids containing MAPT used in interaction assays
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2.2.18.2 Protein:protein interaction assay
HEK293 cells were seeded into 96 well plates at a density of 40000 cells/well. Cells
were transiently transfected with the two constructs of interest. Transfection was
terminated after 5 hrs by replacing Opti-MEM media with normal growth media. Prior
to performing assays, media was changed back to Opti-MEM and baseline luminescence
measured for 5 min at 37°C by a luminometer (Tecan). Keeping the solution at 37°C,
25 µl of Nano-Glo Live cell reagent (1:20 Nano-Glo Live cell substrate in NanoGlo LCS
dilution buffer) was added to each well. Following a repeat baseline measurement of
luminescence over 20min with the administered substrate, 10−3M Sulprostone was
added to each well and changes in luminescence recorded over 20min.
2.3 Statistics
All results were analysed using Graphpad prism 7.0 and statistical tests applied as
stated in each chapter.
Chapter 3
DISTRIBUTION AND PATHWAY
OF ACTION OF THE HUMAN
EP3RE RECEPTOR
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3.1 Summary
Prostanoid 3 receptor (EP3) mediated signalling is involved in multiple biological
processes including the thermogenic response to systemic inflammation and blood
pressure regulation. Targeted deletion of EP3 leads to obesity in mice, suggesting an
additional role in energy homeostasis. EP3 is unique amongst the PGE2 receptors as it
is alternatively spliced giving rise to species specific isoforms. Each isoform differs in the
carboxy-terminal part that determines its second messenger and intracellular activity.
The EP3Re isoform is unique to higher primates including man and consists of the
shortest C-terminus. Its localisation in the human brain is not known. In this chapter
we examine the distribution of the EP3Re receptor in the adult human brain using
immunohistochemistry and western blotting and identify the receptors second messenger
system through which it signals. The receptor is found to be ubiquitously expressed
with particularly high levels within the brainstem nuclei and the hypothalamus and it
signals through Gαi coupling with some evidence of Gαq mediated activity. Identifying
the distribution and signalling transduction pathway of the receptor, will allow us to
gain a better understanding of its function in physiological and pathological conditions.
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3.2 Introduction
The human specific EP3Re receptor has not been previously characterised. In this
chapter we aim to establish the distribution and signalling transduction pathways
of EP3Re. The expression of the non-human specific EP3 receptor has previously
been characterised in mouse and rat brains (Ek et al., 2000; Nakamura et al., 2000;
Sugimoto et al., 1994). In these studies antibodies or probes directed against the
common coding region for all isoforms were used and therefore do not distinguish
between individual isoforms. In both the mouse and rat brains, similar patterns of
expression are described. EP3 was found to be present throughout the brain, highly
enriched in the hypothalamus and preoptic areas, the locus coeruleus, raphe nucleus
and brainstem nuclei involved in processing and modulating pain. Based on their
findings, Nakamura et al. concluded that the receptor is likely to play a function
in conveying peripheral signals from the systemic circulation to the brain. This is
supported by its enrichment in regions that lack an effective blood brain barrier such as
the median preoptic nucleus, a region involved in thermoregulation, sleep homeostasis
and osmoregulation (Cerri et al., 2017; McKinley et al., 2015). However, it can be
found also enriched in regions within the blood brain barrier where it may regulate
several neuromodulatory functions of locally synthesised PGE2. Studies in both rat
and mouse brain have reported strong EP3 mRNA expression and immunoreactivity in
monoamine containing nuclei such as the raphe nucleus and locus coeruleus implying
its role in serotonergic and noradrenergic systems. PGE2 binding sites in rat brain
mapped using quantitative autoradiography (Matsumura et al., 1992) correlate with
the EP3 receptors distribution (Ek et al., 2000; Nakamura et al., 2000) suggesting
in the rat brain, PGE2 effects within the CNS are largely mediated by the EP3 receptor.
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In addition to immunohistochemical analysis, several functional animal studies have
examined the role of EP3 signalling in the central nervous system. One of the most es-
tablished functions of EP3 mediated signalling is its role in thermoregulation and febrile
response (Hatae et al., 2002b; Lazarus et al., 2007; Morrison, 2016; Oka et al., 2003).
The preoptic area regulates the dorsomedial hypothalamic thermogenesis promoting
neurons by balancing GABAergic inhibition and glutamatergic excitatory signals (Cao
et al., 2004; Nakamura et al., 2005). The excitatory input is thought to arise from
EP3 positive neurons in the median preoptic nucleus that project to the dorsomedial
hypothalamus (Fig. 3.1). Animal studies show selective deletion of EP3 receptors
within the median preoptic nucleus results in loss of the febrile response as elicited by
lipopolysaccharide (LPS) (Lazarus et al., 2007). Selective deletion of EP1 and EP4
receptors, also found within the preoptic area, does not result in loss of the febrile
response (Lazarus, 2006) suggesting this is predominantly mediated by EP3 signalling.
Studies exploring the signal transduction pathways of the EP3 receptor have identified
that most EP3 isoforms couple to Gi, although, as described in Chapter 1, other
transduction pathways have been demonstrated based on variations in its C terminus
(Hatae et al., 2002a; Kotani et al., 2000). Similar to the studies of EP3 distribution
and expression, most of the signalling assays have examined bovine or mouse isoforms
(Hatae et al., 2002a; Irie et al., 1994; Katoh et al., 1996). A few studies however,
have looked at signalling of isoforms identified only in humans. Kotani et al examined
the human EP3 isoforms V and VI using Chinese Hamster Ovary cells (CHO) by
measuring cAMP accumulation, IP3 accumulation and MAPK activity. Stimulation of
EP3 in cells transfected with both isoforms V and VI inhibited forskolin induced cAMP
accumulation and MAPK activity. Both these responses were eliminated on treatment
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Fig. 3.1 EP3 and the pyrexial response. Hyperthermia is generated by a system of
neurons including the PVH, DMH, and the RP, which activate thermogenic brown adipose
tissue and heat conservation (vasoconstriction) responses. This thermogenic system is
normally restrained by inhibitory neurons in the MnPO. Some MnPO neurons project to
the RP; there are also projections to neurons in the PVH and the DMH, which in turn
provide excitatory inputs to the RP. During fever, hyperthermic neurons in the MnPO are
inhibited by EP3 receptors, thus disinhibiting, i.e., releasing, thermogenesis. MnPO - Median
preoptic area, RP - Raphe pallidus nucleus, PVH - Paraventricular hypothalamus, DMH -
Dorsomedial hypothalamus (Lazarus 2006).
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with pertussis toxin, suggesting predominant Gi activity (Kotani et al., 2000). When
CHO cells were transfected with a single isoform, cAMP accumulation was observed in
the presence of EP3 VI but not V, demonstrating that differences in the isoforms at
the C terminus results in activation of different transduction pathways (Kotani et al.,
2000). The brain distribution and signalling pathways of the human EP3Re isoform
has not been previously characterised.
The main aim of the study presented in this chapter was to:
1. Identify the areas within the human brain that express the EP3Re isoform
2. Understand the main EP3Re signalling pathways under normal physiological
conditions
This study, by characterising the human specific EP3Re receptor distribution and
signalling pathways will lead to a better understanding of the EP3Re receptor function
in physiological and pathological conditions.
3.3 Materials and Methods
3.3.1 Antibodies
All primary and secondary antibodies used are listed in Table 2.1 and Table 2.2
(Section 2.1.1.).
3.3.2 Human brain samples
Four µm paraffin embedded and frozen sections from 5 healthy human control brains
were obtained by ethical-committee approved procedures from the Cambridge Brain
Bank. Three serial sections from 11 different brain regions (midbrain, pons, medulla,
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basal ganglia, hypothalamus, hippocampus, cerebellum, frontal, temporal, occipital
and parietal cortices) from each subject were used for this study. Full clinical details
of each subject can be found in Table 2.3 (Section 2.1.2).
3.3.3 Immunohistochemistry
The distribution of the receptor was characterised by immunohistochemistry using a
human EP3Re specific antibody (Abcam 94496) as well as an antibody directed against
all EP3 isoforms (Abcam 115667). Staining was performed on paraffin embedded
sections using the protocol described in 2.2.1. Prior to mapping the receptor’s
distribution, the specificity and optimum conditions for using the antibody needed
to be established. To this end, following removal of paraffin as indicated in 2.2.1,
sections were stained with and without prior antigen retrieval performed with 10mM
citrate buffer at 95° for 20mins or left at 60° overnight. Specificity of the staining was
determined by pre-adsorbing the EP3Re antibody with PTGER3 blocking peptide
(Abcam 151180) as described in 2.2.2. This was performed on 2 adjacent sections
from the medulla of 3 different patients, one section was stained with the pre-adsorbed
antibody while the other was stained using the non-preadsorbed antibody at the same
dilution. In this way it was possible to determine the specificity of the antibody and its
suitability to be used for the remaining experiments. Having determined the specificity
and optimal dilution and staining conditions immunohistochemistry was performed on
paraffin embedded sections taken from 11 different regions (3 adjacent sections from
each region) from 5 control brains using the antibody directed against EP3 and EP3Re.
3.3.4 Immunohistochemical evaluation of EP3Re staining
To quantify the relative expression of EP3Re a semi-quantitative five-point rating scale
was used determined as a product of the percentage of positive cells and intensity of
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staining. The percentage of positive cells were rated as follows; 0 points = 0%, 1 point
= 5-25%, 2 points = 25-50%, 3 points = 50-75% and 4 points = 75-100%. The intensity
of the staining was then assessed as follows; 0 = no staining, 1 = weak staining (yellow),
2 = moderate staining (light brown), 3 = strong staining (dark brown). A final score,
from 0 - 12, was calculated based on the product of the number of positive cells x the
intensity of the staining. The ratings were then allocated as follows; 1 - 3 = +, 4 - 6 =
++, 7 - 9 = +++ and 10 - 12 = ++++. Each slide was assessed in this way and the
average score across 5 control brains used for each region.
3.3.5 Western Blot
The distribution of the EP3Re receptor was then quantified by western blotting as
described in 2.2.10. Fresh frozen tissue was obtained from the various brain regions
investigated by immunohistochemistry from 3 of the control subjects who had one
brain hemisphere fresh frozen and the other, used for immunohistochemistry fixed in
formaldehyde. Loading of samples in western blot was normalised using GAPDH. 3
technical replicates were performed for each subject.
3.3.6 Luciferase reporter gene assays
Reporter gene assays are a well described method for determining the second messenger
signalling pathway of G-protein coupled receptors (GPCRs). This is done by following
a signal transduction pathway from ligand binding at the cell surface to nuclear
gene transcription. GPCRs signal via coupling to an intracellular trimeric G-protein.
Activation of the trimeric G-protein results in the dissociation of the Gα subunit from
the βγ dimeric subunit initiating a signalling cascade inducing gene transcription by
various response elements. Response elements associated with G-protein signalling
include cAMP response element (CRE), nuclear factor of activated T-cells response
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element (NFAT-RE), serum response element (SRE), and, serum factor response
element (SRF-RE), which is determined by the subfamily of the Gαs subunit being
Gs, Gi, Gq or G12. Reporter vectors are available with specific response elements for
Gs, Gi, Gq and G12 pathways making them an excellent assay to initially screen the
pathway involved in EP3Re signalling. Luciferase reporter assays were performed as
described in 2.2.12. Human embryonic kidney cells (HEK293) cells were transiently
transfected with either the reporter vector CRE, NFAT or NFAT co-transfected with
the chimeric G-protein Gαδ6qi4myr, alongside the luciferase construct to determine
the presence of Gs, Gq and Gi coupling respectively. These were co-transfected with
either the EP3Re construct or the empty vector pCDNA3.1 as a negative control. The
receptor was then stimulated with the EP3 specific agonist Sulprostone. Assays were
performed in triplicates. Reporter assays were repeated twice for general screening and
three times when verifying results of second messenger assays.
3.3.7 Second messenger assays
Second messenger assays were then performed to confirm the results observed from the
reporter gene assays. Gs coupling was further explored by measuring cAMP (see 2.2.13
for detailed protocol) in response to ligand stimulation in HEK293 cells transiently
transfected with EP3Re. As no elevation in cAMP was observed, pertussis toxin was
added to cells to inhibit any Gi activity that could be masking a cAMP rise in response
to Gs coupling. The original reporter gene assays were then repeated using HEK293A
cells with the gene encoding the Gs alpha subunit (GNAS) deleted.
Gi and Gq coupling was assessed by measuring Inositol monophosphate (IP1) accumu-
lation in response to ligand stimulation as described in 2.2.14. IP1 is a breakdown
product of Inositol triphosphate, a second messenger produced in the presence of
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Gq coupling. The chimeric G protein, Gαδ6qi4myr, converts Gi coupling into a Gq
signalling pathway allowing for a positive readout of IP1 accumulation. HEK293 cells
were transiently transfected with EP3Re and the chimeric G protein, Gαδ6qi4myr,
to measure Gi coupling and with the EP3Re receptor alone to measure Gq coupling.
Cells were then stimulated with Sulprostone and IP1 accumulation measured.
The EP3 receptor has been shown to bind to 3 different ligands, sulprostone, PGE2
and PGD2. Affinity for the EP3Re receptor was then determined using the IP1 assay
and stimulating the receptor with each ligand. All second messenger assays were done
in quadruplicates and repeated 3 times.
All steps in the IP1 assay requiring use of radioactive material were carried out
by Dr Jacek Mokrosinski (Farooqi laboratory, MRC Institute of Metabolic Science)
3.3.8 Statistics
Statistical analysis was carried out using GraphPad prism 7.0. For signalling assays,
half maximal effective concentration (LogEC50) was calculated from data normalised
and fitted to a non-linear regression curve in GraphPad prism 7.0.
All materials and methods are described in detail in Chapter 2.
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3.4 Results
3.4.1 Optimisation of immunohistochemistry and antibody
specificity
3.4.1.1 Staining of brain tissue sections for EP3Re requires antigen re-
trieval
Optimum conditions for use of the EP3Re antibody needed to be verified, due to
lack of published literature on previous use of the antibody. Sections obtained from
the brain bank were paraffin embedded using neutral buffered formalin as a fixative.
In order to map out the distribution of the receptor, I had to establish if antigen
retrieval, the process of unmasking the epitope, was required. Antigen retrieval of 4µm
paraffin embedded sections was performed in 10mM sodium citrate buffer and stained
with the antibody against EP3Re. Figure 3.2 shows brain sections stained for EP3Re
with and without antigen retrieval. No staining can be seen without antigen retrieval
suggesting unmasking of the epitope is required for EP3Re staining. It was noted
that antigen retrieval at 95° over 20 minutes appeared to affect the tissue integrity
however this was not the case when the tissue was left at 60° overnight. All further
immunohistochemistry was therefore performed with antigen retrieval in 10mM citrate
buffer at 60° overnight.
3.4.1.2 EP3Re antibody is specific to the EP3Re receptor
Prior to mapping the distribution of the receptor in the human brain, we decided to
test the specificity of the antibody. In order to do this we used the pre-adsorption
method, a well described technique for testing antibody specificity (Holmseth et al.,
2012) and previously used in the lab for other antibodies. This involves saturating an
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Fig. 3.2 Staining of 4 µm paraffin embedded brain tissue sections for EP3Re
requires antigen retrieval. (A) Brain tissue section stained with EP3Re. (B) Brain
section stained with EP3Re following antigen retrieval in 10mM sodium citrate buffer for 20
min at 95°. At higher magnification vacuolation is noted in the tissue (black arrow heads).
Conditions for antigen retrieval were further optimised by performing antigen retrieval at
different temperatures for differing lengths of time to see if tissue integrity could be better
maintained during the process. (C ) and D show optimisation of antigen retrieval conditions
with C showing a section of brain tissue following antigen retrieval at 95° and D at 60°
overnight in a waterbath. Antigen retrieval performed overnight resulted in improved tissue
integrity.
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antibody with its antigen and using this pre-adsorbed antibody for staining. If any
staining is seen following this, it suggests that the antibody is recognising another
epitope other than the antigen used for pre-adsorption. Paraffin embedded sections
were taken from the medulla of a control patient and stained with the EP3Re antibody
pre-adsorbed with the EP3Re antigen. The results can be seen in figure 3.3. Antigen
pre-adsorption appears to block any staining suggesting that the antibody does not
recognise any other epitope other than the EP3Re receptor in these sections.
Fig. 3.3 Testing of antibody using the using the pre-adsorption method. Paraffin
embedded sections stained with antibody preadsorbed with EP3Re antigen (A) and without
preadsorption (B). No staining is noted when the preadsorbed antibody is using. The EP3Re
antibody does not recognise any other epitope in these sections.
3.4.2 Distribution of the EP3Re receptor in the human brain
The distribution of EP3Re within the brain was determined by immunohistochemistry
using a human EP3Re-specific antibody on post-mortem human brains obtained by
ethical committee-approved procedures by the Cambridge Brain Bank. Fourµm sections
were taken from 15 different regions from 5 control brains. Three adjacent sections
were taken from each region.
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EP3Re immunoreactivity was widely observed throughout the brain displaying char-
acteristic punctuate cytoplasmic staining. The receptor was mainly observed in cells
displaying a neuronal cellular morphology and granular staining of the neuropil was
also often noted. In contrast, when sections were stained with an antibody recognis-
ing all EP3 isoforms, staining was observed in both neurons and glial cells (Figure 3.4).
.
Fig. 3.4 EP3Re immunoreactivity is observed predominantly in cells with a neu-
ronal morphology. Brain sections showing EP3 (left panel) and EP3Re (right panel)
staining. EP3Re immunoreactivity is only observed in cells with a neuronal phenotype
(arrow) while EP3 staining is also noted in cells with a glial morphology (arrowhead)
The strongest EP3Re immunoreactivity observed was in the brainstem nuclei and
hypothalamus with weaker staining noted in the basal ganglia nuclei, and moderate
staining noted in the cortex. A summary of EP3Re staining in the various brain regions
can be seen in table 3.1 and described below.
3.4.2.1 Medulla
Transverse sections taken at the level of the middle portion of the inferior olive showed
intense staining in all 3 nuclei within the inferior olive, the primary olivary nuclei, the
medial accessory olivary nucleus and the dorsal olivary accessory nucleus (figure 3.5).
The staining within the cells had a compact and granular appearance with a dotted
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Table 3.1 Summary of EP3Re staining with relative intensity of staining; + weak, ++medium,
+++ strong ++++ very strong
REGION EP3Re IMMUNOREACTIVITY
Medulla





















Median preoptic area +++
Hippocampus








Purkinje cell layer ++++
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appearance within the neuropil. Moderate staining could also be seen in the reticular
formation and raphe nucleus. Moving further up towards the medulla-pons junction,
cells strongly positive for EP3Re could be seen within the cochlear and vestibular
nuclei. Other regions noted to have moderate EP3Re immunoreactivity included the
hypoglossal nucleus and lateral and medial cuneate nuclei.
3.4.2.2 Pons
Within the pons, at the level of the decussation of the trochlear nerves, strong im-
munoreactivity was noted across the pontine nuclei and along the pontocerebellar
fibres (figure 3.6). Neurons strongly positive for EP3Re are also noted within the locus
coeruleus. Staining appears to be within neurons with a dotted, granular appearance
both within the cytoplasm and the neuropil with weaker staining noted in the neuropil.
3.4.2.3 Midbrain
At the pons-midbrain junction, strong immunoreactivity in neurons was seen at the
raphe nucleus. Moving more rostral, strong to moderate immunoreactivity was found
in neurons within the superior colliculus, the oculomotor nucleus, and the red nucleus,
with weaker staining in the substantia nigra pars reticulata and pars compacta. The
neuro-melanin within the dopaminergic cells of the substantia nigra, made it difficult
to fully assess for the presence of EP3Re in addition to neuro-melanin within these
neurons. Staining of neuro-melanin was however, distinguishable from EP3Re as it
appeared darker, more intense appearing as larger brown globules in contrast with
the finer granular staining of EP3Re. In some of the pigmented neurons, this lighter
granular EP3Re staining could also be identified. The staining of the neuropil in the
substantia nigra took on slightly more diffuse fibrillary background in contrast to the
oculomoter and red nucleus where the staining appeared more granular (Figure 3.4.2.3).
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Fig. 3.5 EP3Re distribution in the medulla. A) Vestibular nuclei B) Inferior olivary
nuclei C) Cochlear nuclei D) Corticospinal tract E) Hypoglossal nucleus F) Reticular formation
and raphe nucleus obscura
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.
Fig. 3.6 EP3Re distribution in the Pons. A) Pontine nuclei B) Pontocerebellar fibres
Fig. 3.7 EP3Re distribution in the midbrain. A) The oculomoter nucleus B) The
red nucleus C )Substantia nigra, where pigmented neurons are also noted (highlighted with
arrows). EP3Re staining in the same neurons is noted with an arrowhead.
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3.4.2.4 Hypothalamus/Pre-optic area
The hypothalamus is part of the limbic system and serves a key role in neuroendocrine
function, regulating hormonal function, circadian rhythms and playing an important role
in regulating homeostatic mechanism. EP3Re positive neurons appeared more numerous
within the periventricular and medial zones with minimal staining seen within the
lateral zone. Intense staining was noted in the mammillary bodies, mammillothalamic
tract, paraventricular nuclei, and, ventromedial nuclei with some intensely labelled
neurons distributed along the wall of the third ventricle within the periventricular
nuclei (figure 3.8). Strong immunoreactivity was noted in the median preoptic area, a
region associated with thermogenesis thought to be mediated by EP3 signalling.
Fig. 3.8 EP3Re distribution in the hypothalamus. (A) Paraventricular nuclei (B)
Medial preoptic area (C) Mammillothalamic tract
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3.4.2.5 Hippocampus
The hippocampus is a major component of the limbic system and plays an important
role in consolidation of short and long term memory. The hippocampal formation
showed strong EP3Re immunoreactivity in neurons in CA1 and CA4 regions with
weaker staining in CA2 and CA3. The granular layer neurons of the dentate gyrus
were strongly positive for EP3Re (Figure 3.9).
Fig. 3.9 EP3Re distribution in the hippocampal formation. The CA1, CA4 and
granular layers show the highest level of immunoreactivity with moderate staining in CA2
and weak staining in CA3 regions
3.4.2.6 Cerebellum
The cerebellar cortex consists of three main layers, the outer molecular layer, the
middle Purkinje cell layer and the densely packed granular layer. The EP3Re receptor
appeared to be present in all three with the Purkinje cells showing some of the strongest
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immunoreactivity. There was also EP3Re staining within the deep nuclei. Figure 3.10
shows the dentate nuclei, one of the four main deep nuclei within the cerebellum.
Fig. 3.10 EP3Re distribution in the cerebellum. A) Purkinje and granular cell layer
B) Dentate nucleus
3.4.2.7 Basal ganglia
Consisting of several subcortical nuclei, the basal ganglia is involved in control of
voluntary movement, eye movement, procedural learning, emotion and cognition. The
main nuclei of the brain are the caudate nucleus, the putamen, the nucleus accumbens,
the globus pallidus, the substantia nigra and the subthalamic nucleus. EP3Re positive
staining was present in the associated nuclei particularly within the putamen and globus
pallidus (Figure 3.11). Staining within the substantia nigra is shown in figure 3.4.2.3.
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Fig. 3.11 Sections taken from the basal ganglia stained with the EP3Re antibody.
Images show neurons stained in A) Globus pallidus internal segment B) Putamen.
3.4.2.8 Cerebral cortex
Sections taken from the cerebral cortex of frontal, parietal, temporal and occipital lobes
all show neuronal EP3Re immunoreactivity. Pyramidal neurons of layer III within
the neocortex showed more intense immunoreactivity for EP3Re than neurons within
granular layers.
3.4.2.9 Biochemical evaluation of EP3Re expression
In addition to the immunohistochemical analysis, western blot was performed to validate
the immunohistochemical findings and quantify protein expression (figure 3.13). Protein
lysate was extracted from 3 of the control subjects, selected due to their similar age
(average age 70, range 68-73yrs) and western blotting performed examining protein
expression across 10 different brain regions. Although there was significantly more
variability in expression across the three individuals, that immunohistochemical analysis
would suggest, the highest level of EP3Re protein expression was in the medulla with
the lowest being in the basal ganglia and occipital cortex.
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Fig. 3.12 EP3Re distribution in the cortex. Staining in A) Parietal B)Frontal C )
Occipital D) Temporal cortices.
3.4.3 Characterisation of EP3Re signalling
The EP3R receptor is one of four E-prostanoid receptors that mediates signalling of
PGE2. These are all G-protein coupled receptors. The EP3Re isoform has never
previously been characterised but based on studies on the bovine and rodent EP3R
isoforms, it has been shown to couple intracellularly to three different Gα subunits,
Gs, Gi and Gq. Using a combination of reporter gene assays and second messenger
assays we explored the possibility that EP3Re couples to all three Gα subunits.
3.4.3.1 Coupling of EP3Re with Gs
In response to ligand binding to cell surface GPCRs that couple to Gs, the activated
intracellular Gαs subunit dissociates from the trimeric G-protein complex, where it
is normally bound to the βγ subunit, and binds to adenyl cyclase producing the
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Fig. 3.13 EP3Re protein expression. Western blot showing protein expression of EP3Re
by brain region across 3 different control subjects can be seen in (A), (B) and (C). (D)
Graphical representation of EP3Re expression across all 3 subjects. There is significant
variability in protein expression across the patients in contrast to immunohistochemical
findings, which showed more consistent staining across individuals. n=3. OC= Occipital
Cortex. TC=Temporal cortex, PC=Parietal cortex, FC=frontal cortex, MB = Midbrain,
Med = Medulla, P = Pons, Hy = Hypothalamus, BG = basal ganglia, Cer = Cerebellum.
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second messenger cyclic adenosine monophosphate (cAMP). This in turn activates
the cAMP-dependent protein kinase A (PKA) with multiple cellular effects including
downstream activation of cAMP response element binding protein (CREB). CREB
acts as a transcription factor binding to a cAMP response element (CRE) sequence
within the promoter of target genes leading to their transcription (Kobilka, 2007). (Fig.
3.14A) .
To determine if EP3Re signalling is mediated by Gs binding, various points along
this signalling cascade can be examined. Initial screening of EP3Re-Gs coupling was
performed by measuring CREB activity using a luciferase reporter gene assay. The
signal amplification, due to the cumulative nature of the assay, makes reporter gene
assays an ideal screening tool as even the smallest amount of Gs binding would be
detected. CRE was built upstream of a luciferase gene and transfected into HEK293
cells alongside EP3Re. If EP3Re couples to Gαs, there should be a subsequent rise
in CREB which in turn binds to the CRE region within the luciferase gene promoter,
increasing luminescence allowing us to quantify EP3Re-Gs coupling. For the purpose
of these experiments the EP3R specific PGE2 analogue, Sulprostone was used. This
was done to minimise any signal from other E-prostanoid receptors. Initial screening
were performed using a fixed dose of EP3Re cDNA (5ng) and Sulprostone (100nM), as
shown in Fig. 3.14B. In response to EP3Re activation by Sulprostone, an increase in
luminescence was noted suggesting EP3Re signals through Gαs coupling. No signal
was seen in the absence of the receptor. The optimal EP3Re cDNA dose was then
determined by repeating assays using varying concentrations of EP3Re cDNA, ranging
from 0-10ng. Optimal receptor activity was detected at 5ng with a reduction in Gs
mediated signalling at higher concentrations. No significant intrinsic receptor activity
is noted, as determined by changes in receptor activity, based on increasing cDNA, in
94
DISTRIBUTION AND PATHWAY OF ACTION OF THE HUMAN EP3RE
RECEPTOR
the absence the ligand (Fig. 3.14C). Experiments were then repeated using varying
concentrations of Sulprostone. A dose response curve shows an increase in Gs mediated
signalling in a Sulprostone dose dependent manner with an average half maximal
response (EC50) detected at a concentration of 1 x 10-9.3M (Fig. 3.14D).
Having determined that EP3Re couples to Gs by measuring production of CREB, it
was important to validate this by measuring the second messenger, cAMP, directly.
The cumulative nature of reporter gene assays means there is significant signal amplifi-
cation, making them an ideal tool for general screening, however gene transcription
occurs significantly downstream from the ligand binding to the receptor, allowing
for the possibility of other confounding factors which may interfere in the signalling
pathway. Measuring the second messenger directly reduces this. HEK293 cells were
transfected with EP3Re cDNA and cAMP measured following Sulprostone exposure.
This was performed with and without the addition of pertussis toxin, which inhibits
any inhibitory Gi activity which might mask any rise in cAMP. No increase in cAMP
was detected in response to EP3Re stimulation both in the absence and presence of
pertussis toxin (Fig. 3.14E and Fig. 3.14F). This suggested that the previously noted
rise in CREB as measured via the reporter gene assay was not being mediated by
cAMP or Gs coupling.
In order to understand this discrepancy, I revisited the reporter gene assay using
HEK293 cells lacking the guanine nucleotide binding protein alpha stimulating (GNAS)
gene, which encodes the αs subunit. An increase in luciferase activity was still noted,
despite there being no Gαs subunit present (Fig. 3.14H). The rise in CREB was not
being mediated through Gs coupling and with no measurable rise in cAMP, there was
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no evidence to support that EP3Re interacts with Gαs. EP3Re was not signalling
through Gαs coupling.
3.4.3.2 Coupling of EP3Re with Gq
In response to ligand binding to cell surface GPCRs that couple to Gq, the activated
intracellular Gαq subunit dissociates from the trimeric G-protein complex, and ac-
tivates phospholipase C (PLC) which cleaves phosphatidylinositol 4,5-bisphosphate
(PIP2) to produce diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 acts
as a second messenger releasing calcium into the cytosol which in turn activates the
calcium/calmodulin dependent phosphatase calcineurin which dephosphorylates the
transcription factor nuclear factor of activated T-cells (NFAT) allowing it to translocate
to the nucleus binding and transcribing target genes containing an NFAT-response
element (RE) sequence (Mizuno and Itoh, 2009)(Fig.3.15A). To investigate EP3Re-Gq
coupling any one of the second messenger molecules generated as a result of Gq activity
as well as gene transcription instigated by NFAT could be measured.
In this study, to detect the presence of EP3Re-Gq coupling, I first performed a
luciferase reporter gene assay using a luciferase gene with an NFAT-RE built upstream
as the reporting vector. If EP3Re coupled to Gαq activating NFAT this would result
in transcription of the luciferase gene emitting a luminescent signal that could be mea-
sured. HEK293 cells were transfected with the NFAT-luciferase gene alongside either
EP3Re or an empty vector. The cells were then treated with the EP3R agonist sulpro-
stone and luminesce measured. The results are shown in figure 3.15B. No significant
increase in signal was noted in response to EP3Re activation suggesting EP3Re was not
signalling via this pathway. The reporter gene assay did not detect EP3Re-Gq coupling.
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Fig. 3.14 Coupling of EP3Re with Gs. A) Gs signalling cascade. Upon ligand binding
the αs subunit dissociates from the βγ subunit increasing cAMP levels by promoting adenyl
cyclase activity. This begins a signalling cascade that results in protein kinase A (PKA)
activation. The PKA catalytic units translocate into the nucleus phosphorylating CREB which
binds to the CRE region within the promoter of target genes instigating gene transcription.
B) Luciferase reporter gene assay using a CRE- reporting vector showed a positive signal in
response to sulprostone suggesting EP3Re coupling with Gs. Assays were run in quadruplicate.
Each point represents the mean +/- standard deviation of 2 independent experiments. C)
Receptor activity is measured at increasing doses of EP3Re cDNA with and without ligand
stimulation. Optimum receptor activity is seen at 5ng of the receptor. No intrinsic receptor
activity is noted in the absence of the ligand, despite increasing the amount of EP3Re cDNA.
D) Dose response of EP3Re expression and luciferase activation, confirming data shown in
(C). Optimum receptor activity is noted at 5ng of EP3Re cDNA with an average LogEC50
of -9.3. E) Gene transcription, as measured through reporter gene assays, in response to
Gs coupling is significantly downstream of ligand binding. We therefore needed to directly
assess the second messenger, cAMP, that is produced in response to receptor Gs coupling.
No increase in cAMP was seen in response to EP3Re stimulation by sulprostone suggesting
EP3Re does not couple to Gs. F) To exclude the possibility that no accumulation in cAMP
was seen due to cAMP inhibition by simultaneous Gi activity, pertussis toxin was used.
Pertussis toxin inhibits Gi protein coupling and was added to cells at a concentration of
100nM. No increase in cAMP is noted to suggest simultaneous Gi activity is preventing cAMP
accumulation. There is no evidence to support the initial findings of the luciferase reporter
gene assay to suggest EP3Re coupling to Gs. We varied the concentration of pertussis toxin
from 100nM up to 1mM with no change in results (data not shown). The original reporter
gene assay was then repeated using wild type HEK293 cells (G) and HEK293 cells lacking
the Gαs subunit (GNAS –ve). CRE activity was detected despite there being no Gαs subunit
suggesting transcription of CRE is not being mediated by Gs coupling. EP3Re does not
signal by coupling to Gs. Unless otherwise stated all assays shown were run in triplicate.
Each point represents the mean +/- standard deviation of 3 independent experiments. Data
from dose response assays were fitted to a non-linear regression curve and normalised in
GraphPad Prism 7.0.
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As the reporter gene assay measured gene transcription occurring significantly down-
stream from ligand binding, it was important to also assess the presence of EP3Re-Gq
coupling by measuring accumulation of a second messenger, upstream of gene tran-
scription such as IP3. IP3 however, is unstable and present only briefly before being
rapidly degraded to produce inositol phosphate (IP1), for which there are readily
available assays. IP1 accumulation is therefore a reflection of PLC activity confirming
the presence of Gq coupling. IP1 accumulation assays were performed in HEK293
cells transfected with EP3Re or an empty vector. Cells were treated with the EP3R
agonist sulprostone at concentrations ranging from 0 – 1x10-6M and IP1 accumulation
measured. Figure 3.15C shows the dose response curve and a small increase in IP1 is
noted with a half maximal effect seen at 1x10-9.3M. This suggested that some EP3Re-Gq
coupling was occurring. The potency of the endogenous EP3R ligands prostaglandin
E2 (PGE2) and prostaglandin D2 (PGD2) were also examined and can be seen in
figures 3.15D and E. Sulprostone has the highest affinity for EP3Re followed by PGE2
and then PGD2.
3.4.3.3 Coupling of EP3Re with Gi
Gi signalling, in contrast to Gs, inhibits cAMP dependent pathways through inhibition
of adenylyl cyclase. Determining the presence of EP3Re-Gi coupling by measuring
a reduction in cAMP dependent pathways can be difficult to assess and quantify.
To address this, we conducted experiments by co-expressing a chimeric G-protein,
consisting of a Gαi/Gαq chimeric subunit, Gαδ6qi4myr, as described by Kostenis et
al. (Kostenis, 2001). This confers Gq-effector coupling on Gi linked receptors allowing
us to measure NFAT mediated transcription and IP1 as markers of Gi receptor coupling.
Initial screening was performed using the luciferase reporter gene assay. HEK293
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Fig. 3.15 Coupling of EP3Re with Gq. A) Gq signalling pathway. Receptor coupling
through Gq results in the activation of phospholipase C by the dissociated Gαq subunit.
This cleaves the membrane phospholipid PIP2 into DAG and IP3 which act as important
second messengers. DAG recruits and activates PKC whilst IP3 instigates the opening of IP3
calcium channels, releasing calcium from the endoplasmic reticulum. This regulates several
signalling cascades including activation of the calcium/calmodulin dependent phosphatase
calcineurin which activates the transcription factor NFAT by dephosphorylating it, leaving it
free to translocate to the nucleus where it is able to instigate gene transcription of target
genes. Outputs measured for reporter gene assays (NFAT) and second messenger assays (IP1)
highlighted in yellow. B) The luciferase reporter gene assay measuring NFAT activity showed
no increase in signal in sulprostone treated cells in the presence of EP3Re compared to
controls. EP3Re was not activating a Gq signalling cascade. Assays were run in quadruplicate.
Each point represents the mean +/- standard deviation of 2 independent experiments. C)
IP1 accumulation assays, a breakdown product of the second messenger IP3 produced on
Gq coupling, were performed to further assess EP3Re-Gq coupling. HEK293 cells were
transfected with EP3Re or an empty vector and treated with varying concentrations of
sulprostone. The dose response curve shows some IP1 being produced in a dose dependent
manner suggesting EP3Re-Gq coupling. The potency of the endogenous ligands PGE2 (D)
and PGD2 (E) were then assessed and compared to the synthetic EP3R agonist sulprostone.
Although PGD2 signals through DP1 and DP2 receptors, some EP3Re activity was noted
at higher concentrations. Sulprostone had the strongest affinity to EP3Re (LogEC50 -9.3)
followed by PGE2 (LogEC50 -8.6) and then PGD2 (LogEC50 -5.5). All IP1 assays were
run in triplicate. Each point represents the mean +/- standard deviation of 3 independent
experiments. Data from dose response assays were fitted to a non-linear regression curve and
normalised in GraphPad Prism 7.0.
PIP2 - phosphatidylinositol-4,5-bisphosphonate; IP3 - Inositol 1,4,5-triphosphate; DAG -
diacylglycerol; PKC - Protein kinase C; ER - Endoplasmic reticulum; NFAT - Nuclear factor
of activated T-cells.
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cells were transfected with EP3Re alongside the chimeric G protein, Gαδ6qi4myr and a
construct containing an NFAT-RE built upstream of a luciferase gene. The receptor was
then activated by exposing cells to the EP3R agonist sulprostone and luminescence mea-
sured as a marker of luciferase transcription. An increase in NFAT-mediated luciferase
activity was noted but only in the presence of Gαδ6qi4myr suggesting EP3Re-Gi cou-
pling (Fig. 3.16B). Cells were then transfected with increasing doses of EP3Re cDNA to
determine the optimal gene dose concentration and presence of intrinsic receptor activ-
ity. Optimal activity was noted between 2.5ng – 5ng (Fig. 3.16C). Any further increase
resulted in reduced receptor activity both in the presence and absence of stimulation.
To validate the findings of the luciferase reporter gene assay, we went on to measure IP1
accumulation, in the presence of Gαδ6qi4myr, as a more upstream target of EP3Re-Gi
coupling. Cells were stimulated with the EP3R agonist sulprostone and in the presence
of Gαδ6qi4myr we noted an increase in IP1 accumulation in a dose dependent manner
confirming the results of the reporter gene assay further supporting EP3Re-Gi coupling.
We then compared the potency of the endogenous ligands PGE2 and PGD2 to the
synthetic EP3R agonist sulprostone and similar to our study of EP3Re-Gq coupling, we
found sulprostone to have the strongest affinity to EP3Re, followed by PGE2 and PGD2.
Our present study has shown EP3Re to signal through Gi and Gq signalling pathways.
There is no evidence to support EP3Re-Gs coupling.
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Fig. 3.16 Coupling of EP3Re with Gi. A) Gi signalling pathway. The red arrow
indicates the usual signalling cascade instigated on Gi coupling. Upon ligand binding the
Gαi subunit dissociates and inhibits adenyl cyclase activity resulting in a reduction in cAMP.
To assess EP3Re-Gi coupling, cells were co-transfected with the G-protein alpha subunit
Gαδ6qi4myr, a chimera between Gαi and Galphaq. This converts a Gi-coupled receptor into
a Gq signalling pathway allowing us to measure IP1 and NFAT mediated transcription to
quantify Gi-coupling. B) Initial screening using the luciferase reporter gene assay showed an
increase in signal in the presence of Gαδ6qi4myr suggesting the signal was being instigated
by EP3Re-Gi coupling. Assays were run in quadruplicate. Each point represents the mean
+/- standard deviation of 2 independent experiments. C) The luciferase reporter gene assay
was performed using increasing doses of EP3Re cDNA with and without ligand stimulation.
Optimum receptor activity is seen at 5ng of the receptor. Any further increase results in
reduced EP3Re activity as measure by Gi coupling. Intrinsic receptor activity is noted
in the absence of the ligand at lower doses of EP3Re cDNA. D) IP1 accumulation was
measured in the presence of Gαδ6qi4myr to validate the results of the luciferase reporter
gene assay. HEK293 cells were transfected with EP3Re and Gαδ6qi4myr and stimulated
with the EP3R agonist sulprostone. There is a dose dependent accumulation of IP1 which is
significantly higher in the presence of Gαδ6qi4myr. This suggests that EP3Re-Gi coupling is
the predominant signalling pathway. E) IP1 accumulation assay performed in the presence
and absence of Gαδ6qi4myr in response to cell stimulation by the endogenous ligand PGE2.
F) IP1 accumulation assay performed in the presence and absence of Gαδ6qi4myr in response
to cell stimulation by the endogenous ligand PGD2. Sulprostone showed the strongest affinity
for the receptor (LogEC50 -10) followed by PGE2 (LogEC50 -9.5) and then PGD2 (LogEC50
-6.5).
Unless otherwise stated all assays were run in triplicate. Each point represents the mean
+/- standard deviation of 3 independent experiments. Data from dose response assays
were fitted to a non-linear regression curve and normalised in GraphPad Prism 7.0. ATP;
Adenosine triphosphate, cAMP; cyclic adenosine monophosphate, PIP2; phosphatidylinositol-
4,5-bisphosphonate, IP3; Inositol 1,4,5-triphosphate, DAG; diacylglycerol, PKC; Protein
kinase C, ER; Endoplasmic reticulum, NFAT; Nuclear factor of activated T-cells.
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3.5 Discussion
This is the first study to characterise the distribution of the EP3Re receptor in the
human brain and the pathway through which it exerts its function. EP3Re appears
to be ubiquitously expressed in the human brain with stronger staining noted in the
brainstem nuclei, cerebellum, hippocampus and hypothalamus. In this study, we found
EP3Re to signal predominantly through a Gi coupled signalling cascade with some
evidence of Gq coupling under normal physiological conditions.
The widespread expression of EP3Re suggests that it could modulate several functions
of PGE2 within the brain, including its possible involvement in thermoregulation,
memory, and appetite control. The receptor enrichment in the hypothalamus and pre-
optic areas supports EP3Re isoforms involvement in thermoregulation and the pyrexial
response, a function known to be modulated by the EP3 receptor family. The role of
individual isoforms is unclear, however as the isoforms differ only by the intracellular
C-terminus, which determines the signalling cascade, it is possible that each isoform
plays a different functional role, although this goes beyond the scope of this study.
Strong staining within the hypothalamus was also noted within the mammillothalamic
tract, which connects the mammillary bodies to the anterior thalamus which plays
a role in spatial memory. PGE2 has previously been shown to be involved in long
term synaptic plasticity (Yang et al., 2009) however in mice this is modulated via the
EP2 receptor. In humans, however, EP3Re could be playing a similar role supported
by its presence in the hippocampal formation. Strong immunoreactivity was noted
in CA1, the main output pathway to the entorhinal cortex and subiculum. CA1 is
thought to be important in autobiographical and spatial memory and is particularly
vulnerable to neuronal loss in Alzheimer’s disease (Padurariu et al., 2012). EP3Re
3.5 Discussion 105
immunoreactivity was also observed within the cerebellum and the pons, an important
relay point between the forebrain and the cerebellum. Strong immunoreactivity was
also noted within the inferior olivary nuclei, a region that relays signals from the
spinal cord to the cerebellum regulating motor control and learning. EP3Re positive
neurons were present in regions consisting predominantly of monoaminergic neurons
such as the serotonergic neurons of the raphe nuclei and noradrenergic neurons in the
locus coeruleus. Monoaminergic systems are involved in cognitive regulation and the
presence of EP3Re may suggest a possible role for EP3Re in cognitive function and
monoamine release.
Our study observed by immunohistochemistry, the highest levels of EP3Re immunore-
activity within the brainstem, hypothalamus and cerebellum. When this was quantified
using western blotting the highest levels were noted again in the brainstem with
lower levels in the basal ganglia, however significant variation was noted between the
3 individuals used for the study, more variability than was suggested based on the
immunohistochemical analysis. Data obtained from the human protein atlas (Uhlen
et al., 2015), which combines RNA data from the genotype tissue expression project
(GTEx) and the functional annotation of the mammalian genome project (FANTOM5)
show levels of EP3 RNA within the human brain to be highest in the amygdala and
hypothalamus with significant variability across the two data sets, where between
139 – 255 individuals were sequenced for each data set, depending on the region.
This variation is similar to our findings examining protein levels and is likely to arise
from variations in gene expression as suggested by the human protein atlas. A larger
cohort would need to be studied to validate these findings. External individual factors
resulting in upregulation of protein expression in certain regions or factors affecting
fresh frozen tissue preservation could also have impacted our results. The study was
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limited to characterising EP3Re distribution, although immunohistochemistry using
the antibody directed against all EP3 isoforms was also performed. In subcortical
structures EP3Re immunoreactivity was observed predominantly in neurons whilst the
antibody directed against all EP3 isoforms showed staining in both neuronal and glial
cells. These results confirm the presence of other isoforms in the brain but the lack of
commercially available antibodies targeting individual isoforms, limited our ability to
explore this further. Future studies using quantitative reverse transcription polymerase
chain reaction (RT-qPCR) would allow us to better determine the expression of in-
dividual EP3 isoforms within the brain and how this compares to EP3Re. The main
limitation of RT-qPCR is the resolution obtained using immunohistochemistry, detail-
ing receptor expression within subcortical nuclei and cellular morphology, would be lost.
We also characterised the main signalling pathways activated by EP3Re. We show
that EP3Re signals predominantly through Gi coupling with evidence of Gq mediated
signalling. Despite the increase in CRE mediated gene transcription, there was no
evidence to suggest this was mediated through Gs coupling. Second messenger assays
showed no cAMP production even in the presence of pertussis toxin and CRE mediated
gene transcription was maintained when cells lacking the Gαs subunit were used to
perform the assays. These findings suggest the increase in CRE activity observed
is not as a result of EP3Re-Gs coupling. It has been observed the Gq coupling and
subsequent increase in Ca2+ can lead to CREB phosphorylation and CRE mediated
gene transcription (Rosethorne et al., 2008; Yang et al., 2013). In our study, EP3Re-Gq
coupling could have been responsible for the increase observed in CRE gene transcrip-
tion. There are several limitations to using reporter gene assays to explore G-protein
signalling. Although they are highly sensitive assays, the output measured is signif-
icantly downstream of the original event. Furthermore there is extensive cross talk
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between the various signalling pathways contributing to a final readout that may have
originated from a different G-protein than the one being assessed, as occurred in this
study. This was overcome through the use of second messenger assays by measuring
cAMP production for Gs coupling and IP1 for Gq and Gi. Measuring calcium mo-
bilisation could also have been used to assess Gq and Gi coupling (with the use of
the chimeric G-protein), however, IP1, a breakdown product of IP3, is upstream of
calcium mobilisation. Several other factors can influence calcium levels independent of
Gq coupling reducing the specificity of the assay making IP1 measurement a better
choice for assessing Gq and Gi activity.
Sulprostone, PGE2 and PGD2 were all found to bind to the EP3Re receptor with
sulprostone having the strongest affinity, followed by PGE2 then PGD2, with the
latter two being endogenous prostaglandins. PGD2 is one of the most abundant
prostaglandins within the central nervous system and has been implicated in regulation
of sleep, thermoregulation and nociception (Joo and Sadikot, 2012). PGD2 has also
been shown to be neurotoxic or neuroprotective depending on the receptor through
which it signals. DP1 in animal models of disease has been found to be protective
while DP2 is neurotoxic (Liang et al., 2005b). Further work will need to be done to
determine if PGD2-EP3Re signalling occurs under normal physiology and if this has
any implications for neurological disease.
These results have demonstrated that EP3Re is widely expressed in neurons throughout
the brain and signals through Gi, with some evidence of Gq, mediated signalling cas-
cades. The varying expression levels of EP3Re in specific neuronal populations could
explain regional specific responses of PGE2 signalling. Further work will be required
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to understand if and how this changes under inflammatory pathological conditions in a




110 THE RELATIONSHIP BETWEEN EP3RE AND TAU
4.1 Summary
Whilst establishing the distribution of the EP3e receptor in the human brain, it was
noted that the EP3Re antibody identified neurons containing what appeared to be
tau neurofibrillary tangles. Inflammatory prostaglandin signalling has been implicated
in the pathology of Alzheimer’s dementia but a direct association between PGE2
signalling and tau pathology is yet to be identified. The possibility that the PGE2
EP3e receptor co-localises with tau tangles could provide a mechanism through which
PGE2 signalling could be contributing to tau pathology. In this chapter I explore the
physical relationship between EP3Re and tau in order to determine if this incidental
finding could be significant. Using immunohistochemistry, we map the distribution
of EP3Re in a primary tauopathy (Progressive supranuclear palsy (PSP)) and in
Alzheimer’s dementia, having first established the antibody was not cross reacting with
tau. I then went on to extract insoluble filamentous tau from Alzheimer’s and PSP
brains with sarkosyl, and probed for the presence EP3Re using western immunoblotting.
To investigate and determine if there is an interaction between tau and EP3Re in
control as well as disease brains, proximity ligation assays on fixed sections and
immunoprecipitation on brain lysates was performed. Finally we directly visualise the
fibrils using electron microscopy labelling the EP3e receptor using immunogold. We
show a close interaction between EP3Re and filamentous tau.
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4.2 Introduction
In chapter 3 we characterised the distribution and signalling pathway of the human
specific E isoform of the prostaglandin E2 (PE2) EP3 receptor (EP3Re). In the course
of establishing the distribution within the human brain, it was noted that the antibody
directed against EP3Re appeared to identify neurons containing neurofibrillary tangles
(NFTs). Neurofibrillary tangles are a pathological hallmark of a group of neurodegen-
erative disorders known as tauopathies (Wang et al., 2015). These include Alzheimer’s
dementia, Progressive Supranuclear Palsy (PSP), Pick’s disease, Corticobasal degen-
eration (CBD) and Frontotemporal dementia with parkinsonism-17 (FTDP-17) (Lee
et al., 2001).
In the 80s several studies identified tau as the principle component of neurofibril-
lary tangles (Kosik et al., 1986; Wood et al., 1986). Enrichment of insoluble tau
aggregates using N-lauryl-sarcosine (sarkosyl) fractionates tau into soluble and in-
soluble components enabling the structural study of different tau species present in
aggregates across different tauopathies (Crowther, 1991; Falcon et al., 2018; Fitzpatrick
et al., 2017; Goedert et al., 1989; Zhang et al., 2020). Ultrastructural analysis of
fibrils isolated from Alzheimer’s dementia show these to be organised as paired helical
filaments (PHFs), a twisted double helicon of subunits giving rise to a structure that
alternates between 8 – 20nm in width (Crowther, 1991; Goedert et al., 1989). A minor
species referred to as straight filaments (SF), a variant of PHFs appearing as single
stranded filaments of 15nm, is also noted (Crowther, 1991). Electron micrographs of
tau filaments within inclusions in other tauopathies show some variability in structure
(Arima, 2006; Falcon et al., 2018; Ksiezak-Reding et al., 1994; Melo et al., 2014). PSP
consists of straight filaments of 13-14nm, CBD a combination of straight filaments
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(15nm) and wide twisted filaments (20nm), whilst in Pick bodies, the principal aggre-
gates in Pick’s disease, consist of 15-18nm straight filaments of varying lengths (Arima,
2006; Falcon et al., 2018). They are structured into β strands that form a pronase
resistant core with unstructured C and N tau terminal domains protruding to form a
fuzzy coat resembling a two layer polyelectrolyte brush (Wegmann et al., 2013). The
fibrils also differ by the tau isoform composition, with AD showing both 3R and 4R
tau, Picks disease 3R tau, and, PSP and CBD 4R tau (Arima, 2006).
In addition to tau, immunohistochemical and sequencing studies have identified other
cytoskeletal proteins, such as microtubule associated protein 2 (MAP2) (Alonso et al.,
1994, 1997, 1996) and neurofilament (Didonna and Opal, 2019) as being components
of neurofibrillary tangles in disease. NFTs have also been shown to display positive
immunoreactivity to a number of different antibodies ranging from structural proteins
to kinases and stress related molecules (Lennox et al., 1988; Richey et al., 1995; Taka-
hashi et al., 2006; Yen et al., 1995). Immunoreactivity does not necessarily reflect
that the protein is a structural component of NFTs, indeed most of these proteins,
are either found in extracellular tau, also known as ghost tangles (thought to occur
following neuronal death and disintegration of the cell membrane), or only some tan-
gles (Takahashi et al., 2006; Yamaguchi et al., 1994). This suggests that they are
unlikely to be structural or essential components of neurofibrillary tangles and could
simply be trapped in the filamentous aggregates. Despite this, they may still play a
role in promoting NFT formation or disease pathology. For example, the G-protein
coupled receptor kinase 2 (GRK2) has been found to co-localise with 40-50% of tau
tangles in Alzheimer’s dementia (Takahashi et al., 2006). Studies have also shown that
dysfunctional GRK2 signalling is associated with amyloid induced neuronal toxicity
(Suo et al., 2004) suggesting, despite not being a structural component of NFTs, its
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Fig. 4.1 Tau filaments. A) The longest tau isoform consists of 441 amino acids (AA) and
contains 4 repeat domains (AA 244-370). In fibrillar tau aggregates the repeat domains are
structured into βstrands forming the fibril core whilst the N and C termini protrude forming
the ’fuzzy coat’. B) Hyperphosphorylated tau organised as paired helical filaments (PHF)
and straight filaments (SF). C) Cryo-EM structure and fitted protein sequence of PHFs and
SFs as seen in cross-section taken from Fitzpatrick et al. (2017).
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presence within tau tangles has functional implications for disease pathology. Ubiquitin
is one of the first non-cytosolic proteins to have been identified as being a structural
component of tau tangles in a number of tauopathies (Lennox et al., 1988; Perry et al.,
1987). Ubiquitin, so called due to its ubiquitous expression, serves multiple functions
including as a cofactor for cytoplasmic proteolysis of abnormal or short lived proteins
(Ristic et al., 2014) and its presence in disease could reflect its inability to degrade
abnormally folded tau. The dysfunction of the ubiquitin proteasome degradation
system is thought to contribute to development of tau pathology (Oddo, 2008). It
is important to note that immunohistochemical analysis of tau tangles in PSP show
no immunoreactivity for ubiquitin (Lennox et al., 1988) suggesting that although it
may be contributing to the mechanism of disease, it is not a key component of all tau
tangles. Ubiquitin is also present in other neurodegenerative conditions likely to reflect
a common mechanism across several disorders rather than one unique to tauopathies
as it is a target for proteasome or trafficking which are common processes (Lennox
et al., 1988; Neumann et al., 2006; Spillantini et al., 1998). Other proteins that have
been identified as associating with tau in tangles include the oestrogen receptor (Wang
et al., 2016), and 14-3-3ζ (Qureshi et al., 2013). Loss of oestrogen signalling has been
shown to negatively impact cognition with loss of neuroprotection against glutamate
and amyloid (Daniel, 2006; Simpkins et al., 2012; Wang et al., 2016) whilst 14-3-3ζ
has been shown to actively promote tau phosphorylation and aggregation (Hashiguchi
et al., 2000; Sluchanko and Gusev, 2011). These studies all support an active role for
components of NFTs in the pathogenesis of disease, either through loss or gain of a
toxic function. An understanding of the constituents of tau tangles is important if we
are to understand how tau pathology develops.
The EP3 receptor mediates several functions of PGE2 within the central nervous
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system, and has been shown to play a critical role in the acute inflammatory response
(Goulet et al., 2004; Morimoto et al., 2014). Shi et al showed in a mouse model of
familial Alzheimer’s, the APPSwe-PS1δE9 (APPS) transgenic mouse, not only that
EP3 is upregulated correlating with disease progression, but that it is also critical for
transducing amyloidβ induced inflammatory responses (Shi et al., 2012a). EP3 deficient
mice displayed a marked reduction in amyloid and inflammatory proteins, with deletion
of only one allele being sufficient to reverse pathology (Shi et al., 2012a). Other studies
have shown that PGE2-EP3 signalling in mice impairs hippocampal synaptic plasticity.
In the same transgenic APPS mouse model, mentioned above, Maingret et al show
that EP3 signalling is responsible for the impaired hippocampal long term potentiation
(LTP) noted in these mice (Maingret et al., 2017). Administration of an EP3R agonist
in young mice is also able to reproduce impaired LTP, something that is fully rescued
on blockade of EP3 receptor signalling (Maingret et al., 2017). Although one must
be careful when translating animal studies to humans, particularly involving the EP3
receptor as these are species specific isoforms (Schmid et al., 1995), the involvement of
EP3 in the human condition has been shown based on its upregulation in post mortem
brains of patients with mild cognitive impairment and Alzheimer’s dementia (Shi et al.,
2012a). If EP3Re is found to be a constituent of tau tangles, this might support a role
for PGE2-EP3Re signalling as contributing to disease pathology in humans.
In this chapter we focus on a possible physical interaction between tau and EP3Re.
Based on the incidental finding of the EP3Re antibody identifying neurofibrillary
tangles in a control brain, we hypothesised that EP3Re is present in tau tangles
in disease. To establish this, we first mapped the distribution of the receptor in a
primary tauopathy, PSP, and in Alzheimer’s disease. We then explored the interaction
between EP3Re and tau through proximity ligation assays, immunoprecipitation and
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electron microscopy and demonstrate that EP3Re interacts with tau under pathological
conditions.
4.3 Materials and Methods
4.3.1 Antibodies
A full list of primary and secondary antibodies can be found in Table 2.1 and 2.2.
4.3.2 Human brain samples
Paraffin embedded and frozen sections from 5 AD and 5 PSP post mortem human
brains were obtained by ethical-committee approved procedures from the Cambridge
Brain Bank. Three serial sections from 11 different brain regions (midbrain, pons,
medulla, basal ganglia, hypothalamus, hippocampus, cerebellum, frontal, temporal,
occipital and parietal cortices) from each subject were used for this study. See Table
2.3 for details on clinical characteristics on each subject. Sarkosyl insoluble extract
from Pick’s disease, Multi-system atrophy (MSA) and Dementia with Lewy Bodies
(DLB), were kindly provided by the Goedert Lab (MRC-LMB, Cambridge). Frozen
tissue from a Parkinson’s disease (PD) brain was obtained from the Oxford brain bank
by ethical committee approved procedures.
4.3.3 Mouse sections
Paraffin embedded sections from the brainstem and cerebellum of 2 P301S transgenic
mice were kindly provided by Jack Brelstaff (Spillantini lab).
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4.3.4 Establishing distribution of EP3Re in tauopathies
Immunohistochemistry was performed as described in 2.2.1 on 40 µm paraffin embedded
sections from 3 AD and 3 PSP subjects using antibody directed against EP3Re diluted
1:250. The results were compared with those obtained in Section 3.4.2. Adjacent
sections from regions associated with tau pathology in both PSP (midbrain, pons,
medulla, and basal ganglia nuclei) and AD (neocortex and hippocampus) were taken
and stained with EP3Re or AT8 antibodies to observe EP3Re distribution in relation
to tau tangles. Sections from these regions from each subject were then double stained
using primary antibodies AT100 and EP3Re, followed by HRP conjugated secondary
antibodies and developed in the peroxidase substrates 3-3’ diaminobenzidine (DAB) or
Vector VIP (V-VIP) providing brown and purple staining respectively. Sections were
also double stained with AT100 and EP3Re using fluorescent-conjugated secondary
antibodies following treatment by auto-fluorescence eliminator as described in 2.2.11
to determine co-localisation. In sections taken from AD, in addition to double-staining
with AT100 and EP3Re, double immunohistochemistry was also performed using
anti-amyloid and anti-EP3Re antibodies. Western blotting was performed to quantify
EP3Re expression in the neocortex and brainstem in 3 AD, 3 PSP and 3 control
subjects. This was compared with AT8 expression in each of these regions.
4.3.5 Determining if EP3Re antibody identifies tau
To determine if EP3Re antibody recognises tau tangles, further immunohistochemistry
was performed on sections obtained from the hindbrain of transgenic P301S mice
(see 2.1.3). P301S mice do not express EP3Re but do develop tau tangles. Adjacent
brainstem and cerebellar sections from 2 P301S mice were stained with anti-EP3Re and
AT8 antibodies as per the protocol described in 2.2.1. Recombinant monomeric tau
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was run on a western blot and probed using EP3Re and tau antibodies to determine if
an epitope from monomeric tau is recognised by the EP3Re antibody. Finally, human
fibrillar tau was extracted using sarkosyl detergent as described in 2.2.3 from frozen
brain tissue from 3x Alzheimer’s case. This was run on western blot and probed using
EP3Re antibody with and without EP3Re peptide preadsorbtion, as described in 2.2.2.
4.3.6 Determining the presence of EP3Re in fibrillary tau
extract
Tau fibrils were extracted from 3 AD and 2 PSP brains using sarkosyl detergent as
described in 2.2.3. Some extracts from each subject underwent further treatment with
guanidinium hydrochloride and alkaline phosphatase to unravel and dephosphorylate
the tau contained in the filaments as described in 2.2.4. Western blotting was performed
on all lysates which were probed for the presence of EP3Re.
4.3.7 Proximity ligation assay between EP3Re and tau
Proximity ligation assays were performed as described in 2.2.9 on paraffin embedded
sections from 3 AD, 3 PSP and 3 age matched control subjects.
4.3.8 Immunoprecipitation of tau in Alzheimer’s
Fresh frozen tissue from the frontal cortex and hippocampus of 3 AD patients and
age matched controls was homogenised in RIPA and tau immunoprecipitated from
the lysate (see section 2.2.6 for detailed protocol). This was then run on a western
blot and probed for the presence of EP3Re. Sarkosyl detergent as described in 2.2.3
was then used to extract tau fibrils from the frontal cortex and hippocampus of 3 AD
subjects and age matched controls. EP3Re was immunoprecipitated from the sarkosyl
4.3 Materials and Methods 119
insoluble extract, as well as the supernatant, which is enriched with soluble tau in AD
subjects. The immunoprecipitate was then run on a western blot and probed for the
presence of tau.
4.3.9 Immunogold negative stain electron microscopy of tau
fibrils
Tau fibrils were extracted from 3 AD, 2 PSP and 1 Picks disease patient using sarkosyl
as described in 2.2.3. Extracts were then used for immunogold electron microscopy
and stained with primary antibody directed against EP3Re and secondary antibody
conjugated to gold particles. Some of the extracts from AD subjects were treated with
pronase, to eliminate the external fuzzy coat from the filaments, prior to application
of the primary antibody. These were then visualised using an electron microscope.
To determine the specificity of any interaction seen between EP3Re and tau fibrils,
extracts containing alpha-synuclein inclusions from subjects with PD, MSA and DLB
were also immunogold labelled with EP3Re antibody and visualised under the electron
microscope. For full details of immunogold electron microscopy protocol please see
2.2.7.
Immunolabelling of extracted tau fibrils from 2 AD subjects was performed with
the assistance of Ben Falcon and Manual Schweighauser (Goedert Lab, LMB, Univer-
sity of Cambridge). Immunogold labelling and images of extracted tau fibrils from 1
AD, 2 PSP, 1 Pick’s disease and all alpha-synuclein fibrils were performed by Mehtap
Bacioglu, (Spillantini lab).
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4.3.10 Statistics
Analyses of differences in EP3Re and phospho-tau (AT8) expression across control
subjects, Alzheimer’s and PSP was performed using two way ANOVA with multiple
comparisons. Statistical significance was considered at p<0.05. Correlation between
EP3Re protein expression and phospho-tau (AT8) was calculated using Pearson’s
correlation. Statistical significance was considered at p <0.05.
4.4 Results
4.4.1 The EP3Re associates with neurons containing struc-
tures similar to tau aggregates in control brain
In examining the distribution of EP3Re in control brain it was noted that in some
hippocampal sections the antibody identified neurons containing structures similar in
morphology to neurofibrillary tangles (NFTs) (Fig. 4.2). With this unexpected finding,
we needed to ensure the antibody was not cross reacting with a tau epitope causing
non-specific binding.
4.4.2 The EP3Re antibody does not recognise tau
In order to establish that the staining results observed in Fig. 4.2 were not an artefact
due to non-specific binding of the EP3Re antibody to tau, paraffin embedded sections
from 5 month-old P301S mice were stained with EP3Re and adjacent sections stained
with the anti-tau phosphorylation dependent antibody AT8. P301S mice express
human tau with the P301S mutation and develop extensive pathology in the brainstem
and deep nuclei of the cerebellum by 5 months of age. As EP3Re is specific to higher
primates, these provide a background expressing tau NFTs and no EP3Re. Results are
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Fig. 4.2 The EP3Re antibody identifies neurons with neurofibrillary tangle-like
morphology in control brain. Control brain hippocampal sections stained with the
EP3Re antibody and a Progressive Supranuclear Palsy (PSP) brain section stained with
the phosphorylation dependent anti-tau antibody, PHF1. The EP3Re antibody identifies
neurons containing aggregates similar in appearance to tau tangles.
shown in figure 4.3A. No specific staining is seen with the EP3Re antibody while AT8
clearly identified the presence of NFTs in the P301S mouse sections. Based on these
results and the staining conditions used the EP3Re antibody did not cross react with
hyperphosphorylated tau.
To exclude non specific binding to monomeric tau I performed a western blot us-
ing human recombinant tau probed with the EP3Re antibody (Fig 4.3B). The EP3Re
antibody failed to identify any of the tau isoforms. All 6 isoforms are seen when the
same blot is probed using the total tau antibody (Dako tau). Therefore anti-EP3Re
antibody does not recognise recombinant monomeric tau. Finally, fibrillar tau was
extracted from an Alzheimer’s brain using sarkosyl and run on a western blot. This
was then probed with the EP3Re antibody preadsorbed with EP3Re peptide so as
to saturate all EP3Re binding sites and determine whether the antibody could still
see neurofibrillary tangles. No bands were seen. It seems therefore that following
122 THE RELATIONSHIP BETWEEN EP3RE AND TAU
preadsorption of EP3Re, no other independent epitopes in fibrillar tau are recognised
by the antibody.
Fig. 4.3 EP3Re antibody does not recognise tau A) Sections taken from the cerebellum
and brainstem of 5 month old transgenic P301S mice. Adjacent sections have been taken from
each mouse. In the upper panel, sections are stained with the phosphorylation dependent tau
antibody AT8. The presence of tau aggregates is clearly visible. These tau aggregates are not
stained by the EP3Re antibody as shown in the lower panel indicating that EP3Re antibody
does not recognise tau tangles in the absence of the receptor. n=2 B) Recombinant human
tau (Sigma-Aldrich 6 human isoforms expressed in E.Coli) probed with EP3Re antibody
then stripped and re-probed with tau antibody (Dako). Despite the long exposure no bands
can be seen when the blot is probed with the EP3Re antibody. All 6 tau isoforms are clearly
seen when probed with anti-tau antibody (HT7). The EP3Re antibody does not recognise
recombinant human tau C) Western blot of sarkosyl extracts from Alzheimer’s disease. The
left panel shows the sarkosyl extract probed for the presence of tau (HT7). Panel on the right
shows the extract probed by the EP3Re antibody before (middle panel) and after (far right
panel) preadsorption with the EP3Re peptide. No bands are seen following preadsorption of
the antibody. A band corresponding to the EP3Re receptor is present around 45kDa. Some
protein bands are stained by the EP3Re antibody below 55kDa and one just above. These
bands do not appear to colocalise with the 60, 64 and 68 kDa bands characteristic of tau
from AD brain.
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4.4.3 Distribution of EP3Re in Tauopathies
To investigate the apparent association between EP3Re and NFTs, I proceeded to
establish the distribution of the receptor in tauopathies. Paraffin embedded sections
from 11 different regions were obtained from 3 patients with a primary tauopathy,
progressive supranuclear palsy (PSP) and 3 patients with a secondary tauopathy,
Alzheimer’s disease (AD) and stained with the EP3Re antibody. Pathologically, PSP
is characterised by the presence of neuronal inclusions consisting of predominantly
4-repeat (4R) tau whilst AD has a mixture of 3-repeat (3R) and 4R tau. In both
PSP and AD brains, the antibody identified neurons containing dense intracellular
aggregates similar to NFTs suggesting an association between EP3Re and NFTs that
is independent of tau isoform composition.
4.4.3.1 EP3Re in PSP
Staining of sections from PSP cases showed a normal pattern of EP3Re expression
as seen in control brains as described in Chapter 3. In addition to the characteristic
punctate cytoplasmic staining in neurons, dense neuronal aggregates are also identified
by EP3Re antibody. Within the neuropil, there also appears to be stained structures
consistent with neuropil threads. Given the similarity in appearance to NFTs, I decided
to focus further analysis on regions associated with tau pathology in PSP, mainly the
basal ganglia and brainstem nuclei. These were stained with EP3Re or the phospho-tau
specific antibody, AT8. This can be seen in Fig 4.4. Aggregates identified by AT8
are very similar in morphology to those identified by EP3Re antibody supporting the
initial observation that the structures being identified by EP3Re antibody are likely
to be tau aggregates. To confirm possible co-localisation of EP3Re and tau within
the neurons, I proceeded to perform double immunohistochemical staining using the
phospho-tau antibody AT100 (DAB) and EP3Re (V-VIP). Initial results proved difficult
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to interpret unequivocally. The density of the aggregates makes it difficult to visualise
the different chromogens (Fig 4.5A).To address this I performed immunofluorescence
staining. Double immunofluorescence staining is a common method used to determine
colocalisation, however, due to the amount of autofluorescence in human tissue, it can
be difficult to visualise the protein of interest. To reduce autofluorescence, sections
were pre-treated using autofluorescence eliminator reagent (Millipore) and then stained
with AT100 and EP3Re antibodies. Figure 4.5B shows double immunofluorescence
staining confirms these are tau aggregates.
4.4.3.2 EP3Re in Alzheimer’s dementia
Similarly to PSP, also in AD patients EP3Re has a distribution similar to control
subjects (Fig 4.6). Neurons containing dense aggregates similar to neurofibrillary
tangles were again stained by the anti-EP3Re antibody. As with PSP, sections from
regions strongly associated with tau pathology in AD, the cortex and the hippocampus,
were stained with the phospho-dependent anti-tau specific antibody AT8 (Fig 4.7).
Neurons identified by AT8 were similar in appearance to some of those identified
by EP3Re antibody further supporting that EP3Re could be associated with tau
aggregates. Double immunofluorescence staining with antibodies directed against
EP3Re and phosphorylated tau (AT100) suggest that also in AD, like PSP, the two
proteins colocalise (Fig 4.8). Alongside intracellular NFTs, AD is also characterised by
the presence of extracellular amyloid plaques. Sections from each brain region were
then double stained with antibodies directed against beta-amyloid and EP3Re (Fig 4.8).
Unlike the intracellular tau aggregates, there was no colocalisation of beta-amyloid
and EP3Re in amyloid plaques.
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Fig. 4.4 EP3Re and Tau in Progressive Supranuclear Palsy. Sections shown have
been taken from the brainstem, basal ganglia and cerebellum where extensive tau pathology
can be found in PSP. From each region a section was stained with either EP3Re antibody
(right panel) or AT8 (left panel) to identify tau pathology. The distribution of the receptor
remains the same as control cases but in addition to the normal cytoplasmic staining observed,
neurons containing dense aggregates (black arrows) are also identified by EP3Re antibody.
These aggregates are similar in appearance to tau aggregates identified by AT8. n=3. Images
shown are representative of the staining observed across all 3 patients.
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Fig. 4.5 EP3Re associates with tau aggregates in Progressive Supranuclear Palsy.
A) Medulla section from a PSP patient double stained with the phospho-tau antibody AT100
and anti-EP3Re. EP3Re positive AT00 negative cells can be seen (red arrow). The density of
AT100 positive inclusions (black arrow) make it is difficult to determine if the aggregate is also
EP3Re positive. There is also significant background staining. B) Double immunofluorescence
staining of PSP sections show EP3Re positive aggregates are tau tangles as identified by
AT100.
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Fig. 4.6 EP3Re in Alzheimer’s dementia. EP3Re staining of sections taken from the
parietal cortex of an AD patient and age matched control. EP3Re distribution is the same in
control and AD cases but in AD sections the antibody also identifies neurofibrillary tangles.
EP3Re positive staining is noted in a neuritic plaque (black arrow). n=3. Images shown are
representative of staining seen across all 3 subjects.
4.4.3.3 EP3Re protein expression is increased in regions associated with
tau pathology
In order to contrast EP3Re expression levels between control and disease brains, brain
lysate from the brainstem and frontal cortex, were obtained from AD, PSP and age
matched controls, samples were run on a gel and immunoblotted with the anti-EP3Re
antibody. This study was performed with tissue from brain regions associated with tau
pathology in AD and PSP. The blot was also probed with the phospho-tau antibody
AT8. There appears to be a correlation between AT8 and EP3Re (R2=0.6, p<0.005)
suggesting that in regions associated with high levels of phosphorylated tau there is an
increase in EP3Re protein expression (Fig. 4.9).
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Fig. 4.7 EP3Re and Tau in Alzheimer’s disease Sections taken from the neocortex and
hippocampus from AD brains. Sections from each region have been stained with either EP3Re
(left panel) or AT8 (right panel). Neurofibrillary tangles (black arrows) identified by EP3Re
antibody are similar in appearance to AT8 positive tangles. n=3. Images representative of
staining seen across all 3 subjects.
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Fig. 4.8 EP3Re co-localises with tau tangles but not amyloid in Alzheimer’s. A)
Neocortical sections from AD subjects stained with EP3Re (VVIP) and βamyloid (DAB).
Extracellular amyloid plaques (red arrowheads) do not show any EP3Re immunoreactivity.
EP3Re positive neurofibrillary tangles can also be seen (black arrows). B) AD sections stained
with AT100 and EP3Re antibodies. Double immunohistochemistry is difficult to interpret
due to density of AT100 positive aggregates (black arrow). EP3Re positive AT100 negative
cells are also seen (red arrows). C) Double immunofluorescence staining of AD sections with
AT100 and EP3Re antibodies. AT00 positive neurons co-localise with EP3Re (white arrows).
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Fig. 4.9 EP3Re expression correlates with levels of tau phosphorylation. A)
Immunoblot showing EP3Re and AT8 levels in the brainstem and frontal cortex of a control,
AD and PSP patient. B) EP3Re expression across AD, PSP and control brains in the
brainstem and frontal cortex. The graph on the right shows EP3Re levels expressed as a fold
increase in comparison to control EP3Re expression by region. Two way ANOVA performing
multiple comparisons by region demonstrates significant differences in EP3Re levels in the
midbrain and frontal cortex between groups. EP3Re is significantly elevated in the midbrain
in PSP and frontal cortex in AD. These are both regions known to exhibit tau pathology
in disease. C) AT8 (phosphorylated tau) levels across AD, PSP and control brain in the
brainstem and frontal cortex. Analysis demonstrates differences in AT8 expression across
regions within the different groups with higher levels of tau phosphorylation in brainstem
regions in PSP when compared to control and AD, and higher levels of tau phosphorylation
in the frontal cortex of AD patients. D) There is a strong correlation between EP3Re
expression and levels of phospho-tau as identified by AT8, R2=0.6, p<0.005. Results shown
representative of 3 technical replicates of 1 AD, 1 PSP and 1 Control subject. AD - Alzheimer’s
disease, PSP - Progressive supranuclear palsy, Ctrl - control.
4.4.4 EP3Re is present in sarkosyl extract from AD and PSP
brains
To further investigate the extent to which the EP3Re receptor associates with hy-
perphosphorylated tau, I proceeded to establish if the receptor was present in brain
lysate containing insoluble filamentous-tau from diseased brains. I used sarkosyl
extraction to obtain aggregates from 2 AD and 1 PSP subject. The preparations
were fractionated into soluble and insoluble tau extracts, with the insoluble extracts
containing filamentous-tau. The insoluble tau, alongside the supernatant containing
sarkosyl soluble proteins, was then run on a gel and a western blot performed using the
anti-EP3Re antibody (Fig. 4.10A). The results show that EP3Re is present in fibrillar
tau extracted from both PSP and AD brains.
The next question I needed to answer was whether the EP3Re receptor was an
intrinsic part of the tau fibril or if the association was only present when tau had
undergone a conformational change secondary to hyperphosphorylation. To answer
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this, I used guanidine isothiocyanate to disaggregate the filamentous-tau extracted
using sarkosyl from frontal cortex of AD subjects and treated the samples with alkaline
phosphatase to remove the phosphate groups. The samples were then probed for the
presence of EP3Re. As figure 4.10B shows, the receptor is present in both the sarkosyl
extract (as previously demonstrated) and in the extract treated with guanidinium and
alkaline phosphatase, suggesting that in AD brains, the EP3Re receptor is intrinsically
associated with the fibril. The EP3Re receptor bands appear distinct from the tau
bands reducing the possibility of antibody cross-reactivity.
When probing the extracts containing fibrillar tau with the EP3Re antibody, it was
noted that the antibody recognises a band of around 55kDa, which is a higher molecular
weight than that expected for the receptor of 46kDa. It was important to investigate
whether the band on the blot was due to non-specific binding of the antibody or if
this corresponded to an oligomer of the receptor. Adding diothiothrietol (DTT) to the
extract prior to running it on the gel and blotting is a method described to dissociate
oligomers (Copani et al. 2000). By adding 20mM of DTT, I was able to eliminate the
55kDa band suggesting that it was an oligomer of the receptor due to disulphide bond
formation (Figure 4.10C).
4.4.5 EP3Re interacts with tau in Tauopathies but not con-
trol brains
Having established the presence of the EP3Re receptor in filamentous tau, I wanted to
explore the extent of this interaction. Paraffin embedded sections were taken from AD,
PSP and age matched controls, probed for the presence of EP3Re and tau, and proxim-
ity ligation assays performed to determine the proximity of the two proteins. A strong
signal can be seen in disease brains which is absent in sections from control suggesting
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Fig. 4.10 EP3Re is present in tau fibrillar extract from AD and PSP A) Im-
munoblot of AD and PSP brain sarkosyl extract probed with antibodies directed against
human tau (HT7) and EP3Re. With sarkosyl extraction the protein is separated into soluble
and insoluble components, with the latter containing PHF-tau. Both soluble (S) and insoluble
(P) components were run on the blot and probed for the presence of EP3Re. The receptor is
present in both extracts (expected weight of 46kDa highlighted by red box). Representative
blot of 5 independent experiments. B) The sarkosyl extract from AD brain (PHF tau)
is treated with guanidinium to unravel the filaments and dephosphorylated with alkaline
phosphatase. The samples probed with the anti- tau antibody (Dako) show that the extract
has been successfully dephosphorylated given the downward shift in the bands when compared
to the sarkosyl extract with no treatment. The immunoblot shows that EP3Re remains
present in both the sarkosyl extract and the untangled and dephosphorylated extract (boxed
bands). C) A heavier molecular weight band just below 55kDa is present when sarkosyl
insoluble extract from AD and PSP subjects is probed for EP3Re, as shown in A and B. This
band disappears following the addition of 20mM DTT to the sarkosyl extract suggesting that
it corresponds to an oligomeric form of the EP3Re receptor. AD - Alzheimer’s dementia,
PSP - Progressive supranuclear palsy, AP - Alkaline phosphatase, DTT - dithiothreitol, PHF
- Paired helical filaments, Rec tau - Recombinant tau.
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a close interaction between EP3Re and tau but only in tauopathies (Fig 4.11A).
I then went on to immunoprecipitate EP3Re from whole brain lysate from the frontal
cortex extracted from Alzheimer’s brains and age matched controls. The precipitated
material was run on a western blot and probed for the presence of EP3Re as shown in
figure 4.11B. The EP3Re receptor is immunoprecipitated alongside tau in Alzheimer’s
brain but not in extract from control brain suggesting a close interaction between EP3Re
and tau present only in disease, further supporting the findings from the proximity
ligation assay. The lysate was then separated into sarkosyl insoluble (filamentous tau)
and the supernatant, containing hyperphosphorylated but not aggregated tau. In the
immunoprecipitate from the sarkosyl insoluble extract bands can be seen around 64kDa
which are absent from the control lane suggesting tau co-immunoprecipitates alongside
EP3Re in the sarkosyl insoluble extract. The presence of heavy and light chain IgG
bands make it difficult to determine if any further bands are present (Fig 4.11C). In
the supernatant of the sarkosyl soluble extract no clear bands can be seen to suggest
tau has been immunoprecipitated alongside EP3Re. (Fig 4.11D).
4.4.6 EP3Re is present in tau fibrils
So far I have shown that EP3Re associates with neurofibrillary tangles and closely
interacts with tau in disease but to determine true co-localisation, I need to directly
visualise tau fibrils. Tau filaments were extracted using sarkozyl from the frontal cortex
of 3 individuals with sporadic AD, 2 with PSP and 1 with Pick’s disease, a tauopathy
characterised by accumulation of 3 repeat (3R) tau inclusions. Fibrils were labelled
with EP3Re antibody and gold nanoparticle conjugated secondary antibody. The
resulting staining on tau filaments was visualised by electron microscopy. Figure 4.12
shows tau filaments are clearly decorated with EP3Re in all analysed tauopathy cases
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Fig. 4.11 Tau interacts with EP3Re in disease but not controls. A) PLA using
EP3Re and HT7 (tau) antibodies performed on paraffin embedded sections obtained from
AD, PSP and control brains. There is a strong signal in tauopathies that is absent in control
brain sections suggesting a close interaction between EP3Re and tau in disease. n=3AD,
3PSP and 3 control. Representative image shown. B) Brain extract from frontal cortex
of control and AD brains immunoprecipitated using anti-Tau HT7 antibody, probed for
EP3Re. EP3Re is co-immunoprecipitated alongside tau in AD but not in control brain
C) EP3Re immunoprecipitated from AD sarkosyl insoluble extract, containing filamentous
tau, and probed for the presence of tau. Sarkosyl insoluble tau from AD brain runs as 4
bands at 62kDa, 64kDa, 68kDa and a lighter band is often seen at around 72kDa. Lower
bands can also be seen in the blot which are likely to represent degradation products. Two
bands are seen in the sarkosyl extract after prolonged exposure around 64kDa and 72kDa
that co-immunoprecipitated alongside EP3Re (black arrows). IgG bands can be seen at
around 50kDa (heavy chain) and 75kDa (combination of heavy and light chain). D) EP3Re
immunoprecipitated from the supernatant fraction. No clear bands are seen, despite prolonged
exposure, to suggest that tau co-immunoprecipitates with EP3Re in the supernatant.
showing that EP3Re co-localises and is a component of tau fibrils. In AD cases this can
be seen with both paired helical filaments (PHFs) and straight filaments (SFs) showing
the interaction is not conformation specific. The antibody directed against EP3Re fails
to label tau filaments created from recombinant tau, lending further support to the
specificity of the antibody. The presence of EP3Re in tau fibrils extracted from AD,
PSP and Pick’s disease shows this interaction is irrespective of tau isoform. Pronase
treatment removing the fuzzy coat eliminates EP3Re suggesting EP3Re binds to tau
in the fuzzy coat and not the pronase resistant core.
4.4.7 EP3Re associates specifically with tau and not with
other protein aggregates associated with neurodegen-
erative disorders.
Having shown that EP3Re is associated with tau fibrils, I wanted to determine if this
interaction is unique to tau or if it is an association that occurs with other aggregated
protein. We know from figure 4.8 that EP3Re does not co-localise with amyloid
4.4 Results 137
Fig. 4.12 EP3Re is present in tau fibrils. A) PHFs extracted from Alzheimer’s dementia,
PSP and Pick’s disease negatively stained and labelled with primary EP3Re antibody and
secondary gold particles. EP3Re can be seen decorating the fibrils in each disease. EP3Re is
present in both straight filaments and paired helical filaments extracted from Alzheimer’s
brains. EP3Re is not present in fibrils made from recombinant tau. B) Fibrils extracted from
Alzheimer’s brain labelled with tau antibody. C) PHFs were treated with pronase stripping
fibrils of the fuzzy coat leaving only the pronase resistant core. Pronase treatment removes
EP3Re labelling suggesting that EP3Re is bound to tau within the fuzzy coat. n= 3 AD, 2
PSP and 1 Pick’s disease
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plaques. We also analysed disorders characterised by the accumulation of aggregates
consisting of TAR-DNA-binding protein-43 (TDP-43) and alpha-synuclein. TDP-43 is
a major component of inclusions found in sporadic and familial frontotemporal lobe
degeneration with ubiquitin positive inclusions (FTLD-U) as well as most forms of
amyotrophic lateral sclerosis. Sections from a patient with FTLDU were stained with
both the TDP-43 antibody and EP3Re (Fig 4.13A). EP3Re fails to identify TDP-43
inclusions. Alpha-synuclein is the primary structural component of insoluble aggregates
found in Parkinson’s disease, Multiple system atrophy (MSA) and dementia with
Lewy bodies (DLB). Paraffin embedded sections from a Parkinson’s disease patient
were stained with anti-alpha synuclein antibody, LB509, to identify alpha-synuclein
aggregates, with adjacent sections stained with EP3Re antibody. Comparing the
pattern of staining, it appears that there is no association between EP3Re and alpha-
synuclein aggregates. Sections from a patient with MSA were then double stained
with EP3Re and LB509. MSA presents with glial cytoplasmic inclusions consisting of
alpha-synuclein. The results of immunohistochemistry are difficult to interpret due
to the density of the alpha-synuclein inclusions and the identification of monomeric
alpha-synuclein in EP3Re positive cells. Co-localistion between EP3Re and alpha-
synuclein aggregates can not be excluded based on this immunohistochemistry study.
To address this, we directly visualised alpha-synuclein fibrils extracted from a PD
patient following labelling with EP3Re primary and gold labelled secondary antibody,
using electron microscopy. EP3Re is not present in alpha-synuclein fibrils. (Fig 4.13D).
This was repeated on alpha-synuclein fibrils extracted from MSA and DLB patients
which showed no labelling of alpha-synuclein with EP3Re (not shown).
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Fig. 4.13 EP3Re does not associate with other protein aggregates associated
with neurodegeneration. A) FTLD-TDP43 section stained with TDP43 and EP3Re
antibodies. There is no obvious co-localisation between TDP43 inclusions (red arrowhead)
and EP3Re (black arrowhead). B) Adjacent sections from the basal ganglia of a PD patient
stained with EP3Re antibody and LB509 (alpha-synuclein). Two different patterns of staining
are seen in the same region between the two proteins. EP3Re antibody fails to identify Lewy
bodies in Parkinson’s sections. C) MSA section double stained with LB509 (alpha-synuclein)
and EP3Re. The double staining is difficult to interpret. As shown, the EP3Re positive
staining (red arrow) can be seen below dense alpha-synuclein inclusions (black arrow) in
some neurons. The density of surrounding aggregates means co-localisation with EP3Re can
not be determined. D) Electron microscopy of alpha synuclein fibrils stained with EP3Re
antibody rules out EP3Re and alpha-synuclein co-localisation in Parkinson’s disease. EM
images of alpha-synuclein fibrils taken by Mehtap Baciolugu.
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4.5 Discussion
This study investigates a possible link between EP3Re and tau in tauopathies and
shows that EP3Re is increased in regions associated with tau pathology. EP3Re
appears to be a previously unidentified component of tau tangles.
The distribution of EP3Re protein in tauopathies is similar to that of control brains with
the exception that it identifies with tau aggregates demonstrating a strong correlation
between EP3Re and phospho-tau protein expression. We know from previous studies,
using an antibody that recognises all EP3R isoforms, that EP3R is upregulated in post
mortem brains of patients with mild cognitive impairment and Alzheimer’s disease
(Shi et al., 2012a) and therefore this is not unexpected. What has previously not been
described is a specific interaction between EP3Re and tau. Immunohistochemistry
alone proved insufficient to show co-localisation due to the density of aggregates. This
was overcome through the use of immunofluorescent staining as well as proximity
ligation assays, immunoprecipitation and electron microscopy. In paraffin embedded
sections we show through proximity ligation assays an interaction between EP3Re
and tau in Alzheimer’s disease and PSP but not in sections from control subjects.
We obtained paired helical filaments (PHFs) from a number of Alzheimer’s patients
and in each case we found that EP3Re co-immunoprecipitated with tau indicating
EP3Re is closely associated to tau in PHFs. This association was not present in control
brain extract, containing monomeric tau. EP3Re fails to identify with other protein
aggregates associated with neurodegenerative disorders examined as part of this study,
such as amyloid, alpha-synuclein or TDP-43 as demonstrated by immunohistochemistry
and immunogold electron microscopy. The specificity of this interaction suggests a
possible role of EP3Re in tau pathology.
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We also show, through electron microscopy studies, that EP3Re is present in tau
tangles irrespective of the type of tau isoforms present in the filaments. EP3Re recep-
tor was present in fibrils extracted from Pick’s disease (3R tau), PSP (4R tau) and
Alzheimer’s dementia (combination of both 3R and 4R tau). Tau fibrils consist of a
core, formed from short β strands, with unstructured tau terminal domains protruding
from the core, known as the fuzzy coat (Wegmann et al., 2013). This coat can be
stripped off by proteolytic digestion as demonstrated here with pronase. In this study
we show removing the fuzzy coat with pronase, also eradicates EP3Re labelling of
the fibrils suggesting the interaction between EP3Re and tau is within the fuzzy coat
and not the pronase resistant core. We also show, through western blotting, that the
interaction between EP3Re and tau remains present following unravelling and dephos-
phorylation suggesting EP3Re is not simply being sequestered by the fuzzy coat but
there is an intrinsic interaction between the tau terminal domains and EP3Re. Prior
to this study, ubiquitin is the only other non-cytosolic protein to have been identified
as being bound to tau in NFTs. Although we have performed many experiments to
exclude that our results represent a cross reactivity between the EP3Re antibody and
tau, showing that the antibody fails to recognise tau in filaments made of recombi-
nant tau or in mouse brain, only mass spectrometry of sarkosyl tau extract could
definitely confirm the absence of cross reactivity and presence of EP3Re in the filaments.
Studies have shown the propensity of tau aggregates to form clusters is influenced
by the charge of the N-terminal projection within the fuzzy coat (Wegmann et al.,
2013). A more acidic environment providing a positive charge results in a filament
more prone to forming clusters. Arachidonic acid, the precursor to PGE2 is known to
rapidly promote tau fibrillisation in vitro, a finding that has been demonstrated for a
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number of free fatty acids (Lim et al., 2014; Wilson and Binder, 1997). The presence
of a PGE2 receptor within the N-terminal projections could reflect a mechanism by
which PGE2 contributes to formation of tau fibrils by creating a more pro-aggregation
environment. This raises the question of whether or not EP3Re remains functional if
bound to tau within the cytoplasm.
As previously described EP3Re is a G-protein coupled receptor (GPCR). Tau has
been known to sequester other GPCRs, such as the oestrogen receptor, resulting in
their loss of function with subsequent clinical implications (Wang et al., 2016). EP3R
receptors in the median preoptic area have been shown to be necessary for the febrile
response with EP3R receptors in the hypothalamus playing an inhibitory role (Lazarus
et al., 2007). Although the specific role of the EP3Re isoform has not been explored,
if the receptor in tauopathies is bound to tau fibrils with subsequent loss of function,
this could lead to deficits in thermoregulation. Thermoregulatory deficits have been
shown to correlate with a rise in the incidence of Alzheimer’s (Tournissac et al., 2017)
with both in vitro and in vivo studies showing an increase in tau phosphorylation in
relation to hypothermia (Bretteville et al., 2012; Whittington et al., 2010). Impaired
thermoregulation due to dysfunctional EP3 signalling, could potentially be contributing
or exacerbating tau pathology.
EP3Re, as a GPCR, is normally bound to the cell membrane. Signal transduction by
GPCRs has traditionally thought to be uniquely confined to the plasma membrane but
recent studies contradict this showing that internalised GPCRs can continue to signal
(Godbole et al., 2017; Irannejad et al., 2013; Jensen et al., 2017; Pavlos and Friedman,
2017). GPCRs are able to initiate signalling from various subcellular locations with
location specific responses (Irannejad et al., 2017). This opens the possibility that
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instead of a loss of EP3Re function, the translocation of EP3Re from the membrane
to within the cytoplasm results in normal receptor function or an altered function.
This is something that will need to be further explored to determine the functional
significance of this finding. Beyond the functional implications of this finding, the
other question this raises is how the interaction occurs. How does a membrane bound
receptor interact with tau within the cytoplasm? There is accumulating evidence
to suggest that tau interacts with the plasma membrane (Maas et al., 2000; Pooler
and Hanger, 2010; Pooler et al., 2012). The projection domain, located in the N-
terminal, is thought to mediate this process, localising tau to the plasma membrane
(Brandt et al., 1995). It has been suggested that the targeting of tau to the plasma
membrane plays a role in cell signalling pathways and neurodevelopment (Pooler and
Hanger, 2010). Once at the plasma membrane tau has been shown to interact with
the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor under
ischaemic conditions (Cardona-Gomez et al., 2006) suggesting other membrane bound
receptors could be targeted by tau at the plasma membrane, including EP3Re, when
the neuron is under stress. Alternatively, tau could be interacting with EP3Re on the
extracellular surface. Tau secretion has been observed in several models of tauopathies
(Chai and et Al., 2012; Katsinelos and et Al., 2018; Sayas et al., 2019). However 90%
of extracellular free tau is monomeric (Dujardin et al., 2014; Wang et al., 2017) and
this study finds no interaction between monomeric tau and EP3Re. EP3Re could still
interact with extracellular aggregated tau. Several in vivo and in vitro studies support
the hypothesis that tau pathology propagates in a prion-like manner (Clavaguera et al.,
2009, 2015; Sonawane and Chinnathambi, 2018). Mechanisms that have been proposed
to explain intra-neural transfer of tau aggregates include being transported into the
extracellular space in exosomes or through ectosomes (Asai et al., 2015; Dujardin et al.,
2014; Wang et al., 2017), through endocytosis and macropinocytosis (Zeineddine and
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Yerbury, 2015), through diffusion and receptor mediated uptake (Holmes et al., 2013;
Takahashi et al., 2015). If, as we have shown, EP3Re interacts with tau aggregates,
then this observed interaction could play a potential role in tau uptake and spreading
through receptor mediated endocytosis. How and when the interaction occurs goes
beyond the scope of this study but will need to be explored further to determine if and
to what extent EP3Re could be contributing to disease pathology.
The main aim of this study was to explore if the incidental finding observed was
a genuine co-localisation between EP3Re and tau tangles or an artefact. One of the
biggest problems I encountered was the ability to accurately interpret immunohisto-
chemistry. Double-immunohistochemistry is challenging to interpret. The density of
aggregates make it difficult to distinguish the presence of more than one chromogen.
Immunofluorescence was initially avoided as human brain tissue exhibits significant
auto-fluorescence. This was eventually overcome through the use of commercially
available auto-fluorescence eliminator.
These experiments, using proximity ligation assays, immunohistochemistry and electron
microscopy, have shown that EP3Re interacts with tau fibrils. One of the limitations
to the study is that we have not examined other isoforms of the receptor and therefore
it is unclear if this interaction is unique to this isoform. The EP3 isoforms differ
by their C-terminus and if the interaction between EP3Re and tau occurs within
the cytoplasm, then it is possible, that only EP3Re binds to tau. However, if this
interaction occurs with extra-cellular tau, and the interaction occurs at the extracellular
N-terminus of EP3Re, then this sequence is shared by all EP3 receptors and I would
not expect there to be a difference across all isoforms. The time limitations and lack
of commercially available antibodies for each isoform have meant this is not something
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that was fully explored but may have significant implications should the receptor prove
to be contributing to tau pathology. Further mass spectrometry studies of sarkosyl
insoluble preparations, and the detection in them of the EP3Re receptor, are needed to
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5.1 Summary
In this chapter, I explore the functional relationship between EP3Re and tau. We
hypothesised, based on the colocalisation of EP3Re and tau neurofibrillary tangles in
tauopathies, that EP3Re is interacting with tau and contributing to tau pathology in
disease. As tau hyperphosphorylation is seen as a key contributing factor to disease, I
initially hypothesised that signalling through the receptor could be contributing to tau
phosphorylation. To test this hypothesis I first stimulated EP3Re in SHSY5Y cells
which express both endogenous EP3Re and tau and measured tau phosphorylation
and kinase activation using western blotting in an attempt to outline a potential
pathway and mechanism. I then went on to explore the function of the EP3Re
receptor in hypothermia, a physiological condition that is known to increase tau
phosphorylation and in which EP3 has been shown to play a role in, to understand how
the receptor behaves under conditions known to drive tau phosphorylation. To better
model pathological conditions, I used HEK293 cells transfected with EP3Re and wild
type tau or tau with the P301S mutation (associated with fronto-temporal dementia)
and examined changes in tau phosphorylation using western blotting in response to
EP3Re activation. To better understand what role the receptor could be playing in
pathological conditions, we explore the functional relationship between tau and EP3Re
in human iPSC derived neurons from a patient with tau mutation as a better model of
disease. Finally, we examine how the presence of the P301S mutation in tau affects the
activity of EP3Re. Using inositol monophosphate (IP1) accumulation as a measure of
EP3Re activity, having previously established the receptor as signalling via Gαi, we
performed assays in the presence of P301S mutation and wild type tau as well as using
microscopy and cell surface ELISA to examine how this tau mutation impacts receptor
cell surface expression and internalisation. We show that activating EP3Re, but only
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in the presence of P301S and P301L tau mutations increases tau phosphorylation and
EP3Re intrinsic activity is necessary for hypothermia mediated tau phosphorylation.
In turn, the presence of the P301S and P301L tau mutations impairs EP3Re activity
as measured by IP1 accumulation and appears to increase EP3Re expression on the
cell surface in both transfected HEK293 cells and human iPSC derived neurons. Our
findings are consistent with a functional relationship between EP3Re and tau. Further
work is required to fully establish if EP3Re is exacerbating or driving tau pathology in
disease and whether this could be a potential therapeutic target.
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5.2 Introduction
We have shown in previous chapters the distribution of the receptor under normal
physiological conditions and in tauopthies and that the receptor is a component of
neurofibrillary tangles, co-localising with tau filaments in disease. In this chapter,
we aim to understand the function of EP3Re in relation to tau and if this could be
contributing to tau pathology. Here, we discuss the known functions of EP3 in the
context of neurodegenerative disorders before exploring the proposed mechanisms in
tauopathies in which EP3Re could be playing a role.
The EP3 receptor mediates several functions within the central nervous system (CNS)
with the most well characterised being thermoregulation. EP3 expressing neurons in
the preoptic area are critical for the febrile response and stimulation of cutaneous vaso-
constriction and brown adipose tissue thermogenesis (Ivanov and Romanovsky, 2004;
Morrison, 2016). In models of CNS disorders, the receptor has been strongly implicated
in mediating inflammatory responses leading to neuronal damage and impaired neu-
ronal function. EP3 has been shown to mediate PGE2 effects on vascular permeability,
oedema, blood-brain barrier damage, neutrophil infiltration and microglial infiltration
(Han et al., 2016; Iadecola et al., 2001; Ikeda-Matsuo et al., 2011, 2010; Lan et al., 2017).
EP3 accumulate at sites of ischaemic injury (Iadecola et al., 2001) and is implicated
in secondary neuronal damage following an initial vascular insult (Han et al., 2016;
Ikeda-Matsuo et al., 2011, 2010; Saleem et al., 2009). Oxygen glucose deprivation of
mouse hippocampal slice cultures from EP3 -/- deficient mice show cell death is signifi-
cantly reduced in the absence of EP3 (Saleem et al., 2009). Further supporting a toxic
role for EP3 in neurological disorders, treatment of mice and rats with an EP3 agonist
increases infarct volumes and exacerbates NMDA induced toxicity, findings absent on
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inhibition or genetic deletion of the EP3 receptor (Ahmad et al., 2007; Ikeda-Matsuo
et al., 2010). In models of intracerebral haemorrhage, both EP3-/- deficient mice and
those treated with an EP3 antagonist show a significant reduction in lesion volume with
reduced astrogliosis, microglial activation, blood brain barrier breakdown, and neu-
trophil infiltration with better survival rates (Han et al., 2016; Leclerc et al., 2015, 2016).
Alongside vascular disorders, EP3 activity has also been described in the context
of neurodegenerative diseases. In models of Amyotrophic Lateral Sclerosis (ALS),
PGE2 has been shown to be elevated promoting inflammation and motor neuron death
(Almer et al., 2002; Drachman et al., 2002). In contrast, administration of PGE2 at
physiological levels to organotypic spinal cord slices in a model of ALS paradoxically
rescues motor neurons (Bilak et al., 2004). Bilak et al show this to be mediated by
the EP3 receptor. Treating cells with pertussis toxin, which inhibits Gi signalling, pre-
vents this effect showing that this is mediated by EP3-Gi coupling signal transduction
pathway (Bilak et al., 2004). This suggests that EP3 can mediate both neurotoxic
and neuroprotective effects depending on levels of inflammation and PGE2 production.
In mouse models of Alzheimer’s dementia EP3 has been shown to mediate amyloid
induced toxicity (Maingret et al., 2017; Shi et al., 2012a) and very recently Cao et al
show that tau phosphorylation in the transgenic APP/PS1 mouse is dependent on EP3
activity, alongside EP1 and EP2 (Cao et al., 2019). They show that EP3 promotes
tau phosphorylation through a p25-dependent Cyclin dependent kinase 5 (CDK5)
mechanism (Cao et al., 2019). Although these mice do not develop tau aggregates,
the cardinal pathological finding in human tauopathies, the rise in phospho-tau is
associated with cognitive deficits (Cao et al., 2019).
The mechanism of development of tau aggregates, is poorly understood. The identifica-
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tion of hyper-phosphorylated tau as the main component of tangles (Lee et al., 1991)
has meant that tau phosphorylation is one of the most studied aspects of disease devel-
opment. Tau is a microtubule associated protein and serves to promote microtubule
stability. The microtubule binding domain is situated at the carboxyl terminus where
there are three or four repeat domains (regulated by alternative splicing of exon 10)
(Xie et al., 2016). This region is flanked by serine and threonine residues that when
phosphorylated regulate tau’s interaction with microtubules (Wang et al., 2013). This is
a highly dynamic and necessary process to regulate axonal transport (Rodríguez-Martín
et al., 2013). In tauopathies however, tau becomes hyperphosphorylated and detaches
from microtubules resulting in progressive destabilisation and loss of microtubules,
synapses and neuronal disintegration (Mietelska-Porowska et al., 2014). There is also
evidence to suggest phosphorylation of tau inhibits degradation of tau by proteolysis
(Poppek et al., 2006). Assessment by a combination of monoclonal phospho-tau an-
tibodies and mass spectrometry reveals several site of tau phosphorylation, some of
which are unique to pathology (Laurent et al., 2018; Noble et al., 2013). There are
considered to be 85 potential sites of phosphorylation in tau (Laurent et al., 2018)
and it has become apparent that some epitopes are phosphorylated in a sequential
manner. For the monoclonal antibody AT100, to recognise phospho-tau, tau is required
to have undergone a conformational change as a result of sequential phosphorylation
at Thr212 and Ser214 (Zheng-Fischhofer et al., 1998) and allows AT100 to recognise
filamentous aggregates of tau more specifically than other anti-tau antibodies (Allen
et al., 2002). This has not been shown to occur under normal physiological conditions
(Zheng-Fischhofer et al., 1998). Figure 5.1 shows known tau phosphorylation sites
accompanied by the epitopes recognised by major tau antibodies (Šimić et al., 2016).
Elucidating the signalling pathways that influence tau phosphorylation has been an
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Fig. 5.1 Sites of tau phosphorylation and epitopes recognised by major tau
antibodies. Epitopes phosphorylated only in the normal brain, only in Alzheimer’s dementia
and sites the can be associated with both normal and Alzheimer’s dementia are shown. Figure
adapted from Simic et al., 2016
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important focus for understanding disease pathogenesis. Excessive tau phosphorylation
is thought to occur when there is a disruption in the balance between tau kinases and
phosphatases. Several kinases have been implicated in disease pathology including
glycogen synthase kinase 3 (GSK3), cyclin dependent kinase 5 (cdk5), and p38 mitogen
activated protein kinases (MAPK) (Ferrer et al., 2005; Hanger et al., 1992; Lee and
Kim, 2017). Although the association between tau phosphorylation and aggregation is
not fully understood, it is thought that progressive phosphorylation leads to misfolding
of tau and its subsequent oligomerization into insoluble aggregates (Augustinack et al.,
2002; Su et al., 2008). There are both in vitro and in vivo studies that support a direct
association between tau phosphorylation and subsequent aggregation. Despres et al.
show using kinase assays and nuclear magnetic resonance (NMR) spectroscopy that the
combined phosphorylation of serine 202, threonine 205 and serine 208, in the absence
of serine 262 phosphorylation yields a tau sample that readily forms aggregates as
identified by thioflavin T and electron microscopy, directly linking tau phosphorylation
and aggregate formation in vitro (Despres et al., 2017). In animal studies, inhibition
of kinases such as GSK3 and p38 MAPK, reduce levels of tau phosphorylation and
tau pathology with significant improvements in memory and cognitive deficits (Lee
and Kim, 2017; Onishi et al., 2011). Targeting tau phosphorylation thus remains an
important therapeutic strategy. Other post-translation modifications that have been
implicated in disease include tau truncation acetylation, oxidation, ubiquitination, and
methylation (Delobel et al., 2008; Ercan-Herbst et al., 2019; Martin et al., 2011).
There is growing evidence that changes in tau occur years before the onset of clini-
cal disease by which point significant neuronal loss has already occurred (Bateman
et al., 2012; Khan, 2018). Intervening at this preclinical stage is thus the most likely
therapeutic strategy to yield positive results. Inflammatory prostaglandin signalling
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is thought to play an important role in this preclinical stage of disease, in particular
PGE2 (Andreasson, 2010; Breitner et al., 2011). Studies have shown non-steroidal
anti-inflammatory drugs (NSAIDs) reduce the risk of developing Alzheimer’s demen-
tia, but this beneficial effect is most pronounced at the preclinical stage of disease
((ADAPT Research Group et al., 2009; Breitner et al., 2011). Identifying which PGE2
E-prostanoid (EP) receptors are involved at this stage in disease will be critical in
providing a more targeted therapeutic strategy. Although the association between EP
receptor mediated signalling and tau pathology is poorly understood, several studies
have shown EP receptors to contribute to amyloid pathology in Alzheimer’s dementia
(Andreasson, 2010; Bazan et al., 2002; Figueiredo-Pereira et al., 2016; Johansson et al.,
2015; Liang et al., 2005a; Shi et al., 2012a; Wei et al., 2010; Wood, 2012; Woodling
and Andreasson, 2016). Liang et al show that deletion of EP2 in the APPSwe-PS1δE9
mouse model of familial Alzheimer’s disease results in a marked reduction in oxidative
damage and reduced amyloid burden (Liang et al., 2005a). They suggest this to be
through increased clearance of Aβ42 and/or reduced generation. In the presence of EP2,
they note an increase in β-CTF, a product of APP cleavage by BACE1, suggesting EP2
modulates BACE1 cleavage increasing generation of Aβ42. EP2 has also been shown to
impair microglial function resulting in reduced Aβ42 clearance (Johansson et al., 2015).
Inhibiting microglial EP2 signalling not only decreases inflammation but in mouse
models of disease also rescues memory (Johansson et al., 2015). The EP3 receptor has
also been implicated in Alzheimer’s disease pathology. Using the APPSwe-PS1δE9
mouse model of familial Alzheimer’s disease, Shi et al showed that EP3 contributes
to synaptic dysfunction as well as amyloid plaque burden, both of which are rescued
on EP3 deletion. They show that deletion of just one allele is sufficient to reduce
amyloid plaque burden and rescue pre-synaptic proteins. EP3 signalling is thought
to suppress amyloid clearance whilst increasing inflammatory oxidative stress and
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βsecretase activity (Shi et al., 2012a). EP3 activity also negatively correlates with the
pro-survival kinase, protein kinase B (AKT) (Shi et al., 2012a; Wang et al., 2010).
There are fewer studies exploring EP receptors and tau pathology. In tauopathies
it has been proposed that an initial stimulus, such as generation of amyloid plaques
in Alzheimer’s disease, activates glial cells releasing inflammatory cytokines and
prostaglandins which induce neurotoxicity (McGeer and McGeer, 2013). This then
leads to impairment of the ubiquitin/proteasome pathway and activation of caspase
which in turn cleaves tau creating a tau species prone to aggregation generating paired
helical filaments and tangles (Gamblin et al., 2003; Metcalfe et al., 2012). Arnaud et al.
(2009) demonstrated in cell culture that prostaglandins are able to induce caspase
mediated cleavage of tau in keeping with the proposed hypothesis linking inflammatory
prostaglandin signalling to tau pathology. More recently PGE2 has also been impli-
cated in tau phosphorylation. Alzheimer’s dementia is associated with dysregulated
calcium signalling (Wang et al., 2017) and Cao et al. show this to cause an increase in
PGE2 leading to tau phosphorylation via EP1, EP2 and EP3 (Cao et al., 2019) pro-
viding a direct correlation between EP3 activity and tau phosphorylation in murine cells.
An understanding of the role of EP3Re in tauopathies relies on experimental conditions
in which the behaviour of human tau can be studied. The species-specific isoforms of
EP3 make animal models of tauopathy unsuitable for the purpose of the project. A
suitable model that recapitulates all the features of human tauopathies is yet to be es-
tablished. Cellular models using human cell lines provide an accessible way of studying
complex pathogenic events at a single cell level. Both neuronal and non-neuronal cell
lines are currently used. Models based on non-neuronal cell lines lack endogenous tau
making them a simple and inexpensive model to evaluate the effects of overexpressing
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exogenous tau with mutations associated with familial tauopathies in comparison to
exogenous wild type tau. Most of these cells are also very well characterised making
them suitable for a wide variety of molecular and biochemical techniques. Cell lines,
such as the human neuroblastoma cell line, SHSY5Y, have the added advantage of a
neuronal phenotype (Agholme et al., 2010). They express tau when undifferentiated,
and when differentiated express levels of mature tau comparable to the human adult
brain (Agholme et al., 2010). Most tau models are based on the hypothesis that the key
pathogenic event is tau aggregation. In vitro this can be replicated by adding co-factors
to recombinant tau, such as sulphated glycosaminoglycans, heparin, or arachidonic acid
to promote tau polymerisation (Goedert et al., 1996; Pérez et al., 2002), seeding cells
with tau fibrils (Karikari et al., 2019; Xu et al., 2016), inducing tau phosphorylation
by inhibiting phosphatase activity or activating tau kinases (Shea and Fischer, 1996),
or, overexpressing tau with fronto-temporal dementia (FTD) associated mutations. Xu
et al. show that exposing HEK293 cells to extracellular tau fibrils converts cellular
transfected soluble tau to insoluble thioflavin-S positive tau resembling neurofibrillary
tangles (Xu et al., 2016) and propose this as a mechanism of being able to study
disease pathogenesis in vitro. This has been replicated by several groups and is a
well-established method of studying the spread and propagation of tau pathology
(DeVos et al., 2018; Falcon et al., 2015; Frost et al., 2009; Woerman et al., 2016).
In vitro models of tauopathy can also be generated by altering the balance between
tau phosphorylation and dephosphorylation. Loss of tau dephosphorylation through
inhibition of tau phosphatases produces a tau species that is prone to aggregation, a
pathological hallmark of tauopathies. Treating cells with okadaic acid, an inhibitor of
protein phosphatases PP1 and PP2A, results in tau hyperphosphorylation, including
phosphorylation of Alzheimer’s dementia associated epitopes (Caillet-Boudin and Dela-
courte, 1997; Seidel et al., 2012; Shea and Fischer, 1996; Yadikar et al., 2020). Okadaic
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acid treated cells also show impaired microtubule assembly and stability (Shea and
Fischer, 1996). PP2A inhibition and rapid and extensive tau phosphorylation has also
been noted as a result of anaesthesia (Planel et al., 2007). Planel et al show this to
be due to anaesthesia induced hypothermia, as the phenotype is rescued on return
to normothermia (Planel et al., 2007). They then went on to propose a cell-based
model of tauopathy based on hypothermia induced tau phosphorylation (Bretteville
et al., 2012). Exposing primary cell lines and ex vivo brain slices of wild type mice
to hypothermia results in phosphorylation of Alzheimer’s dementia related epitopes
without affecting total tau levels, proposing a model compatible with endogenous
levels of tau expression (Bretteville et al., 2012). They show this to be mediated
by GSK3β and CDK5 as treatment with lithium chloride and roscovitine, GSK3β
and CDK5 respective inhibitors, prevent this (Bretteville et al., 2012). Cell based
models of tauopathy can also be created by overexpressing tau (Houck et al., 2016),
or expressing tau with fronto-temporal dementia (FTD) associated mutations (Ritter
et al., 2018). Tau mutations, such as P301L, promote β sheet structure formation
enhancing aggregation and creation of paired helical filaments (Lewis et al., 2000;
Rizzu, 2000; Rodríguez-Martín et al., 2016). Ritter et al. (2018) show in COS7 cells
that the presence of the FTD N279K mutation is sufficient to increase levels of tau
phosphorylation in comparison to wild type tau (Ritter et al., 2018). Although tauopa-
thy models using primary cell lines do have certain limitations, due to their viability
and ease of use, they provide a simple and effective way of modelling disease.
A more recent approach to modelling tauopathies has been the use of induced pluripo-
tent stem cells (iPSCs). The discovery that terminally differentiated cells, such as
fibroblasts, can be reprogrammed into stem cells has allowed the creation of a system
that captures the patient’s exact genetic make-up to study the underlying disease
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mechanisms. Expressing the transcription factors Oct3/4, Sox2, Klf4 and c-Myc (Taka-
hashi et al., 2006) returns cells to pluripotency allowing for subsequent differentiation
into neurons. Neurons derived from iPSCs can be generated from individuals bearing
genetic mutations in MAPT associated with familial frontotemporal dementia (Iovino
et al., 2015; Strang et al., 2019). Several models of tauopathy rely on tau overexpression
but the ability to grow neurons from these individuals with familial disease allow us to
study these mechanisms under normal physiological expression levels. Neurons derived
from iPSCs from patients with familial tauopathies as well as sporadic disease have been
shown to recapitulate several of the pathological features of the disease (Iovino et al.,
2015; Muratore et al., 2014; Shi et al., 2012c). Neurons derived from iPSCs of patients
harbouring mutations in the amyloid precursor protein (APP), associated with familial
Alzheimer’s dementia, and those obtained from sporadic disease, display increase Aβ
production as well as tau phosphorylation (Muratore et al., 2014; Ochalek et al., 2017;
Ovchinnikov et al., 2018). Neurons derived from iPSCs harbouring mutations in the
MAPT gene , alongside increases in levels of tau phosphorylation, display a unique
neuronal phenotype with changes in 3R:4R tau isoform ratios, deficiencies in neurite
outgrowth, and, activation of stress response pathways (García-León et al., 2018; Iovino
et al., 2015; Silva et al., 2016; Verheyen et al., 2018). These neurons display an upregu-
lation of stress pathway genes such as superoxide dismutase 1 (SOD1 ), sulfiredoxin 1
(SRXN1 ) and, nuclear factor erythroid-2-related factor 2 (NRF2 ) a phenotype that
can be rescued on downregulation of MAPT expression using CRISPR/Cas9 (Silva
et al., 2016; Verheyen et al., 2018) showing that these neurons are able to capture
several aspects of tauopathies. These make them an ideal model to study the be-
haviour of EP3Re in tauopathies and validate any findings observed in primary cell lines.
In this present chapter, we hypothesise, based on what we know on PGE2 signalling in
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tauopathies and our previous findings of EP3Re and tau tangle co-localisation, that the
receptor is contributing to tau pathology. We have shown through electron microscopy
that EP3Re interacts with tau in the fuzzy coat, where most epitopes identified by
tau phospho-dependent antibodies also localise (Friedhoff et al., 2000; Wegmann et al.,
2013). This raises the possibility that EP3Re physically interacts with tau tangles and
could play a role in tau phosphorylation. As part of our investigation to understand
this, our aims in this study are to:
• Understand changes in tau in response to EP3Re signalling under normal physio-
logical conditions
• Understand changes in tau in response to EP3Re signalling in models of tauopathy
• Determine if EP3Re signalling is altered in tauopathies
To this end we will be using primary cell lines as well as neurons derived from induced
pluripotent stem cells to model disease.
5.3 Materials and Methods
5.3.1 Immunocytochemistry
Localisation of the EP3Re receptor was examined in the human neuroblastoma cell line,
SHSY5Y cells (See 2.2.7.1 for further details). In view of their neuronal phenotype
it was possible that they would express the EP3Re receptor. SHSY5Y cells were
stained for the presence of the receptor using the human EP3Re specific antibody. The
presence of the receptor was assessed by confocal microscopy on the Leica SP8.
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5.3.2 Silencing EP3Re expression
Predesigned siRNA duplexes were obtained from Qiagen directed against PTGER3.
Standard forward transfection was initially performed using lipofectamine RNAiMAX
(Invitrogen) according to manufacturers instructions. SHSY5Y cells were plated into
6 well plates and grown till they were 60-80% confluent. SiRNA lipid complexes
were created using 5-20µl/ml of lipofectamine RNAiMAX and siRNA varying in
concentration from 30-150pmol to determine optimal transfection conditions. The lipid
complex was left to incubate for 5min before being applied to cells. The media was
then changed after 72hrs before being used for experiments. Green fluorescent protein
(GFP) cDNA was used as a positive control for transfection whilst non-targeting siRNA
obtained from Qiagen was used as a negative control. For reverse transfection, lipid
complexes were prepared inside the wells prior to adding SHSY5Y cells.
5.3.3 Detecting changes in tau phosphorylation in response
to EP3Re signalling in SHSY5Y and HEK293 cells
Tau phosphorylation in response to EP3Re activation was assessed in SHSY5Y cell
and HEK293 cells.
SHSY5Y cells were plated into 12 well plates at a density of 0.1 x 106 per well.
Prior to experiments serum was changes to serum free media. The EP3 agonist sulpro-
stone was then added for 30min at concentrations varying from 0 – 10−6M and changes
in tau phosphorylation measured by immunoblotting using the phospho-tau specific
antibodies PHF1 or AT8. Western immunoblots were also probed for the presence of
active kinases AKT and GSK3 and normalised to total kinase present and GAPDH.
Changes observed were verified by silencing the receptor using siRNA directed against
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EP3Re as described in 2.2.10. All experiments were done in duplicate and repeated 3
times.
HEK293 cells were plated into 12 well plates at a density of 0.1 x 106 per well.
The following day cells were transfected with DNA constructs encoding EP3Re along-
side wild type tau or tau with the P301S mutation as detailed in 2.2.9. On termination
of transfection, cells were maintained in serum free media till the following day when
they were exposed to varying concentrations of the EP3 agonist sulprostone for 30min.
Tau phosphorylation in response to EP3Re activity was determined by immunoblotting
using the phospho-tau antibody AT8 and normalised to total tau.
5.3.4 Modelling tauopathies in SHSY5Y cells
5.3.4.1 Tau seeding as a model of tauopathy
The protocol was performed as described by Falcon et al. (2015). SHSY5Y cells were
plated onto poly-l-lysine coated coverslips in 12 well plates at a density of 0.1 x 106.
Cells were then seeded with sarkozyl insoluble extract from Alzheimer’s dementia
subjects (see 2.2.4) diluted in OptiMEM (Gibco) at a concentration of 100ng/ml.
After 3hr the media was replaced with normal growth media (RPMI supplemented with
10% FBS). Cells were then incubated for 3 days before being washed in PBS and fixed
in methanol for immunohistochemistry or protein lysate extracted for immunoblotting.
The presence of phosphorylated tau was assessed by immunohistochemistry using the
phospho-tau antibody AT8 whilst aggregated tau was assessed using pFTAA. This was
validated on western immunoblotting using the phospho-tau antibody AT100, which
has been shown to be specific for pathological filamentous aggregated tau.
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5.3.4.2 Hypothermia as a model of tauopathy
Hypothermia was used as a model of tauopathy following the protocol described by
Bretteville et al. (2012). SHSY5Y cells were plated into 2x 12 well plates at a density of
0.1 x 106 per well and kept in serum free media for 24hr prior to performing experiments.
One plate was then transferred to a 32°C incubator whilst the other was kept at 37°C
for 2hr. If cells were treated with sulprostone, this was applied after 1hr30min at
which point cells were then returned to their respective incubators for a further 30min.
After 2hr cells were lysed in RIPA buffer and immunoblotting performed to measure
levels of tau phosphorylation. To determine the role of EP3Re in hypothermia induced
tau phosphorylation, experiments were performed following transfection with siRNA
targeting EP3Re 72hrs prior to performing experiments as described in 2.2.10. All
experiments were repeated 3 times.
5.3.5 EP3Re signalling in the presence of Tau
To determine if tau affects EP3Re function, using Gi coupling as a measure of EP3Re
function, we performed IP accumulation assays. HEK293 cells were plated into 96 well
plates and transfected with EP3Re and either wild type tau or tau with the P301S
mutation alongside the chimeric G-protein Gαδ6qi4myr. Cells were then stimulated
with the EP3 ligand sulprostone and IP1 accumulation measured. For details of
protocol see 2.2.16. All assays were run in quadruplicate and repeated 3 times.
5.3.6 Molecular interaction between EP3Re and Tau
To understand if there is a dynamic interaction between tau and EP3Re in a cell
model of disease, we used a NanoLuc® Binary Technology (NanoBiT®) protein:protein
interaction assays. EP3Re and MAPT constructs were ligated into NanoBiT® vectors
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containing a Large BiT (LgBiT) subunit, an 18kDa peptide, or its complementary
Small BiT (SmBiT) 11kDa peptide as described in 2.2.18. The SmBiT and LgBiT
peptides were expressed at either the C or N terminus of each protein to allow us to
identify the terminus at which the interaction occurs. HEK293 cells were seeded into a









Luminescence was measured over a period of 20min. Assays were run in quadruplicates
and repeated 3 times for wild type tau and once for P301S tau. The vectors used
were created with the assistance of Edson Mendes de Oliveira (Institute of Metabolic
Science, Cambridge). Assays for wild type tau were performed by Kieran Ryan and for
P301S tau by Edson Mendes de Oliveira.
5.3.7 iPSC derived neurons
Neural embryonic stem cells derived from female dermal fibroblasts using the Shi
protocol (Shi et al., 2012b) were obtained from Axol. Neurons derived from induced
pluripotent stem cells with wild type tau and tau with the P301L mutation were grown
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as described in 2.2.8 and stained for the presence of the EP3Re at D0 and D30. After
35 days of differentiation, beta tubulin positive neurons were detected denoting mature
neurons. The interaction between EP3Re and tau in these neurons was assessed using
proximity ligation assays as described in 2.2.12. Neurons were treated at D35 with the
EP3 agonist sulprostone for 30min, fixed and stained for the presence of phosphorylated
tau, using the phospho-tau antibody AT8. The presence of tau aggregates was assessed
by staining cells with the fluorescent pentameric oligothiophene, pFTAA.
All results were assessed using confocal microscopy on the Leica SP8.
Two rounds of differentiation were done by myself and the third round was performed
by Mehtap Baciologu.
5.3.8 Statistics
Statistical analysis was carried out using GraphPad prism 7.0. For signalling assays,
half maximal effective concentration (LogEC50) was calculated from data normalised
and fitted to a non-linear regression curve in GraphPad prism 7.0. Two way ANOVA
with multiple comparisons were performed to determine effect of tau on EP3Re sig-
nalling assays as well as differences in EP3Re expression and tau phosphorylation
in iPSC derived neurons. EP3Re expression in cells was calculated by measuring
integrated density and subtracting the area of the cell x mean background intensity
to give the corrected total cell fluorescence. This was obtained from 10 fields of view
from each round of cell differentiation. Results of NanoBiT protein:protein interaction
assays were plotted in GraphPad prism 7.0. Significance for all tests was assumed at
p<0.05.
All materials and methods are described in detail in Chapter 2.
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5.4 Results
5.4.1 EP3Re signalling and wild type tau pathology
We first wanted to understand how EP3Re interacts with wild type tau. As most
tauopathies are sporadic, it was important to investigate if EP3Re activity alone
is sufficient to drive disease pathology. Focusing predominantly on abnormal tau
phosphorylation, we used SHSY5Y cells, that express endogenous tau, as well as
HEK293 cells transfected with wild type tau to determine if signalling through EP3Re
could be contributing to disease pathology.
5.4.1.1 SHSY5Y cells express endogenous EP3Re
SHSY5Y cells are a human neuroblastoma cell line and express a number of human-
specific proteins and protein isoforms, although EP3Re expression has never previously
been investigated. SHSY5Y cells were stained with antibody directed against EP3Re
to determine their suitability for further experiments. SHSY5Y cells were positive
for EP3Re, demonstrating the characteristic punctate cytoplasmic staining identified
previously in human tissue (Fig. 5.2).
Fig. 5.2 SHSY5Y cells stained with EP3Re antibody. SHSY5Y cells are positive for
endogenous EP3Re, which appear localised to the cytoplasm.
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5.4.1.2 Silencing EP3Re expression
Prior to understanding if EP3Re mediated signalling affects tau phosphorylation, I
needed to establish a system by which EP3Re expression could be regulated. Small
interfering RNA (siRNA) is an established method to silence gene expression by de-
grading mRNA after transcription, preventing translation. Predesigned siRNA directed
against EP3Re were obtained from Qiagen and delivered using lipofectamine. Suc-
cessful silencing was verified using western immunoblotting. Initial attempts using
10nM siRNA and standard forward transfection, where cells are attached prior to
transfection, showed minimal transfection efficiency with no statistical significant reduc-
tion in EP3Re protein expression (Fig. 5.3D). Transfection efficiency was significantly
improved using higher concentrations of siRNA (Fig. 5.3F). A maximum effect was
seen at a concentration of 50nM siRNA using reverse transfection, where cells are
plated into wells containing siRNA-lipid complexes, with a resulting reduction of over
60% in EP3Re protein expression. Although both forward and reverse transfection at
concentrations of 20nM and 50nM siRNA yielded statistically significant reductions in
EP3Re expression, subsequent experiments were performed using reverse transfection
at 50nM siRNA due to the high efficiency and shorter experiment times.
5.4.1.3 EP3Re and Tau phosphorylation
Having established endogenous EP3Re expression could be silenced in SHSY5Y cells,
I wanted to explore the effect of EP3Re mediated signalling on tau phosphorylation.
This was examined in SHSY5Y cells, expressing endogenous wild type tau, and in
HEK293 cells, transfected with both EP3Re and wild type tau.
SHSY5Y cells were treated with the EP3 selective agonist sulprostone and changes
in tau phosphorylation identified by the phosphorylation specific antibody PHF1
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Fig. 5.3 Silencing EP3Re expression using siRNA. A) GFP was used as a positive
control and to optimise transfection conditions. siRNA-lipid complexes were formed using
recommended lipofectamine concentrations of 5 µl/ml, 12 µl/ml and 20 µl/ml. Significant
uptake was not seen at 5 µl/ml (not shown) but at 12 µl/ml and 20 µl/ml up to 75% of viable
cells were GFP+ve following the media change at 72hrs. B) Data shown from 3 independent
experiments. No statistical significant difference in transfection efficiency so 12 µl/ml used for
subsequent experiments. Analysed using two tailed T-test with mean+/- standard deviation
shown. Statistical significance determined at p<0.05. C) Initial experiments performed using
10nM siRNA showed no reduction in EP3Re expression as quantified by western blotting. D)
Graphical representation of (C). Individual data points with mean +/- standard deviation
shown. Two tailed t-test showed no statistical significance taken at p<0.05. E) Cells were
transfected with 20nM or 50nM siRNA using standard forward and reverse transfection.
Representative western blot shown. Graphical representation of 3 independent experiments
can be seen in (F). Maximum reduction in EP3Re expression is noted using 50nM siRNA
reverse transfecting cells. Data analysed using two-way ANOVA with multiple comparisons.
Statistical significance determined at p<0.05.
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(Ser202/Thr205). Cells exposed to sulprostone show an increase in tau phosphorylation
in a dose dependent manner (Fig. 5.4A). As sulprostone targets all EP3 isoforms, to
verify the contribution of EP3Re, EP3Re expression was silenced and experiments
repeated. In the absence of EP3Re expression, the increase in phosphorylated tau was
no longer statistically significant (Fig. 5.4D). In SHSY5Y cells, EP3Re is the main
isoform mediating tau phosphorylation. To understand the mechanism behind this
increase, I then examined the activity of tau kinases AKT, GSK3α and GSK3β. EP3
has previously been described as negatively correlated with the pro survival kinase AKT
whilst some studies show EP3 to increase AKT activity. In this present study, although
a trend is noted suggesting an increase in AKT in response to EP3Re activation, this
failed to reach statistical significance (Fig. 5.4E). GSK3α did not shown any change
in activity in response to EP3Re stimulation (Fig. 5.4G), however GSK3β showed a
statistically significant reduction in activity. In the absence of EP3Re this reduction
is no longer significant (Fig. 5.4H) suggesting the noted reduction was mediated by
EP3Re. Phosphorylation is not the only post translational modification associated
with disease. Tau truncation at Asp-421 by caspase 3 is thought to be an early event
in the oligomerisation and formation of aggregates in Alzheimer’s (Means et al 2015;
Flores-Rodriguez et al 2015). Activated caspase 3 has been shown to co-localise with
NFTs in tauopathies, alongside truncated tau. It has previously been proposed that
prostaglandin signalling increases caspase activity (Arnaud, Myeku and Figueiredo-
Pereira, 2009). To explore if EP3Re could be contributing to disease pathology via
this mechanism, SHSY5Y cells were exposed to the EP3 agonist sulprostone and the
presence of active caspase 3 measured by western blotting. No difference is noted in
caspase 3 activity before and after EP3Re stimulation by sulprostone. EP3Re me-
diated activity does not appear to contribute to tau truncation by caspase 3 (Fig. 5.4I).
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Fig. 5.4 EP3Re signalling and tau phosphorylation in SHSY5Y cells. A) SHSY5Y
cells exposed to sulprostone showed an increase in tau phosphorylation in a dose dependent
manner. B) Graph showing results of 3 independent experiments. All experiments run in
duplicate. C) Western blot showing SHSY5Y cells treated with the EP3 agonist sulprostone.
Levels of tau phosphorylation (ser396/ser404) and AKT were assessed. There was an increase
in tau phosphorylation in response to sulprostone that does not occur when EP3Re is
silenced. Although a trend is noted suggesting an increase in AKT, this fails to reach
statistical significance. D) Graphical representation of PHF1 levels in response to EP3R
activity following 3 independent experiments. All experiments performed in duplicate. E)
Graphical representation of active levels of AKT following sulprostone treatment following 3
independent experiments. All experiments performed in duplicate. F) Western blot showing
levels of active GSK3α and β, as identified by phosphorylation on tyrosine279 and tyrosine
216 respectively and inactive GSK3α and β as identified by phosphorylation on serine21 and
serine9 respectively. There was a reduction in the ratio of active:inactive GSK3β which was
not seen in GSK3α in response to sulprostone treatment. G) Graphical representation of data
obtained from 3 independent experiments measuring active:inactive GSK3α. H) Graphical
representation of data obtained from 3 independent experiments measuring active:inactive
GSK3β. The reduction in active GSK3β failed to reach statistical significance when EP3Re
expression was silenced suggesting EP3Re activity was necessary to inactivate GSK3β. I)
SHSY5Y cells exposed to sulprostone show no differences in caspase 3 activation. J) Graphical
representation of 3 independent experiments. All experiments done in duplicate. All graphs
show individual data points+/- standard deviation. Data analysis was done using 2 way
ANOVA with multiple comparisons. Statistical significance determined at p<0.05.
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In Chapter 3, using HEK293 cells, we established that EP3Re signals through Gi
coupling. To correlate tau phosphorylation with EP3Re activity, HEK293 cells were
exposed to varying concentrations of sulprostone, selected to correspond with different
points of EP3Re activity as measured by IP1 accumulation. Figure 5.5 shows an
increase in tau phosphorylation (AT8 ser202/thr205) in response to sulprostone in a
dose dependent manner (p<0.0001). An increase is however also noted in the absence of
EP3Re suggesting that other EP3 receptors are present in the cells, which is confirmed
on western blotting using the pan-EP3 antibody. Any increase noted can therefore not
be attributed to EP3Re activity alone.
HEK293 cells treated with the highest concentration of sulprostone, showed a higher
increase in tau phosphorylation in the presence of EP3Re in comparison to cells lacking
the e isoform when compared to untreated cells.
5.4.1.4 Effect of tau on EP3Re signalling
To determine if EP3Re signalling is affected by the presence of wild type tau, HEK293
cells were transfected with both the receptor and wild type tau alongside the chimeric
G protein, Gαδ6qi4myr, which couples Gi binding residues on the internal surface
of the GPCR to a Gq signalling pathway. This allows for measurement of inositol
monophosphate (IP1) accumulation in response to Gi coupling. On stimulation of cells
with and without wild type tau by the EP3R agonist sulprostone, no differences in IP1
accumulation are noted. In the presence of wild type tau, there is no change in EP3Re
receptor activity as measured by Gi coupling (Fig. 5.6).
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Fig. 5.5 EP3Re signalling increases phosphorylation of wild type tau in HEK293
cells. A) Immunoblot showing levels of phospho-tau (AT8) in response to treatment with
sulprostone in HEK293 cells expressing wild type tau with and without EP3Re. B) Graphical
representation of data of 3 independent experiments. Level of tau phosphorylation is positively
correlated with level of sulprostone and EP3 activity both in the presence and absence of the
e isoform (p<0.0001). At higher concentrations of sulprostone, the presence of the EP3Re
receptor results in higher levels of tau phosphorylation (p<0.0001) in comparison to EP3
alone. Analysis done using 2 way ANOVA with multiple comparisons. Statistical significance
determined at p<0.05. C) Western blotting confirms that HEK293 cells express other isoforms
of EP3 as recognised by a pan-EP3 antibody. They do not express EP3Re. n=2
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Fig. 5.6 EP3Re stimulation in HEK293 cells with and without wild type tau
HEK293 were transiently transfected with EP3Re, wild type tau and the chimeric G protein
Gαδ6qi4myr. Inositol monophosphate (IP1) accumulation was measured in response to
stimulation by sulprostone. A dose dependent increase in IP1 accumulation is noted in
HEK293 cells with and without wild type tau. No differences are noted in receptor activity
in response to the presence of wild type tau. Cumulative data are shown from 3 different
experiments with the mean and standard deviation. Data was fitted to a non-linear regression
curve and normalised in GraphPad prism 7.0. Differences in signalling were assessed by
performing two tailed unpaired t-tests. Statistical significance was considered at p<0.05.
5.4.1.5 Molecular interaction between EP3Re and Tau
We next went on to explore the molecular interaction between EP3Re and wild type
tau. Previous experiments using proximity ligation assays and immunoprecipitation
exploring the interaction between EP3Re and tau, failed to identify an association
between EP3Re and monomeric tau. All these studies, however, describe a static
interaction. To investigate how they might interact in a dynamic context I used a
structural complementation reporter system, NanoLuc® binary technology (NanoBiT®).
MAPT and EP3Re constructs were fused to a large 18kDa peptide (LgBiT) or a
complementary small 11 amino acid peptide (SmBiT) at either the N- or C- terminus.
In the presence of the substrate, a luminescent signal is emitted when the two proteins
are in close proximity to one another. By creating multiple constructs where the
fused peptides are at either the C- or N- terminus, if a signal is seen, this allows for
orientation and localisation of the site of interaction. HEK293 were transfected with
EP3Re and MAPT fused to a LgBiT or SmBiT and the baseline interaction measured.
Cells were then exposed to sulprostone to determine if an interaction occurs following
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activation of the receptor. Figure 5.7 shows no increase in luminescence relative to the
negative control. There is no detectable interaction between EP3Re and monomeric
wild type tau.
Fig. 5.7 There is no detectable molecular interaction between EP3Re and wild
type tau. HEK293 cells were transfected with MAPT and EP3Re constructs fused with
either a LgBiT or SmBiT peptide at the N- or C- terminus. A and B show results from all
combinations of vectors used to determine if there is a dynamic molecular interaction between
EP3Re and tau. No interaction is detected. A non-interacting protein (HaloTag) with the
corresponding interacting half of the pair was used as a negative control. Protein Kinase C
Alpha (PRKACA) and Protein Kinase CAMP-Dependent Type II Regulatory Subunit Alpha
(PRKAR2A), two proteins known to interact, were used as a positive control. Experiment
performed with 8 technical replicates of each interaction with 3 independent experiments.
Data shown from one experiment.
5.4.2 EP3Re signalling in a model of disease
So far, I have examined the relationship between EP3Re and wild type tau in primary
cell lines. To understand how the receptor behaves in tauopathies, it was important to
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use an appropriate disease model, given EP3Re’s specificity to higher primates. There
are few in vitro models that allow for the study of the human nervous system. Here
we explore models of disease using both human primary cells lines and iPSC derived
neurons.
5.4.2.1 Modelling disease in SHSY5Y cells
SHSY5Y cells express both endogenous EP3Re and tau. They are often used as models
of disease due to their neuronal phenotype. An initial SHSY5Y based model of disease
was created by exposing cells to fibrillar tau extract from an AD subject. Three days
after an initial 3hr incubation with tau fibrils, cells were assessed for the presence
of tau aggregates using pFTAA, which was then further validated by western blots
by probing for the presence of Thr212/Ser214 phosphorylated tau (AT100). Despite
initial promising results by microscopy suggesting the presence of tau aggregates in the
fibril treated sample and not the control, as identified by pFTAA, this could not be
validated by western blot (Fig. 5.8). Both the treated and untreated cells appeared to
express tau phosphorylated at AT100 and AT8 epitopes with no discernible difference
in AT100 phosphorylation levels. Following three independent experiments, with the
same result, this model was not used for any further experiments.
Hypothermia as a model of tauopathy in SHSY5Y cells
Hypothermia has been shown to lead to tau hyperphosphorylation and has been pro-
posed as a mechanism behind age related tau pathology. Given the involvement of
EP3 in thermoregulation, and the association with hypothermia and hyperphospho-
rylation, we hypothesised that EP3Re could be involved in hypothermia mediated
tau phosphorylation. We initially repeated the experiment as described by Planel
et al. (2012) to show that a drop in temperature does increase tau phosphorylation.
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Fig. 5.8 Modelling tauopathies in SHSY5Y cells using tau fibrils. A) Live image
of SHSY5Y cells on day 1 of seeding assay. No pFTAA positive cells were seen prior to
seeding cells with fibrils extracted from AD brain. B) Cells were exposed to fibrillar tau
extracted from AD brain for 3hrs before the media was changed and fixed 3 days later. Cells
exposed to fibrillar tau show positive pFTAA staining. C) Protein extract lysed from cells
and immunoblotted for phosphorylated tau. Differences in tau phosphorylation could not be
validated by western blotting despite consistent pFTAA staining.
178 INVESTIGATING THE INTERACTION BETWEEN EP3RE AND TAU
SHSY5Y cells were kept at 32°C for 2 hrs (Fig. 5.9). This resulted in an increase
in tau phosphorylation by a factor of 4.5. EP3Re expression was then silenced and
experiments repeated. Reduced EP3Re expression prevented hypothermia induced
tau phosphorylation. Treating the cells with sulprostone at 32°C was not associated
with any further changes in tau phosphorylation compared with untreated cells. To
determine if this could be correlated with EP3Re signalling, IP1 accumulation assays
were performed in HEK293 cells at 37°C and at 32°C. A reduction in temperature
resulted in a 50% reduction in receptor activity as measured by Gi coupling. Reduced
EP3Re activity as measured by Gi coupling, is thus unlikely to account for changes in
tau phosphorylation associated with hypothermia.
5.4.2.2 Modelling disease in HEK293 cells
To further explore EP3Re function in the context of tauopathy, we then went on to
examine the relationship between EP3Re and tau in a model of familial tauopathy.
The MAPT P301S mutation was first reported in an Italian family with early fron-
totemporal dementia and parkinsonism (Bugiani et al 1999) and has been reported
in several families since (Sperfeld et al. 1999; Lossos et al 2003; Yasuda et al, 2000).
The mutation alters microtubule binding and promotes aggregation of tau (Bugiani
et al 1999). P301S tau and EP3Re were transfected into HEK293 cells and treated
with sulprostone for 30min. Levels of tau phosphorylation were then assessed by
immunoblotting. Similar to results seen in HEK293 cells transfected with wild type
tau, an increase in tau phosphorylation was seen in response to EP3 activity. This
increase in tau phosphorylation was also noted in the absence of EP3Re, suggesting
other EP3 isoforms also contribute to tau phosphorylation in HEK293 cells (Fig. 5.10).
To further characterise the relationship between EP3Re and P301S tau, we next
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Fig. 5.9 Hypothermia as a model of tauopathy. A) Western immunoblot showing
levels of tau phosphorylation in response to hypothermia with graphical representation of
blot. A drop in 5°C is enough to increase levels of tau phosphorylation by a factor of 4.5.
Experiments run in triplicate. Data shown representative of one independent experiment.
Data analysed using unpaired t-test, p=0.0022. B) SHSY5Y cells were then transfected with
either siRNA directed against EP3Re (siEP3e) or non targetting siRNA (siNT). Silencing
of EP3Re inhibits hypothermia induced tau phosphorylation. Data shown results of 3 inde-
pendent experiments. Analysed using 2 way ANOVA with multiple comparisons. Statistical
significance taken at p<0.05. C) To determine role of active EP3Re signalling in hypothermia
induced tau phosphorylation, cells were transfected with either siNT or siEP3e. SHSY5Y
cells lacking EP3Re fail to show the increase in tau phosphorylation associated with the drop
in temperature. There is no statistical difference between untreated and sulprostone treated
cells. Experiments were run in duplicates with data generated from 3 independent experi-
ments shown. Data analysed using 2 way ANOVA with multiple comparisons. Statistical
significance accepted at p<0.05. D) IP1 accumulation assays performed in HEK293 cells in
the presence of the chimeric G-protein, Gαδ6qi4myr, so as to measure Gi activity. A 50%
reduction is noted in EP3Re activity in response to a 5°C reduction in temperature. All
experiments were run in triplicates. Cumulative data are shown from 3 different experiments
with the mean and standard deviation. Data was fitted to a non-linear regression curve and
normalised in GraphPad prism 7.0
examined the cellular localisation of EP3Re in this model. HEK293 cells transfected
with flag tagged EP3Re alongside wild type tau or P301S tau, were treated with either
sulprostone or ligand diluent (PBS), fixed and stained for the presence of the receptor
using a FLAG antibody and a wheat germ agglutinin dye to identify the membrane.
Results were examined by confocal microscopy. HEK293 cells expressing P301S tau
appeared to show an increase in EP3Re expression on the membrane following exposure
to sulprostone than the cells expressing wild type tau. To quantify this, FLAG ELISA
was performed before and after sulprostone exposure. Although a trend was seen
suggesting that the presence of P301S tau resulted in reduced FLAG tagged EP3Re
internalisation following ligand exposure, this did not reach statistical significance
(Fig. 5.10).
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Fig. 5.10 Modelling tauopthies in HEK293 cells. A) Immunoblot showing levels of
phospho-tau (AT8) in response to treatment with sulprostone in HEK293 cells expressing
P301S tau with and without EP3Re. B) Graphical representation of data of 3 independent
experiments. Level of tau phosphorylation increases in association with sulprostone levels
(p<0.0001). The presence of the e isoform does not increase levels of tau phosphorylation and,
in contrast to the results we show with wild type tau, at certain concentrations the presence of
the e isoform results in lower levels of tau phosphorylation in response to sulprostone. Analysis
done using 2 way ANOVA with multiple comparisons. Statistical significance determined at
p<0.05. C) HEK293 cells were transfected with FLAG tagged EP3Re alongside wildtype
tau or P301S tau. Cells were treated with sulprostone for 15min and stained before and
after treatment for the receptor as well as the membrane. Following sulprostone treatment,
EP3Re distribution in cells containing wild type tau appeared to move away from the
membrane suggesting receptor internalisation, in contrast with cells containing P310S tau,
where the receptor remained prominent on the membrane. D) EP3Re internalisation following
15min sulprostone exposure was assessed using a FLAG ELISA. Although a trend is seen
suggesting reduced EP3Re internalisation in response to sulprostone exposure, this fails to
reach statistical significance. Twelve technical repeats were performed for each condition with
data shown from 3 independent experiments. Results were analysed with One way ANOVA
using multiple comparisons. Statistical significance was taken at p<0.05.
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5.4.2.3 Modelling disease in induced Pluripotent Stem Cell (iPSC) de-
rived neurons
Human iPSC derived cortical neural stem cells were obtained from Axol from a control
subject and an isogenic line edited using CRISPR-Cas9 technology to introduce the
P301L mutation, the most frequent cause of familial frontotemporal dementia, into
the MAPT gene. iPSCs with the MAPT N279K mutation were also differentiated,
however, several attempts at differentiation were unsuccessful and therefore this iPSC
line was not used for experiments.
EP3Re expression in iPSC derived neurons
EP3Re expression was initially examined in neural stem cells. Figure 5.11A shows
that both lines expressed EP3Re at this stage with no significant differences in EP3Re
intensity. Cells were then differentiated into neurons and by day 35, mature neurons
as identified by beta III-tubulin, were noted in the cultures. Mature neurons continued
to be positive for EP3Re, with predominant expression noted in cell bodies and little
immunoreactivity noted in axons.
EP3Re interacts with tau in iPSC derived neurons with P301L MAPT
mutation but not wild type tau
We next went on to characterise the physical interaction between tau and EP3Re
in iPSC derived neurons. Proximity ligation assays between tau and EP3Re were
performed on neurons derived from the control and isogenic P301L line. Figure 5.11F
shows a signal was noted in the P301L line but not the control suggesting an interaction
between EP3Re and tau that is present only in the P301L line.
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Fig. 5.11 Modelling tauopathies in iPSC derived neurons. A) Neural stem cells
have been stained for the presence of EP3Re as well as PAX6, a marker for neural progenitor
cells. EP3Re was expressed in both the control and P310L heterozygous line. B) Graph
showing intensity of EP3Re fluorescence staining. There was no difference in EP3Re signal
between control and P301L neural embryonic stem (NES) cells. Average intensity calculated
from 10 fields of view from 3 rounds of differentiation. All experiments performed in triplicate.
Unpaired t-test was used to determine differences in staining intensity. Statistical significance
was taken at p<0.05. C) At D35 both control and P301L cultures showed the presence of
neurons as identified by beta tubulin III. D) D35 iPSC derived neurons expressed EP3Re. E)
Graph showing intensity of immunofluorescence EP3Re staining in both control and P301L
iPSC derived neurons. There was no significant difference in EP3Re staining between the
two lines. Data shown from 3 independent rounds of differentiation. Analysed using unpaired
t-test. Statistical significance taken at p<0.05. F) Duolink proximity ligation assay done
in fixed cells using antibodies directed against EP3Re and tau. There was an interaction
between EP3Re and tau in the P301L line which was absent in the control line. Proximity
ligation assays done in triplicates. Representative image of two rounds of differentiation.
184 INVESTIGATING THE INTERACTION BETWEEN EP3RE AND TAU
EP3R stimulation increases tau phosphorylation in iPSC derived neurons
Day 35 neurons were exposed to the EP3 agonist sulprostone for 30min and levels of
tau phosphorylation assessed by immunocytochemistry using the phospho-tau antibody
AT8. At D35 the control line failed to show significantly increased AT8 staining in com-
parison to untreated neurons. In contrast, the neurons expressing the P301L mutation
showed an increase in AT8 levels (Fig. 5.12). In iPSC derived neurons, EP3 signalling
increased tau phosphorylation but only when the P301L mutation was present does
it reach statistical significance. Neurons were also assessed for the development of
tau aggregates using the fluorescent pentameric oligothiophene pFTAA, which has
been shown to identify filamentous tau (Brelstaff et al 2015). No positive pFTAA
staining was noted in the treated neurons. Although EP3 stimulation increases tau
phosphorylation this did not lead to development of filamentous tau at day 35.
5.4.2.4 Effect of the tau P301S mutation on EP3Re signalling
We have shown that the presence of wild type tau does not affect EP3Re activity as
measured by Gi coupling. To determine if the tau P301S mutation affects EP3Re
activity, IP1 assays were repeated in HEK293 cells transfected with the chimeric G
protein Gαδ6qi4myr alongside EP3Re and P301S tau. There was a 40% reduction
in EP3Re activity, as measured by IP1 accumulation, in the presence of P301S tau
when compared to wild type tau or no tau. P301S tau impaired EP3Re/Gi coupling
in HEK293 cells. The loss of the inhibitory effect of Gi should result in an increase
in cAMP and any downstream effects of this. When we examined cAMP response
element binding protein (CREB) using a luciferase reporter gene assay, this was noted
to increase in the presence of P301S tau supporting a loss of inhibitory Gi signalling.
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Fig. 5.12 EP3 stimulation increased tau phosphorylation in iPSC derived neu-
rons. A) Confocal images of iPSC derived neurons exposed to sulprostone. There was an
increase in tau phosphorylation but only in the MAPT P301L line did this reach statistical
significance (B). Data shown from 3 independent rounds of differentiation and analysed using
two way ANOVA with multiple comparisons. Statistical significance taken at p<0.05. C)
Sulprostone treated iPSC derived neurons did not show any evidence of aggregated filamen-
tous tau as identified by pFTAA. Experiments repeated 3 times per round of differentiation.
Representative image following 2 rounds of differentiation.
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Fig. 5.13 EP3Re signalling in the presence of P301S tau. A. Inositol accumulation
in HEK293 cells transfected with EP3Re and P301S tau alongside the chimeric G-protein
Gαδ6qi4myr. There was a 40% reduction in EP3Re activity in the presence of P301S tau.
Data was fitted to a non-linear regression curve and normalised in GraphPad prism 7.0.
Experiments were done in quadruplicates with cumulative data from 3 different experiments
shown. Two-tailed unpaired t-tests were performed to determine if P301S tau affected
EP3Re signalling. Statistical significance determined at p<0.05. B. EP3Re and CREB in
the presence of P301S tau. An increase in CREB activity was noted supporting impaired
EP3Re-Gi coupling with a subsequent loss in cAMP inhibition in the presence of P301S tau.
Cumulative data shown from 3 independent experiments. All experiments done in triplicate.
Data was fitted to a non-linear regression curve and normalised in GraphPad prism 7.0
and one-way ANOVA with multiple comparisons performed on Emax values. Statistical
significance determined at p<0.05.
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5.4.2.5 Molecular interaction between EP3Re and P301S tau
Finally we went on to examine the dynamic molecular interaction between EP3Re and
P301S tau using the NanoBiT® protein:protein interaction assay. NanoBiT® vectors
were fused to the C-terminal of the EP3Re receptor construct and either the C- or N-
terminus of tau with the P301S mutation. HEK293 cells were transfected with both
vectors and assays run for 20min to determine if EP3Re and P301S tau interact. No
detectable signal was noted suggesting there was no interaction between P301S tau
and the EP3Re C-terminal in HEK293 cells (Fig. 5.14). An interaction between the
extracellular EP3Re N-terminus and tau was not examined.
Fig. 5.14 There was no detectable molecular interaction between EP3Re and
P301S tau. HEK293 cells were transfected with MAPT with the P301S mutation and
EP3Re constructs fused with either a LgBiT or SmBiT peptide at the N- or C terminus. There
was no detectable interaction. A noninteracting protein (HaloTag) with the corresponding
interacting half of the pair was used as a negative control. Protein Kinase C Alpha (PRKACA)
and Protein Kinase CAMP-Dependent Type II Regulatory Subunit Alpha (PRKAR2A), two
proteins known to interact, were used as a positive control. Eight technical replicates were
performed for each interaction. Data shown from one experiment, representative of three
independent experiments.
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5.5 Discussion
In this study we show that signalling through EP3 increases levels of tau phosphoryla-
tion in cell-based models of tauopathy. A summary of key findings regarding EP3Re
and tau phosphorylation is summarised in table 5.1.
Table 5.1 Summary of results by cell-based model
CELL WILD TYPE TAU DISEASE MODEL
SHSY5Y EP3Re stimulation increased
tau phosphorylation and re-
duced GSK3β activity
In a hypothermia based model
EP3Re activity mediated hy-
pothermia induced tau phos-
phorylation
Transfected HEK293
EP3 stimulation increased tau
phosphorylation (not specific
to e isoform)
EP3 stimulation increased tau
phosphorylation in models
based on P301S tau (not spe-
cific to e isoform)
Wild type tau had no effect on
EP3Re signalling as measured
by EP3Re-Gi coupling
P301S tau impaired EP3Re sig-
nalling as measured by EP3Re-
Gi coupling
human iPSC derived neurons No change in tau phosphoryla-
tion in response to EP3 stimu-
lation
EP3 stimulation increased tau
phosphorylation
Initial results obtained in SHSY5Y cells expressing endogenous tau, show an in-
crease in tau phosphorylation at PHF1 tau epitopes (serine 396/404) in response to
EP3 activity. In SHSY5Y cells we show this to be predominantly mediated via EP3Re.
Unexpectedly, we noted an inhibition by EP3Re of GSK3β, an important kinase impli-
cated in Alzheimer’s dementia. Although unexpected, this is not surprising as PGE2,
the endogenous EP3Re ligand, has been shown to inhibit GSK3 activity (Beurel et al.,
2010). GSK3 is modulated via its phosphorylation by AKT at serine 9, and although
the data is conflicting on the relationship between EP3 and AKT, studies in rat cere-
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bellar astrocytes have shown PGE2 to promote AKT phosphorylation and subsequent
activation via the EP3 receptor (Paniagua-Herranz et al., 2017). Although a trend is
noted suggesting EP3Re activity promotes AKT activity in SHSY5Y cells, providing a
mechanism by which GSK3 activity is inhibited, this failed to reach statistical signifi-
cance in our present study. Other studies have shown PGE2 induced GSK3 inhibition
to be driven via protein kinase A and cAMP through EP2 and EP4 (Fujino et al., 2002).
Study of EP3Re activity in HEK293 cells, as measured by Gi coupling, shows an
increase in tau phosphorylation in association with an increase in EP3Re activity,
regardless of whether the receptor is in the presence of wild type tau or tau with the
P301S mutation, although these results are confounded by the presence of other EP3
isoforms. Overexpression of the e isoform when examining the signal transduction
pathways, seems sufficient to differentiate EP3Re activity from other EP3 isoforms
but, when examining levels of tau phosphorylation, it is difficult to determine the
precise contribution of the e isoform. EP3 activity increases tau phosphorylation in a
sulprostone dose dependent manner, but what is unclear is to what extent the e isoform
contributes to this, given that an increase is noted in both the presence and absence
of EP3Re. The absence of inositol accumulation in the HEK293 cells lacking the e
isoform suggest that increases in tau phosphorylation, in cells without EP3Re following
sulprostone treatment, is not mediated by Gi coupling. The finding in HEK293 cells
that other EP3 isoforms contribute to tau phosphorylation suggests that in SHSY5Y
cells, where no effect is seen in the absence of EP3Re, the e isoform is likely to be the
predominant isoform expressed due to their neuronal phenotype. The fact that tau is
endogenously present may also be relevant.
In this study we also show that intrinsic EP3Re activity is necessary for tau in-
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duced hypothermia. Signalling assays previously performed in HEK293 cells showed
a degree of EP3Re intrinsic activity in the absence of its ligand. Further activation
of the receptor, using sulprostone, fails to result in any further changes in tau phos-
phorylation. The mechanism behind this is unclear. Signalling assays to correlate
this with changes in EP3Re activity, show a reduction in temperature results in a
depression of EP3Re activity, as measured by IP1 accumulation, which fails to support
our findings. The discrepancy could be attributed to an alternative EP3Re signalling
cascade independent of Gi coupling. Bretteville et al. 2012 propose that hypothermia
induces tau phosphorylation by downregulating protein phosphatase 2A (PP2A) ac-
tivity (Bretteville et al., 2012). EP3Re intrinsic activity may be necessary for this to
occur, but the scope of this study does not examine a possible interaction between
EP3Re and phosphatase activity, something that would have been interesting to explore.
We subsequently went on to examine how tau impacts EP3Re functions and show
EP3Re activity, as measured by Gi coupling, is inhibited in the presence of tau with the
P301S mutation. In keeping with this, when we examined EP3Re signalling by looking
at the cAMP response element binding protein, this was increased in the presence of
P301S tau confirming the loss of cAMP inhibition due to impaired Gi activity. A trend
was also noted suggesting the presence of P301S tau disrupts receptor internalisation,
although, this did not reach statistical significance. A number of pathological MAPT
P301 mutations have been described in association with frontotemporal dementia,
P301L, P301S and P301T (Bugiani et al., 1999; Erro et al., 2019; Spillantini et al.,
1998). P301 is located within the microtubule binding domain in exon 10, and thus P301
mutations impair tau’s ability to promote microtubule assembly (Goedert et al., 2000).
Disrupted microtubule assembly can lead to defects in intracellular transport and may
explain why we see an impairment in the function of the receptor. GPCRs following
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activation, are targeted for internalisation into endocytic compartments (Mohan et al.,
2012). It is then recycled back to the plasma membrane following re-sensitisation
(Mohan et al., 2012). The classical canonical model of GPCR signalling states that
receptor internalisation is a prerequisite for re-sensitisation. If this is impacted due
to disrupted cellular transport and trafficking due to dysfunctional microtubules then
this could result in reduced EP3Re function due to impaired re-sensitisation. Another
possible theory is that the receptors physical interaction with tau impairs its ability to
function, however assessing the molecular interaction between EP3Re and tau using a
dynamic protein:protein interaction showed no interaction between EP3Re and wild
type or P301S tau in HEK293 cells.
The NanoBit® protein:protein interaction assay has several limitations. The assay only
explores the interaction between monomeric tau and not aggregated tau, and unless the
assay is run till the point pathology develops, it is difficult to determine at which point
EP3Re interacts with tau. The cells only express both proteins before experiments are
performed for 24hrs and observed for 20mins to determine if an interaction is present
in contrast to the assessments done in fixed cells or tissue, which examine a single time
point of an interaction between two endogenous proteins. Although EP3Re fused to a
Nanobit® vector at the extracellular facing N-terminal was used for experiments, tau
would only have been expressed within the cytoplasm. Any interaction between tau and
the N-terminal of EP3Re would not be detectable. The current experimental design
only allows for detection of interactions that occur within the cytoplasm. The presence
of a tag at each terminal may also have implications as to how the two proteins are
able to interact.
We have established that in primary cell lines EP3Re activity increases tau phos-
192 INVESTIGATING THE INTERACTION BETWEEN EP3RE AND TAU
phorylation in the presence of wild type tau as well as in models of disease, either
by using hypothermia in SHSY5Y cells or expressing P301S tau in HEK293 cells. To
understand if this is reflected in human disease, a better human model of tauopathy
was required. To this end, we used neurons derived from iPSCs to understand if EP3Re
signalling could be contributing to tau pathology by increasing tau phosphorylation.
The use of iPSC derived neurons allows us to study the disease pathogenesis us-
ing patient derived pathogenic cells endogenously expressing both proteins. This is
particularly important given that we are trying to understand how a human specific
receptor behaves in disease. The iPSC derived neurons recapitulated some of the
results seen in studies performed on fixed tissue and primary cell lines. The iPSC
derived neurons are shown to express the receptor at day 35 of differentiation, when
neurons are present as shown by the presence of beta tubulin. Interestingly positive
EP3Re immunoreactivity is also present in neural stem cells. Although we didn’t look
at EP3Re expression at multiple time points in between, it would have been interesting
to see if expression varied as neurons matured. There is no discernible difference
between expression of the receptor at the stages looked at between neurons derived
from control lines and those derived from the P301L heterozygous line. Proximity
ligation assays, similar to those done in fixed tissue sections, show an interaction
between EP3Re and tau in neurons derived from the P301L line, but not control lines
at day 35 of differentiation. The tau antibody used for these experiments was not
conformation specific, and therefore it is difficult to say if this interaction is dependent
on the tau conformation. These neurons at day 35 do not have tau tangles, as defined
by pFTAA, suggesting that in the iPSC derived neurons, EP3Re interaction with tau
is not dependent on tau being aggregated.
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We show EP3 activation increases tau phosphorylation in P301L iPSC derived neurons
but not neurons derived from isogenic controls. We know from work down by Iovino et
al. characterising these neurons that those with the P301L MAPT mutation mature
faster than those with wild type tau. Exposing neurons derived from the isogenic
control to sulprostone at a later time point may have yielded a statistically significant
increase in tau phosphorylation not seen at 35 days. Attempts to silence EP3Re to
determine the contribution of this specific isoform to tau phosphorylation using siRNA
targeting the receptor were unsuccessful. This will need to be further investigated
using a more suitable tool to delete EP3Re expression. In this present study I can
only state that EP3 signalling in iPSC derived neurons increases tau phosphorylation.
We were unable to show this subsequently leads to development of tau aggregates
in our experimental models of tauopathy. Previous characterisation of the P301L
line (Iovino et al., 2015) show even if left to mature for up to 150 days they do not
develop filamentous tau aggregates and therefore do not recapitulate all the features of
tauopathy. Neurons derived from patients with the MAPT N279K mutation have also
been described (Iovino et al., 2015). At 150 days, these cells have increased levels of tau
phosphorylation, but importantly also develop filamentous tau aggregates (Iovino et al.,
2015). Unfortunately, attempts to study EP3 signalling in this line were unsuccessful.
They developed into non-neuronal cells or failed to survive. Due to time constraints, sev-
eral of the experiments on iPSC derived neurons were only performed on two biological
replicates and will need to be repeated a third time to ensure these findings remain valid.
In conclusion, in this present study we show that EP3 signalling increases tau phos-
phorylation in models of tauopathy based on P301 tau mutations but not necessarily
in the presence of wild type tau under normal physiological conditions. In turn P301S
tau impairs EP3Re activity as measured by Gi coupling. We also show that EP3Re
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is necessary for hypothermia induced tau phosphorylation. The study is limited by
the fact only one tau mutation was examined to study the behaviour of EP3Re in
tauopathies. Future studies will need to explore the behaviour of the receptor in the
presence of other tau mutations to determine if the effects seen are unique to P301
mutations or if this occurs in all mutations associated with tauopathies. The findings
of the study also suggest the e isoform is not the only receptor mediating the effects of
sulprostone on tau phosphorylation but other EP3 receptors are also playing a role.
Further work will be required to study each isoform in turn to determine which of the





This project evolved from an incidental finding suggesting an interaction between tau
and EP3Re. Our aim was to better understand EP3Re distribution and function in
human brain and its relationship, if any with tau. Studies have implicated inflammatory
PGE2 signalling in tauopathies but due to the broad effects of PGE2, inhibiting its
production would have systemic effects and implications beyond disease pathology. A
greater understanding of the tau-EP3Re interaction is required to consider taking a
more targeted approach. The work performed during my PhD shows that the e isoform
of the PGE2 EP3 receptor is expressed throughout the human brain and appears to
localise with tau aggregates in tauopathies. This is the first study to characterise
the distribution of EP3Re in the human brain, where we found neuronal expression
throughout the brain, with strong expression in brainstem nuclei and the hypothalamus.
We also show that EP3Re signals through Gi coupling and the presence of the tau
P301S mutations appears to impede this. We also found that signalling through EP3
increases tau phosphorylation in our models of disease. Based on studies using P301S
tau mutations, the EP3 receptor, and in particular the e isoform, was found to play a
role in hypothermia mediated tau phosphorylation.
6.2 EP3Re signalling and tau phosphorylation - A
potential role in tau pathology
The PGE2 EP receptors are all G-protein coupled receptors (GPCRs) and thus signal
via Gi, Gq or Gs and associated second messenger signalling cascades. Similar to other
studies looking at EP3 signalling (Hatae et al., 2002b; Hizaki et al., 1997; Morimoto
et al., 2014), which suggest EP3 couples predominantly to Gi, we found the human
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EP3Re receptor to signal preferentially through Gi coupling. The original linear dogma
of one receptor coupling to one G-protein has however proven to be inadequate. Most
G-protein coupled receptors interact with diverse G proteins eliciting multiple intracel-
lular signals. To this end several other EP3 isoforms have been shown to interact with
multiple G-proteins and in this present study our assays have shown EP3Re is also
capable of coupling with Gq. It is unclear why certain GPCRs are able to couple to
multiple Gα subunits whilst others are more selective. Three-dimensional modelling of
GPCRs have revealed multiple latent intracellular cavities to which G-proteins interact
with at varying strengths (Sandhu et al., 2019). It has been proposed that incorporation
of selective residues throughout evolution within these cavities is sufficient to reshape
the intracellular cavity making multiple binding partners possible (Sandhu et al., 2019).
Targeting these residues, inhibiting or promoting one signalling cascade over another,
creates a potential therapeutic strategy should EP3Re-Gi or EP3Re-Gq coupling have
functional implications in disease. To this end, we attempted to correlate EP3Re
signalling with tau pathology, mainly focusing on tau phosphorylation. In figure 6.1
we summarise the key findings and postulate possible mechanisms underlying the
relationship between EP3Re and tau under normal physiological conditions and in our
models of tauopathy.
Under normal physiological conditions and in the presence of wild type tau, we found
EP3Re activation inhibited GSK3β but not GSK3α. GSK3, and in particular GSK3β,
is an important serine/threonine kinase strongly implicated in tau phosphorylation
and Alzheimer’s dementia, and is a proposed therapeutic target for disease (Griebel
et al., 2019; Hooper et al., 2008; Lauretti and Praticò, 2020; Llorens-Martín et al., 2014;
Serenó et al., 2009). The mechanism through which EP3Re inhibits GSK3β is not yet
clear, however, we found a trend suggesting an increase in active AKT. AKT, when
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Fig. 6.1 A) EP3Re signalling under normal physiological conditions. EP3Re
signals predominantly through Gi coupling. Upon ligand binding the receptor undergoes
a conformational change resulting in dissociation of the Gαi subunit from the βγ subunit.
The Gαi subunit inhibits adenyl cyclase preventing cAMP production from ATP. Data
obtained from experiments in SHSY5Y cells show EP3Re activation to be associated with
a reduction in active GSK3β. This could be mediated by the increase observed in AKT
which in turn phosphorylates and inactivates GSK3. Studies have shown that AKT can be
activated through direct binding of the βγ subunit or indirectly through PI3K. The increase
in tau phosphorylation observed in our SHSY5Y and HEK293 cell lines should be interpreted
with caution given that this is not observed in the iPSC derived neurons. It remains to be
determined whether the noted increase in tau phosphorylation is mediated by AKT, or by a
yet uncharacterised mechanism.
B) EP3Re signalling in models of tauopathy. In our models of tauopathy based on
hypothermia and P301L tau mutations, we observed a reduction in EP3Re-Gi coupling.
This would result in an increase in cAMP and downstream signalling targets such as cAMP
dependent protein kinases and CREB. In keeping with this, in our disease model based
on P301S tau, we also observed an increase in CREB. We also note an increase in tau
phosphorylation in our models of disease in response to EP3Re activation by sulprostone.
This is not mediated through EP3Re Gi-coupling, as our signalling assays in HEK293 cells
show an increase in tau phosphorylation in the absence of EP3Re-Gi coupling. This is likely to
occur either due to the loss of previously observed GSK3β inhibition by EP3Re, loss of cAMP
inhibition, activating kinases downstream of cAMP, such as PKA, or, alterations in non-
GPCR dependent mechanisms, such as changes in beta-arrestin recruitment. ATP- Adenosine
triphosphate, cAMP – cyclic adenosine monophosphate, CREB – cAMP response element
binding protein, AKT – RAC-alpha serine/threonine-protein kinase, PI3K – phosphoinositide
3-kinase, GSK3β - glycogen synthase kinase 3β.
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phosphorylated is, in turn, able to inhibit GSK3 via phosphorylation at serine9 and
EP3Re could reduce GSK3β activity via this mechanism. With this apparent reduction
in GSK3β, one would expect an associated reduction in phosphorylated tau, however,
data obtained from our experiments in SHSY5Y and HEK293 cells show an increase in
tau phosphorylation in response to EP3Re activation by the EP3 agonist sulprostone.
This does appear to be independent of Gi coupling and not specific to EP3Re as this
response is seen in HEK293 cells lacking the e isoform suggesting this is being mediated
by other EP3 isoforms. In figure 6.1 we suggest this increase in tau phosphorylation,
could be mediated by AKT, which is known to phosphorylate tau at serine 214 (Ky-
oung Pyo et al., 2004), or an uncharacterised mechanism. In the control iPSC derived
neurons expressing wild type tau, no increase in tau phosphorylation is seen in response
to EP3Re stimulation by sulprostone. This contrasts with our findings in SHSY5Y
and HEK293 cell lines where an increase in tau phosphorylation is noted. In view
of the findings in iPSC derived neurons, the results obtained in our human cell lines
should be interpreted with caution. HEK293 cells were transfected and would likely
have expressed levels of tau above endogenous levels unlike the iPSC derived neurons,
where one would expect a more physiological level of tau expression comparable to
what we find in vivo. SHSY5Y cells also express PHF1 and AT8 phospho-tau epitopes
during proliferation (Pope et al., 1994) which could have contributed to the levels of
tau phosphorylation noted. The discrepancy noted between iPSC derived neurons and
human cell lines creates some uncertainty as to the contribution of EP3 or EP3Re
to tau phosphorylation under normal physiological conditions. Continuous treatment
of control iPSC derived neurons with sulprostone, modelling a chronic inflammatory
process, may have resulted in a similar increase in phosphorylated tau, as seen in human
cell lines but time limitations meant we were unable to fully explore this hypothesis.
The evidence that EP3Re increases tau phosphorylation under pathological conditions
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is more consistent. We have found an increase in phospho-tau in SHSY5Y and HEK293
in our models of tauopathy based on expressing P301S tau, hypothermia, as well as
iPSC derived neurons expressing tau with the P301L mutation. The finding that EP3Re
increases tau phosphorylation in our models of disease but not consistently in the pres-
ence of wild type tau would suggest that inflammatory signalling via EP3Re on its own
is not sufficient to drive disease pathology but a primary stimulus, such as hypothermia
or tau mutation, is required. Our results also demonstrate that the effects on tau are not
unique to the e isoform. This is supported by the recent findings that the murine EP3
receptor increases tau phosphorylation in murine neuroblastoma cells (Cao et al., 2019).
Signalling assays performed in HEK293 cells expressing P301S tau, as well as cells
exposed to hypothermia, showed a reduction in EP3Re-Gi coupling as measured using
our second messenger IP1 assay, not seen when wild type tau is expressed at nor-
mothermia. This supports our view that any resulting tau phosphorylation seen in
the presence of EP3Re activity is independent of Gi coupling. In keeping with loss of
inhibitory Gi signalling, we also note an increase in cAMP response element binding
protein (CREB) in the presence of P301S tau but not wild type tau. The downstream
effects observed are likely to be mediated by an alternative signalling cascade.
6.3 Signalling via G-protein or alternative path-
ways
G-protein independent signalling such as β-arrestin dependent mechanisms, have
been shown to trigger endocytosis and more importantly activate kinases leading to
specific signalling pathways (Jean-Charles et al., 2017). β-arrestins are well known
regulators of G-proteins. Following GPCR activation, β-arrestin has been shown to
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translocate from the cell membrane, binding to the receptor, uncoupling it from the
G-protein promoting receptor internalisation and desensitisation (Gainetdinov et al.,
2004). Interestingly, in HEK293 cells expressing P301S tau, we found a reduction
in receptor internalisation following sulprostone exposure. We hypothesise that this
could be secondary to changes in microtubule function and transport contributing to
the reduction in EP3Re-Gi coupling noted, but changes in β-arrestin function could
have similar implications. GPCR-β-arrestin complexes are able to instigate G-protein
independent signalling cascades and have been shown to interact with kinases such as
AKT, JNK and p38 (Jean-Charles et al., 2017; Reiter et al., 2012), kinases known to
phosphorylate tau. This provides an alternative signalling mechanism, independent
of EP3Re-Gi coupling, that could account for the changes that we observe on tau
phosphorylation which do not correlate with Gi activity. Individual EP3 isoforms have
been shown to internalise differently and this is believed to be determined by differences
in C-terminus (Bilson et al., 2004). Although internalisation of EP3Re has not been
previously characterised, EP3 I and f have been shown to internalise with β arrestin.
Further characterisation of EP3Re by investigating β-arrestin recruitment and function
would be important to determine if this signalling mechanism could be implicated in
the changes observed in our models of disease. This discrepancy between impaired
EP3Re signalling and an increase in EP3Re mediated tau phosphorylation in our
models of disease could therefore be explained by differences in GPCR independent vs
dependent signalling, with one being suppressed whilst the other drives tau pathology
in tauopathies. Alternatively, this could be a protective mechanism in which EP3Re
initially promotes tau phosphorylation which in turn suppresses EP3Re activity. In
support of this hypothesis studies have shown an increase in PGE2 in early Alzheimer’s
disease, when it could be driving tau pathology, with lower levels in advanced disease
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stages (Combrinck et al., 2006; Montine et al., 1999), once neurodegeneration is
advanced.
6.4 Thermoregulation
The reduction in EP3Re function as measured by Gi coupling in our models of disease
could have implications beyond tau pathology. An alteration in EP3Re function could
be reflected in impaired thermoregulation and autonomic dysfunction as described
clinically in tauopathies (Carrettiero et al., 2015; Engelhardt and Laks, 2008; Oliveira
et al., 2019). EP3 expressing paraventricular neurons in the hypothalamus have been
shown to mediate PGE2 central excitatory effects on the sympathetic nervous system
including hypertension and tachycardia (Ariumi et al., 2002; Chen et al., 2012; Zhang
et al., 2011). In our study we have shown EP3Re to be expressed in the paraventricular
neurons of the hypothalamus and is thus likely to be one of the isoforms mediating
PGE2 effects on the sympathetic nervous system. If the changes observed in EP3Re-Gi
coupling in the presence of P301S tau do occur in human disease, this could con-
tribute to the impairments in the sympathetic nervous system function associated with
tauopathies (Oliveira et al., 2019).
Thermoregulation and generation of pyrexia is a well characterised function of EP3.
Loss of thermoregulation has been demonstrated in Alzheimer’s as well as normal
ageing (Norman et al., 1985; Vandal et al., 2016) and could be associated with impaired
EP3Re function as measured by Gi-coupling. EP3 receptors in the median preoptic nu-
cleus have been shown to mediate PGE2 induced febrile response (Lazarus et al., 2007;
Morrison and Nakamura, 2011). In our present study we found EP3Re to be expressed
in the median preoptic nucleus as well as the dorsomedial hypothalamus, two critical
areas in thermoregulation, and is thus likely to be one of the EP3 isoforms involved
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in thermoregulation. Selective deletion of EP3 receptors in the mouse brain, and in
particular the median preoptic nucleus, not only eradicates the pyrexial response, but
also promotes hypothermia (Lazarus et al., 2007). Interestingly we show in SHSY5Y
cells that hypothermia induced tau phosphorylation is dependent on EP3Re. Similar
to sulprostone induced tau phosphorylation, this is independent of EP3Re-Gi coupling.
The mechanism behind hypothermia induced tau phosphorylation has been largely
attributed to inhibition of serine/threonine protein phosphatase 2 (PP2A) (Bretteville
et al., 2012; Planel et al., 2004). However other mechanisms could also be involved.
Diabetic murine models, based on impaired leptin signalling, display an increase in tau
phosphorylation associated with a reduction in their basal temperature. These changes
reverse on return to normothermia (El Khoury et al., 2016). In these mice it is notable
that no deregulation of kinases or phosphatases was found, specifically PP2A. This
suggests a mechanism independent of PP2A inhibition.
If EP3Re function is impaired in human disease, as we have shown it to be in our
models of disease, then this could account for the changes in thermoregulation that have
been noted in Alzheimer’s (Vandal et al., 2016). With the proposal that hypothermia
may even drive tau phosphorylation (El Khoury et al., 2016; Tournissac et al., 2017), a
potential mechanism emerges linking impaired EP3 function and tau phosphorylation
through deficits in thermoregulation and hypothermia.
6.5 Tau tangles and EP3Re
This study expanded from the finding that in tauopathies EP3Re is present in tau
tangles. Although our in vitro experiments show EP3R/EP3Re signalling increases tau
phosphorylation, it is unclear if EP3Re remains functional if bound to tau within the
cytoplasm. Signalling cascades through GPCRs are traditionally thought to emanate
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at the cell membrane, however, there is growing evidence that translocated GPCRs are
capable of interacting with intracellular membranes, binding with different partners and
instigating different signalling cascades compared to when bound to the cell membrane
(Jong et al., 2018). Indeed, EP3 has been shown to signal not only from the cell
membrane but also when translocated to the nuclear membrane (Bhattacharya et al.,
1999). The significance of the physical interaction between EP3Re and fibrillary tau
that we identify in this study is unclear. Tau aggregates have been known to sequester a
number of proteins including molecular chaperones with resulting functional inhibition
of chaperone-dependent events of protein folding and clathrin mediated endocytosis
(Yu et al., 2019). The findings reported in this study could represent EP3Re being
entrapped by aggregated tau rather than the receptor being an intrinsic component of
tau tangles. Our interaction assays show no interaction between monomeric tau and
EP3Re, nor do they show an association between the intracellular EP3Re C- terminus
and the N- or C- terminus of tau. This leaves the possibility that an interaction
could be occurring between tau and the EP3Re extracellular N- terminus, although
due to time constraints we were not fully able to explore this possibility. If this
proves to be the case, this proposes a potential role for EP3Re in tau propagation by
internalising extracellular tau aggregates into the cell however, more studies and use
of mass spectrometry of tangle extracts can determine the interaction specificity and
nature of the interaction between EP3Re and tau in neurofibrillary tangles. If this
interaction were confirmed it will provide important evidence for a role of EP3Re in
tauopathies.
6.6 Limitations and future direction
In the present study we have described the distribution of EP3Re in human brain,
the signalling mechanism associated with it, and the interaction between EP3Re and
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tau. We, however, cannot state that this interaction is unique to the e isoform and
experiments performed measuring tau phosphorylation in HEK293 cells would suggest
that other isoforms may also contribute to increase tau phosphorylation. The study of
individual isoforms is challenging due to the lack of commercially available antibodies.
Further work examining EP3 RNA would allow us to identify all the isoforms present
in the human brain and compare this to isoforms expressed in our primary cell lines
and iPSC derived neurons. Furthermore, in iPSC derived neurons we were only able to
study the effect of EP3 signalling on tau phosphorylation, and not specifically EP3Re.
Attempts to silence EP3Re were unsuccessful due to the poor survival rate of the
neurons. Genomic engineering using guide RNAs complexed with the nuclease Cas9
from the microbial clustered regularly interspaced short palindromic repeats (CRISPR)
adaptive immune system has proven to be a highly valuable tool in molecular biology.
Several studies have successfully used CRISPR-Cas9 in iPSC derived neurons, as
well as primary cell lines, to model disease (Fang et al., 2006; Komor et al., 2016;
Ortiz-Virumbrales et al., 2017; Srikanth et al., 2015). In contrast to siRNA, which
reduces gene expression, CRISPR-Cas9 would provide irreversible gene knockout and
a more specific mechanism to further study the role of EP3Re in tauopathies. This
would allow us to determine the specific contribution of the e isoform to our results,
although it would be difficult to exclude the possibility of a redundancy effect in EP3Re
knockout neurons, whereby the function of EP3Re is overtaken by other EP3 isoforms.
Our studies in HEK293 cells and iPSC derived neurons was also limited to tau
mutations involving P301 – P301L or P301S. To understand if our findings could be
relevant across all tauopathies, further work will be required examining the relationship
between EP3Re and tau in the presence of other tau mutations. Tau mutations fall
into two major categories, those that influence alternative splicing of tau and those
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that alter tau at the protein level (Goedert, 2003; Strang et al., 2019). The mutations
used in our present study alter tau at the protein level disrupting its functions, such
as axonal transport and microtubule binding, promoting filament formation and tau
aggregation (Goedert and Jakes, 2005). P301 is situated in exon 10 and therefore
P301S and P301L tau mutations are present in 4R tau isoforms. Although we show
EP3Re to interact with aggregates consisting of both 3R and 4R tau, we do not know
if the results of our functional assays, such as Gi-coupling, would be replicated with
tau mutations outside of 4R tau. The P301L and P301S tau mutations are in the
microtubule binding domain and thus reduce the ability of tau protein to interact with
microtubules impairing microtubule extension and stabilisation (Dayanandan et al.,
1999; Falcon et al., 2015; Goedert and Jakes, 2005). Disrupted microtubule function
may contribute to the changes we see in EP3Re function, such as reduced receptor
internalisation and Gi-coupling. Studying the impact of other tau mutations such as
N279K, which has its effect at the RNA level by increasing exon 10 splicing, disrupting
the 3R:4R tau isoform ratio, will be important to determine if our findings are relevant
in other tau mutations. The association of EP3Re with tangles in sporadic Alzheimer’s
and PSP would support that the interaction is not specific for a disease, tau mutation
or tau isoform.
Fully recapitulating a complex disease process in a two-dimensional (2D) cell cul-
ture system is challenging. Three-dimensional (3D) brain organoid systems generated
from human pluripotent stem cells have shown great potential at being able to model
the complex interactions between glial cells and neurons (Lancaster and Knoblich,
2014), which our two-dimensional cultures fail to capture. Our study is also limited
to EP3Re neuronal signalling by the models we have available. Microglia are the
resident immune cells within the central nervous system and are key mediators of
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the neuroinflammatory process (Bachiller et al., 2018). Activated microglia produce
pro-inflammatory factors, including PGE2 (Zhang et al., 2009). The possibility that
microglial PGE2 secretion may influence or be influenced by EP3Re expression needs
to be explored and the interplay between microglia and neurons with regards to EP3Re
signalling further characterised. Other EP receptors have been shown to interact with
microglial. PGE2-EP2 signalling has been shown to suppress beneficial microglial func-
tions such as chemotaxis and amyloid clearance (Johansson et al., 2015). PGE2-EP3Re
signalling could be exerting a similar effect. Future studies using 3D brain organoids
would allow us to better understand the role of EP3Re signalling in non-neuronal cells,
as well as how this could influence neuronal-glial interaction.
In summary, we have shown that EP3Re is widely distributed in the human brain,
interacts with tau in tauopathies, and, signalling through EP3 and EP3Re increases
tau phosphorylation in our cellular models of disease. This is independent of Gi
coupling, the main EP3Re signalling pathway identified in our study. Further work is
required to fully elucidate the mechanism is and understanding if targeting inflamma-
tory prostaglandin signalling through EP3Re or other EP3 isoforms could ameliorate
tau pathology.
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Appendix A
EP3RE-FLAG (Flag sequence in red)
GAATTCACCATGGACTACAAGGATGACGATGACAAAATGAAGGAGACCC
GGGGCTACGGAGGGGATGCCCCCTTCTGCACCCGCCTCAACCACTCCTAC
ACAGGCATGTGGGCGCCCGAGCGTTCCGCCGAGGCGCGGGGCAACCTCA
CGCGCCCTCCAGGGTCTGGCGAGGATTGCGGATCGGTGTCCGTGGCCTT
CCCGATCACCATGCTGCTCACTGGTTTCGTGGGCAACGCACTGGCCATGC
TGCTCGTGTCGCGCAGCTACCGGCGCCGGGAGAGCAAGCGCAAGAAGTC
CTTCCTGCTGTGCATCGGCTGGCTGGCGCTCACCGACCTGGTCGGGCAG
CTTCTCACCACCCCGGTCGTCATCGTCGTGTACCTGTCCAAGCAGCGTTG
GGAGCACATCGACCCGTCGGGGCGGCTCTGCACCTTTTTCGGGCTGACC
ATGACTGTTTTCGGGCTCTCCTCGTTGTTCATCGCCAGCGCCATGGCCGT
CGAGCGGGCGCTGGCCATCAGGGCGCCGCACTGGTATGCGAGCCACATG
AAGACGCGTGCCACCCGCGCTGTGCTGCTCGGCGTGTGGCTGGCCGTGC
TCGCCTTCGCCCTGCTGCCGGTGCTGGGCGTGGGCCAGTACACCGTCCA
GTGGCCCGGGACGTGGTGCTTCATCAGCACCGGGCGAGGGGGCAACGGG
ACTAGCTCTTCGCATAACTGGGGCAACCTTTTCTTCGCCTCTGCCTTTGC
CTTCCTGGGGCTCTTGGCGCTGACAGTCACCTTTTCCTGCAACCTGGCCA
CCATTAAGGCCCTGGTGTCCCGCTGCCGGGCCAAGGCCACGGCATCTCA
250
GTCCAGTGCCCAGTGGGGCCGCATCACGACCGAGACGGCCATTCAGCTT
ATGGGGATCATGTGCGTGCTGTCGGTCTGCTGGTCTCCGCTCCTGATAAT
GATGTTGAAAATGATCTTCAATCAGACATCAGTTGAGCACTGCAAGACAC
ACACGGAGAAGCAGAAAGAATGCAACTTCTTCTTAATAGCTGTTCGCCTG
GCTTCACTGAACCAGATCTTGGATCCTTGGGTTTACCTGCTGTTAAGAAA
GATCCTTCTTCGAAAGTTTTGCCAGATGAGAAAAAGAAGACTCAGAGAG
CAATTAATCTGCAGTTTGCAGAACTCTCAGATACAGAGGGCAACTGCACA
TTGTGGGCAAGTACAAACCTATCGTGTGCTGAACAGAGAAGAAATGGAG
GTACTCGTGAGCAGCATTAATGTGTACACCAGAATCTCAACAGTAAAGAC
AGAATAATGACTCGAG
TAU-VENUS
ATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGA
CGTACGGGTTGGGGGACAGGAAAGATCAGGGGGGCTACACCATGCACCA
AGACCAAGAGGGTGACACGGACGCTGGCCTGAAAGCTGAAGAAGCAGGC
ATTGGAGACACCCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGACCC
AAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGATGACAA
AAAAGCCAAGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGA
GCAGCCCCTCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGATTCCAG
CAAAAACCCCGCCCGCTCCAAAGACACCACCCAGCTCTGGTGAACCTCCA
AAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCCCAGGCACTC
CCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAG
CCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGC
CAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAAT
GTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAG
251
GCGGGAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCA
GTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGC
AGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAA
GTGTGGCTCATTAGGCAACATCCATCATAAACCAGGAGGTGGCCAGGTG
GAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGA
TTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAA
GATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACA
GACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGACA
CGTCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATG
GTAGACTCGCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCTGCCTCCCT
GGCCAAGCAGGGTTTGGAATTCGGATCCGGATCCATGGTGAGCAAGGGC
GAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCG
ACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGC
CACCTACGGCAAGCTGACCCTGAAGCTGATCTGCACCACCGGCAAGCTGC
CCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGC
TTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGC
CATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC
GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG
TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACAT
CCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCA
CCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCA
CAACATCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAAC
ACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAG
CTACCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATG
GTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG
AGCTGTACAAGTAA
252
P301STAU-VENUS
ATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGA
CGTACGGGTTGGGGGACAGGAAAGATCAGGGGGGCTACACCATGCACCA
AGACCAAGAGGGTGACACGGACGCTGGCCTGAAAGCTGAAGAAGCAGGC
ATTGGAGACACCCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGACCC
AAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGATGACAA
AAAAGCCAAGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGA
GCAGCCCCTCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGATTCCAG
CAAAAACCCCGCCCGCTCCAAAGACACCACCCAGCTCTGGTGAACCTCCA
AAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCCCAGGCACTC
CCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAG
CCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGC
CAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAAT
GTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAG
GCGGGAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCA
GTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGC
AGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAA
GTGTGGCTCATTAGGCAACATCCATCATAAATCAGGAGGTGGCCAGGTG
GAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGA
TTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAA
GATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACA
GACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGACA
CGTCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATG
GTAGACTCGCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCTGCCTCCCT
253
GGCCAAGCAGGGTTTGGAATTCGGATCCGGATCCATGGTGAGCAAGGGC
GAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCG
ACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGC
CACCTACGGCAAGCTGACCCTGAAGCTGATCTGCACCACCGGCAAGCTGC
CCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGC
TTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGC
CATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC
GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG
TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACAT
CCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCA
CCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCA
CAACATCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAAC
ACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAG
CTACCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATG
GTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG
AGCTGTACAAGTAA
NFAT-LUC
TCATAGGACCTCTCACACACAGTTCGCCTCTTTGATTAACGCCCAGCGTT
TTCCCGGTATCCAGATCCACAACCTTCGCTTCAAAAAATGGAACAACTTT
ACCGACCGCGCCCGGTTTATCATCCCCCTCGGGTGTAATCAGAATAGCTG
ATGTAGTCTCAGTGAGCCCATATCCTTGCCTGATACCTGGCAGATGGAAC
CTCTTGGCAACCGCTTCCCCGACTTCCTTAGAGAGGGGAGCGCCACCAGA
AGCAATTTCGTGTAAATTAGATAAATCGTATTTGTCAATCAGAGTGCTTT
TGGCGAAGAAGGAGAATAGGGTTGGCACCAGCAGCGCACTTTGAATCTT
254
GTAATCCTGAAGGCTCCTCAGAAACAGCTCTTCTTCAAATCTATACATTA
AGACGACTCGAAATCCACATATCAAATATCCGAGTGTAGTAAACATTCCA
AAACCGTGATGGAATGGAACAACACTTAAAATCGCAGTATCCGGAATGA
TTTGATTGCCAAAAATAGGATCTCTGGCATGCGAGAATCTCACGCAGGCA
GTTCTATGAGGCAGAGCGACACCTTTAGGCAGACCAGTAGATCCAGAGG
AGTTCATGATCAGTGCAATTGTCTTGTCCCTATCGAAGGACTCTGGCACA
AAATCGTATTCATTAAAACCGGGAGGTAGATGAGATGTGACGAACGTGT
ACATCGACTGAAATCCCTGGTAATCCGTTTTAGAATCCATGATAATAATT
TTTTGGATGATTGGGAGCTTTTTTTGCACGTTCAAAATTTTTTGCAACCC
CTTTTTGGAAACGAACACCACGGTAGGCTGCGAAATGCCCATACTGTTGA
GCAATTCACGTTCATTATAAATGTCGTTCGCGGGCGCAACTGCAACTCCG
ATAAATAACGCGCCCAACACCGGCATAAAGAATTGAAGAGAGTTTTCACT
GCATACGACGATTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTT
CTGCCAACCGAACGGACATTTCGAAGTACTCAGCGTAAGTGATGTCCACC
TCGATATGTGCATCTGTAAAAGCAATTGTTCCAGGAACCAGGGCGTATCT
CTTCATAGCCTTATGCAGTTGCTCTCCAGCGGTTCCATCTTCCAGCGGAT
AGAATGGCGCCGGGCCTTTCTTTATGTTTTTGGCGTCTTCCATGGTGGCT
TTACCAACAGTACCGGAATGCCAAGCTTGGGCAGGAGTTGAGGTTACTG
TGAGTAGTGATTAAAGAGAGTGATAGGGAACTCTTGAACAAGAGATGCA
ATTTATACTGTTAATTCTGGAAAAATATTATGGGGGTGTCAAAATGTCCT
CGAGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTT
CATACAGAAGGCGTACGCCTTCTGTATGAAACAGTTTTTCCTCCTCGAGG
GGGGGTGGGGATACAAAAGTAACTCAGAAAACATCGGGGCTAGCACGCG
TAAGAGCTCGGTACCTATCGATAGAGAAATGTTCTGGCACCTGCACTTGC
ACTGGGGACAGCCTATTTTGCTAGTTTGTTTTGTTTCGTTTTGTTTTGAT
GGAGAGCGTATGTTAGTACTATCGATTCACACAAAAAACCAACACACAGA
255
TGTAATGAAAATAAAGATATTTTATTGCGGCCGCTCCAAGTACCTCCCGT
ACCTTAATATTACTTACTTATCATGGTAGCTTGGGCTGGCGTAATAGCGA
AGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCG
AATGGCAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTT
TGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCC
TTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTT
TGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGC
GAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAA
TCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTA
AAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGC
GAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGC
AAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATG
CGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGG
AACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCA
TGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGT
ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATT
TTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATG
CTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAA
CAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGA
TGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC
GCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTT
GGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACA
GTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGG
CCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTT
TTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGG
AGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGT
256
AGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC
TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATA
AATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGG
GCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGT
CAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCT
CACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTT
TAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGAT
CCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCC
ACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACC
AGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGG
TAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT
CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGT
GTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACG
ACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCAC
GCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTC
GGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC
TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTT
CCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTG
AGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATG
257
ATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCGCGCCC
ACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGACG
GATCCTTATCGATTTTACCACATTTGTAGAGGTTTTACTTGCTTTAAAAA
ACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTT
GTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAG
CATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTG
GTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGCTCGAAGCGGCCG
GCCGCCCCGACTCTAGAATTACACGGCGATCTTTCCGCCCTTCTTGGCCT
TTATGAGGATCTCTCTGATTTTTCTTGCGTCGAGTTTTCCGGTAAGACCT
TTCGGTACTTCGTCCACAAACACAACTCCTCCGCGCAACTTTTTCGCGGT
TGTTACTTGACTGGCGACGTAATCCACGATCTCTTTTTCCGTCATCGTCT
TTCCGTGCTCCAAAACAACAACGGCGGCGGGAAGTTCACCGGCGTCATC
GTCGGGAAGACCTGCGACACCTGCGTCGAAGATGTTGGGGTGTTGGAGC
AAGATGGATTCCAATTCAGCGGGAGCCACCTGATAGCCTTTGTACTTAAT
CAGAGACTTCAGGCGGTCAACGATGAAGAAGTGTTCGTCTTCGTCCCAG
TAAGCTATGTCTCCAGAATGTAGCCATCCATCCTTGTCAATCAAGGCGTT
GGTCGCTTCCGGATTGTTTACATAACCGGACATAA
FA2-CREB
AAGCTTNNNNATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTT
GCCGACTTAAAAAGCTCAAGTGCTCCAAAGAAAAACCGAAGTGCGCCAA
GTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAAAGG
TCTCCGCTGACTAGGGCACATCTGACAGAAGTGGAATCAAGGCTAGAAA
GACTGGAACAGCTATTTCTACTGATTTTTCCTCGAGAAGACCTTGACATG
ATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGGATT
258
ATTTGTACAAGATAATGTGAATAAAGATGCCGTCACAGATAGATTGGCTT
CAGTGGAGACTGATATGCCTCTAACATTGAGACAGCATAGAATAAGTGC
GACATCATCATCGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACT
GTATCGCCGGAATTCGGATCCGACTCTGGAGCAGACAACCAGCAGAGTG
GAGATGCTGCTGTAACAGAAGCTGAAAGTCAACAAATGACAGTTCAAGC
CCAGCCACAGATTGCCACATTAGCCCAGGTATCCATGCCAGCAGCTCATG
CGACGTCATCTGCTCCCACTGTAACCTTAGTGCAGCTGCCCAATGGGCAG
ACAGTCCAGGTCCATGGGGTCATCCAGGCGGCCCAGCCATCAGTTATTCA
GTCTCCACAAGTCCAAACAGTTCAGTCTTCCTGTAAGGACTTAAAAAGAC
TTTTCTCCGGAACTCAGATTTCAACTATTGCAGAAAGTGAAGATTCACAG
GAGTCTGTGGATAGTGTAACTGATTCCCAAAAACGAAGGGAAATCCTTT
CAAGGAGGCCTTCCTACAGGAAAATTTTGAATGACTTATCTTCTGATGCA
CCAGGGGTGCCAAGGATTGAAGAAGAAAAATCAGAAGAAGAGACTTCAG
CCCCTGCCATCACCACTGTAACAGTGCCAACCCCGATTTACCAAACTAGC
AGTGGGCAGTATATTGCCATTACCCAGGGAGGAGCAATACAGCTGGCTA
ACAATGGTACCGATGGGGTACAGGGCCTGCAGACATTAACCATGACCAA
TGCAGCTGCCACTCAGCCGGGTACTACCATTCTACAATATGCACAGACCA
CTGATGGACAGCAGATTCTAGTGCCCAGCAACCAAGTTGTTGTTCAAGCT
GCCTCTGGTGATGTACAAACATACCAGATTCGCACAGCACCCACTAGCAC
CATTGCCCCTGGAGTTGTTATGGCGTCCTCCCCAGCACTTCCTACACAGC
CTGCTGAAGAAGCAGCACGAAAGAGAGAGGTTCGTCTAATGAAGAACAG
GGAAGCAGCAAGAGAATGTCGTAGAAAGAAGAAAGAATATGTGAAATGT
TTAGAGAACAGAGTGGCAGTGCTTGAAAACCAAAACAAAACATTGATTG
AGGAGCTAAAAGCACTTAAGGACCTTTACTGCCACAAGTCAGATTAATTT
GGGATCCACTAGTTCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCT
AGAGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGA
259
CAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAA
GTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATT
CCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATG
AGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGC
TACTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAG
AAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCT
GTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGGA
AAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTTGATGTATA
GTGCCTTGACTAGAGATCATAATCAGCCATACCACATTTGTAGAGGTTTT
ACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAA
TGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTAC
AAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACT
GCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCT
GGATCATCCCGCCATGGTATCAACGCCATATTTCTATTTACAGTAGGGAC
CTCTTCGTTGTGTAGGTACCGCTGTATTCCTAGGGAAATAGTAGAGGCA
CCTTGAACTGTCTGCATCAGCCATATAGCCCCCGCTGTTCGACTTACAAA
CACAGGCACAGTACTGACAAACCCATACACCTCCTCTGAAATACCCATAG
TTGCTAGGGCTGTCTCCGAACTCATTACACCCTCCAAAGTCAGAGCTGTA
ATTTCGCCATCAAGGGCAGCGAGGGCTTCTCCAGATAAAATAGCTTCTGC
CGAGAGTCCCGTAAGGGTAGACACTTCAGCTAATCCCTCGATGAGGTCT
ACTAGAATAGTCAGTGCGGCTCCCATTTTGAAAATTCACTTACTTGATCA
GCTTCAGAAGATGGCGGAGGGCCTCCAACACAGTAATTTTCCTCCCGACT
CTTAAAATAGAAAATGTCAAGTCAGTTAAGCAGGAAGTGGACTAACTGA
CGCAGCTGGCCGTGCGACATCCTCTTTTAATTAGTTGCTAGGCAACGCCC
TCCAGAGGGCGTGTGGTTTTGCAAGAGGAAGCAAAAGCCTCTCCACCCA
GGCCTAGAATGTTTCCACCCAATCATTACTATGACAACAGCTGTTTTTTT
260
TAGTATTAAGCAGAGGCCGGGGACCCCTGGGCCCGCTTACTCTGGAGAA
AAAGAAGAGAGGCATTGTAGAGGCTTCCAGAGGCAACTTGTCAAAACAG
GACTGCTTCTATTTCTGTCACACTGTCTGGCCCTGTCACAAGGTCCAGCA
CCTCCATACCCCCTTTAATAAGCAGTTTGGGAACGGGTGCGGGTCTTACT
CCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCA
TGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCT
CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTT
TTGCAAAAAGCTAATTCGGCGTAATCTGCTGCTTGCAAACAAAAAAACCA
CCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTT
TCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTC
TAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCT
ACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGA
TAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAG
GCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGG
AGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGA
AAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGC
GGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACG
CCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGT
CGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCA
GCAACGCAAGCTAGCTTCTAGCTAGAAATTGTAAACGTTAATATTTTGTT
AAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGG
CGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGCCCGAGATAGGG
TTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGG
ACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCGCCC
ACTACGTGAACCATCACCCAAATCAAGTTTTTTGGGGTCGAGGTGCCGTA
AAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACG
261
GGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGG
AGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACC
ACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTACTATGGTTG
CTTTGACGAGACCGTATAACGTGCTTTCCTCGTTGGAATCAGAGCGGGA
GCTAAACAGGAGGCCGATTAAAGGGATTTTAGACAGGAACGGTACGCCA
GCTGGATTACCAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGT
CATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAAT
GTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTA
TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAA
GGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTT
GCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG
GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTT
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCC
GTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCA
GAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATA
ACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCT
AACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTT
GGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCAC
GATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAA
CTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGA
TAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTA
TTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGC
AGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGA
CGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGAT
262
AGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT
ATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTCTCTAGCGCGTT
GACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTA
GTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGG
CCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGA
CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGG
GTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCA
TATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCT
GGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAC
ATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTA
CATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTC
CACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTA
GGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAG
AGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGG
AGACCC
FR-LUC
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAA
TCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTG
TTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGC
AAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTT
TGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTAT
TGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCA
TATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTG
263
ACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCA
TAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTT
ACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTA
CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCC
CAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT
AGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGG
CGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGA
CGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAAT
GTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCTCTCCCTATCAGTGATAGAGATCTC
CCTATCAGTGATAGAGATCGTCGACGAGCTCGTTTAGTGAACCGTCAGA
TCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGG
GACCGATCCAGCCTCCGGACTCTAGCGTTTAAACTTAAGCTTGGCATTCC
GGTACTGTTGGTAAAGCCACCATGGAAGACGCCAAAAACATAAAGAAAG
GCCCGGCGCCATTCTATCCGCTGGAAGATGGAACCGCTGGAGAGCAACT
GCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTA
CAGATGCACATATCGAGGTGGACATCACTTACGCTGAGTACTTCGAAAT
GTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATACAAAT
CACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGT
GTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATT
TATAATGAACGTGAATTGCTCAACAGTATGGGCATTTCGCAGCCTACCGT
GGTGTTCGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAAA
AAGCTCCCAATCATCCAAAAAATTATTATCATGGATTCTAAAACGGATTA
CCAGGGATTTCAGTCGATGTACACGTTCGTCACATCTCATCTACCTCCCG
GTTTTAATGAATACGATTTTGTGCCAGAGTCCTTCGATAGGGACAAGAC
AATTGCACTGATCATGAACTCCTCTGGATCTACTGGTCTGCCTAAAGGTG
264
TCGCTCTGCCTCATAGAACTGCCTGCGTGAGATTCTCGCATGCCAGAGAT
CCTATTTTTGGCAATCAAATCATTCCGGATACTGCGATTTTAAGTGTTGT
TCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGATATTTGATAT
GTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTCT
GAGGAGCCTTCAGGATTACAAGATTCAAAGTGCGCTGCTGGTGCCAACC
CTATTCTCCTTCTTCGCCAAAAGCACTCTGATTGACAAATACGATTTATC
TAATTTACACGAAATTGCTTCTGGTGGCGCTCCCCTCTCTAAGGAAGTCG
GGGAAGCGGTTGCCAAGAGGTTCCATCTGCCAGGTATCAGGCAAGGATA
TGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAGGGGGAT
GATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGG
TTGTGGATCTGGATACCGGGAAAACGCTGGGCGTTAATCAAAGAGGCGA
ACTGTGTGTGAGAGGTCCTATGATTATGTCCGGTTATGTAAACAATCCG
GAAGCGACCAACGCCTTGATTGACAAGGATGGATGGCTACATTCTGGAG
ACATAGCTTACTGGGACGAAGACGAACACTTCTTCATCGTTGACCGCCTG
AAGTCTCTGATTAAGTACAAAGGCTATCAGGTGGCTCCCGCTGAATTGG
AATCCATCTTGCTCCAACACCCCAACATCTTCGACGCAGGTGTCGCAGGT
CTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGA
GCACGGAAAGACGATGACGGAAAAAGAGATCGTGGATTACGTCGCCAGT
CAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGGACG
AAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAGAGA
GATCCTCATAAAGGCCAAGAAGGGCGGAAAGATCGCCGTGTAATTCTAG
NNNNAGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACA
GTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCC
TCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGT
GCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAA
ATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGG
265
GGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAG
CAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGA
ACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCAT
TAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGC
CAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCA
CGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGG
TTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGG
TGATGGTTCACGTACCTAGAAGTTCCTATTCCGAAGTTCCTATTCTCTAG
AAAGTATAGGAACTTCCTTGGCCAAAAAGCCTGAACTCACCGCGACGTCT
GTCGAGAAGTTTCTGATCGAAAAGTTCGACAGCGTCTCCGACCTGATGC
AGCTCTCGGAGGGCGAAGAATCTCGTGCTTTCAGCTTCGATGTAGGAGG
GCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTCTACAAA
GATCGTTATGTTTATCGGCACTTTGCATCGGCCGCGCTCCCGATTCCGGA
AGTGCTTGACATTGGGGAATTCAGCGAGAGCCTGACCTATTGCATCTCCC
GCCGTGCACAGGGTGTCACGTTGCAAGACCTGCCTGAAACCGAACTGCC
CGCTGTTCTGCAGCCGGTCGCGGAGGCCATGGATGCGATCGCTGCGGCC
GATCTTAGCCAGACGAGCGGGTTCGGCCCATTCGGACCGCAAGGAATCG
GTCAATACACTACATGGCGTGATTTCATATGCGCGATTGCTGATCCCCAT
GTGTATCACTGGCAAACTGTGATGGACGACACCGTCAGTGCGTCCGTCG
CGCAGGCTCTCGATGAGCTGATGCTTTGGGCCGAGGACTGCCCCGAAGT
CCGGCACCTCGTGCACGCGGATTTCGGCTCCAACAATGTCCTGACGGACA
ATGGCCGCATAACAGCGGTCATTGACTGGAGCGAGGCGATGTTCGGGGA
TTCCCAATACGAGGTCGCCAACATCTTCTTCTGGAGGCCGTGGTTGGCTT
GTATGGAGCAGCAGACGCGCTACTTCGAGCGGAGGCATCCGGAGCTTGC
AGGATCGCCGCGGCTCCGGGCGTATATGCTCCGCATTGGTCTTGACCAAC
TCTATCAGAGCTTGGTTGACGGCAATTTCGATGATGCAGCTTGGGCGCA
266
GGGTCGATGCGACGCAATCGTCCGATCCGGAGCCGGGACTGTCGGGCGT
ACACAAATCGCCCGCAGAAGCGCGGCCGTCTGGACCGATGGCTGTGTAG
AAGTACTCGCCGATAGTGGAAACCGACGCCCCAGCACTCGTCCGAGGGC
AAAGGAATAGCACGTACTACGAGATTTCGATTCCACCGCCGCCTTCTATG
AAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCT
CCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTA
TTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACA
AATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCAT
CAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGG
CGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACA
ATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTG
CCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCT
TTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACG
CGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTC
ACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTC
ACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGG
AAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCA
CAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAA
AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC
GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCG
TGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTC
GTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCG
CTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACG
ACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG
GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGC
267
TACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC
CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCT
GGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA
AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG
TGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA
GGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATC
TAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAG
TGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCT
GACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGG
CCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATT
TATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCC
TGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTA
GAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCT
ACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTC
CGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAA
AAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCC
GCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGT
CATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGT
CATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTC
AATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA
TTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTG
AGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATC
TTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAAT
GCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATAC
TCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATG
268
AGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC
